(19) DANMARK

(10) DK/EP 3914600 T3

(12) Oversættelse af europæisk patentskrift

Patent- og Varemærkestyrelsen

(51) Int.Cl.: *C 07 D 513/04 (2006.01)* *A 61 K 31/437 (2006.01)* *A 61 P 35/00 (2006.01)*
C 07 D 519/00 (2006.01)

(45) Oversættelsen bekendtgjort den: **2024-10-07**

(80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2024-08-07**

(86) Europæisk ansøgning nr.: **20700918.4**

(86) Europæisk indleveringsdag: **2020-01-21**

(87) Den europæiske ansøgnings publiceringsdag: **2021-12-01**

(86) International ansøgning nr.: **EP2020051347**

(87) Internationalt publikationsnr.: **WO2020152132**

(30) Prioritet: **2019-01-22 EP 19152961**

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Patenthaver: **Merck Patent GmbH, Frankfurter Strasse 250, 64293 Darmstadt, Tyskland**

(72) Opfinder: **TANZER KRAUEL, Eva-Maria, 5 Riverhurst Road Apt. 642, BILLERICA, MA 01821, USA**
SCHIEMANN, Kai, Am Roedergraben 8, 64342 Seeheim-Jugenheim, Tyskland
CRESPO, Alejandro, 39 Fernwood Rd., West Newton, MA, 02465, USA

(74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**

(54) Benævnelse: **THIAZOLOPYRIDINDERIVATER SOM ADENOSINRECEPTORANTAGONISTER**

(56) Fremdragne publikationer:
WO-A1-2005/000842
WO-A1-2005/028484
WO-A1-2019/025099

DESCRIPTION

Description

[0001] The invention relates to thiazolopyridine derivatives which fall under the general formula I,



I

and the compounds of the present invention for use for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Background of the invention

[0002] Adenosine is an ubiguitous modulator of numerous physiological activities, particularly within the cardiovascular, nervous and immune systems. Adenosine is related both structurally and metabolically to the bioactive nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and cyclic adenosine monophosphate (cAMP), to the biochemical methylating agent S-adenosyl-L-methione (SAM) and structurally to the coenzymes NAD, FAD and coenzym A and to RNA.

[0003] Via cell surface receptors, adenosine modulates diverse physiological functions including induction of sedation, vasodilatation, suppression of cardiac rate and contractility, inhibition of platelet aggregability, stimulation of gluconeogenesis and inhibition of lipolysis. Studies show that adenosine is able to activate adenylate cyclases, open potassium channels, reduce flux through calcium channels, and inhibit or stimulate phosphoinositide turnover through receptor-mediated mechanisms (Muller C. E. and Stein B., Current Pharmaceutical Design, 2: 501, 1996; Muller C. E., Exp. Opin. Ther. Patents, 7(5): 419, 1997).

[0004] Adenosine receptors belong to the superfamily of G-protein-coupled receptors (GPCRs). Four major subtypes of adenosine receptors have been pharmacologically, structurally and functionally characterized (Fredholm et al., Pharm. Rev., 46: 143-156, 1994) and referred to as A_1, A_{2A}, A_{2B} and A_3. Though the same adenosine receptor can couple to different G-proteins, adenosine A_1 and A_3 receptors usually couple to inhibitory G-proteins

referred to as G_i and G_0 which inhibit adenylate cyclase and down-regulate cellular cAMP levels. In contrast, the adenosine A_{2A} and A_{2B} receptors couple to stimulatory G-proteins referred to as G_S that activate adenylate cyclase and increase intracellular levels of cAMP (Linden J., Annu. Rev. Pharmacol. Toxicol., 41: 775-87 2001).

[0005] According to the invention, "adenosine-receptor-selective ligands" are substances which bind selectively to one or more subtypes of the adenosine receptors, thus either mimicking the action of adenosine (adenosine agonists) or blocking its action (adenosine antagonists). According to their receptor selectivity, adenosine-receptor-selective ligands can be divided into different categories, for example ligands which bind selectively to the A_1 or A_2 receptors and in the case of the latter also, for example, those which bind selectively to the A_{2A} or the A_{2B} receptors. Also possible are adenosine receptor ligands which bind selectively to a plurality of subtypes of the adenosine receptors, for example ligands which bind selectively to the A_1 and the A_2, but not to the A_3 receptors. The abovementioned receptor selectivity can be determined by the effect of the substances on cell lines which, after stable transfection with the corresponding cDNA, express the receptor subtypes in question (Olah, M. E. et al., J. Biol. Chem., 267: 10764-10770, 1992). The effect of the substances on such cell lines can be monitored by biochemical measurement of the intracellular messenger cAMP (Klotz, K. N. et al., Naunyn Schmiedebergs Arch. Pharmacol. 357: 1-9, 1998).

[0006] It is known that the A_1 receptor system include the activation of phospholipase C and modulation of both potassium and calcium ion channels. The A_3 subtype, in addition to its association with adenylate cyclase, also stimulates phospholipase C and so activates calcium ion channels.

[0007] The A_1 receptor (326-328 amino acids) was cloned from various species (canine, human, rat, dog, chick, bovine, guinea-pig) with 90-95 % sequence identify among the mammalian species. The A_{2A} receptor (409-412 amino acids) was cloned from canine, rat, human, guinea pig and mouse. The A_{2B} receptor (332 amino acids) was cloned from human and mouse with 45 % homology of human A_{2B} with human A_1 and A_{2A} receptors. The A_3 receptor (317-320 amino acids) was cloned from human, rat, dog, rabbit and sheep.

[0008] The A_1 and A_{2A} receptor subtypes are proposed to play complementary roles in adenosine's regulation of the energy supply. Adenosine, which is a metabolic product of ATP, diffuses from the cell and acts locally to activate adenosine receptors to decrease the oxygen demand (A_1 and A_3) or increase the oxygen supply (A_{2A}) and so reinstate the balance of energy supply / demand within the tissue. The actions of both subtypes are to increase the amount of available oxygen to tissue and to protect cells against damage caused by a short-term imbalance of oxygen. One of the important functions of endogenous adenosine is preventing damage during traumas such as hypoxia, ischaemia, hypotension and seizure activity. Furthermore, it is known that the binding of the adenosine receptor agonist to mast cells expressing the rat A_3 receptor resulted in increased inositol triphosphate and intracellular

calcium concentrations, which potentiated antigen induced secretion of inflammatory mediators. Therefore, the A_3 receptor plays a role in mediating asthmatic attacks and other allergic responses.

[0009] These adenosine receptors are encoded by distinct genes and are classified according to their affinities for adenosine analogues and methylxanthine antagonists (Klinger et al., Cell Signal., 14 (2): 99-108, 2002).

[0010] Concerning the role of adenosine on the nervous system, the first observations were made on the effects of the most widely used of all psychoactive drugs being caffeine. Actually, caffeine is a well-known adenosine receptor antagonist that is able to enhance the awareness and learning abilities of mammals. The adenosine A_{2A} receptor pathway is responsible for these effects (Fredholm et al., Pharmacol. Rev., 51 (1): 83-133, 1999; Huang et al., Nat Neurosci., 8 (7): 858-9, 2005), and the effects of caffeine on the adenosine A_{2A} receptor signaling pathway encouraged the research of highly specific and potent adenosine A_{2A} antagonists.

[0011] In mammals, adenosine A_{2A} receptors have a limited distribution in the brain and are found in the striatum, olfactory tubercle and nucleus acumbens (Dixon et al., Br. J. Pharmacol., 118 (6): 1461-8, 1996). High and intermediate levels of expression can be observed in immune cells, heart, lung and blood vessels. In the peripheral system, G_3 seems to be the major G-protein associated with adenosine A_{2A} receptor but in the striatum, it has been shown that striatal adenosine A_{2A} receptors mediate their effects through activation of a G-protein referred to as $G_o$if (Kull et al., Mol. Pharmacol., 58 (4): 772-7, 2000), which is similar to G_3 and also couples to adenylate cyclase.

[0012] To date, studies on genetically modified mice and pharmacological analysis suggest that A_{2A} receptor is a promising therapeutic target for the treatment of central nervous system (CNS) disorders and diseases such as Parkinson's disease, Huntington's disease, attention deficit hyperactivity disorders (ADHD), stroke (ischemic brain injury), and Alzheimer's disease (Fredholm et al., Annu. Rev. Pharmacol. Toxicol., 45: 385-412, 2005; Higgins et al.; Behav. Brain Res. 185: 32-42, 2007; Dall' Igna et al., Exp. Neurol., 203 (1): 241-5, 2007; Arendash et al., Neuroscience, 142 (4): 941-52, 2006; Trends in Neurosci., 29 (11), 647-654, 2006; Expert Opinion Ther. Patents, 17, 979-991, 2007; Exp. Neurol., 184 (1), 285-284, 2003; Prog. Brain Res, 183, 183-208, 2010; J. Alzheimer Dis., Suppl 1, 1 17-126, 2010; J. Neurosci., 29 (47), 14741-14751, 2009; Neuroscience, 166 (2), 590-603, 2010; J. Pharmacol. Exp. Ther., 330 (1), 294-303, 2009; Frontiers Biosci., 13, 2614-2632, 2008) but also for various psychoses of organic origin (Weiss et al., Neurology, 61 (11 Suppl 6): 88-93, 2003).

[0013] The use of adenosine A_{2A} receptor knockout mice has shown that adenosine A_{2A} receptor inactivation protects against neuronal cell death induced by ischemia (Chen et al., J. Neurosci., 19 (21): 9192-200, 1999 and Monopoli et al., Neuroreport, 9 (17): 3955-9, 1998) and the mitochondrial toxin 3-NP (Blum et al., J. Neurosci., 23 (12): 5361-9, 2003). Those

results provided a basis for treating ischasmia and Huntington's disease with adenosine A_{2A} antagonists. The blockade of adenosine A_{2A} receptors has also an antidepressant effect (El Yacoubi et al., Neuropharmacology, 40 (3): 424-32, 2001). Finally, this blockade prevents memory dysfunction (Cunha et al., Exp. Neurol., 210 (2): 776-81, 2008; Takahashi et al., Front. Biosci., 13: 2614-32, 2008) and this could be a promising therapeutic route for the treatment and/or prevention of Alzheimer's disease.

[0014] For reviews concerning A_{2A} adenosine receptors see e.g. Moreau et al. (Brain Res. Reviews 31: 65-82, 1999) and Svenningsson et al. (Progress in Neurobiology 59: 355-396, 1999).

[0015] To date, several adenosine A_{2A} receptor antagonists have shown promising potential for treatment of Parkinson's disease. As an example, KW-6002 (Istradefylline) completed a phase III clinical trial in the USA after studies demonstrated its efficacy in alleviation of symptoms of the disease (Bara-Himenez et al., Neurology, 61 (3): 293-6, 2003 and Hauser et al., Neurology, 61 (3): 297-303, 2003). SCH420814 (Preladenant), which is now in phase II clinical trial in the USA and produces an improvement in motor function in animal models of Parkinson's disease (Neustadt et al., Bioorg. Med. Chem. Lett., 17 (5): 1376-80, 2001) and also in human patients (Hunter J. C, poster Boston 2006 - http://www.a2apd.org/Speaker abstracts/Hunter.pdf).

[0016] Besides the welcome utility of A_{2A} receptor antagonists to treat neurodegenerative diseases, those compounds have been considered for complementary symptomatic indications. These are based on the evidence that A_{2A} receptor activation may contribute to the pathophysiology of a range of neuropsychiatric disorders and dysfunctions such as depression, excessive daytime sleepiness, restless legs syndrome, attention deficit hyperactivity disorder, and cognitive fatigue (Neurology, 61 (Suppl 6), 82-87, 2003; Behav. Pharmacol., 20 (2), 134-145, 2009; CNS Drug Discov., 2 (1), 1-21, 2007).

[0017] Some authors suggest the application of A_{2A} antagonists for the treatment of diabetes (WO1999035147; WO2001002400). Other studies suggest the involvement of A_{2A} adenosine receptors in wound healing or atrial fibrillation (Am. J. Path., 6, 1774- 1778, 2007; Arthritis & Rheumatism, 54 (8), 2632-2642, 2006).

[0018] Some of the potent adenosine A_{2A} antagonists discovered in the past by the pharmaceutical companies, have advanced into clinical trials showing positive results and demonstrating the potential of this compound class for the treatment of neurodegenerative disorders like Parkinson's, Huntington's or Alzheimer's disease, but also in other CNS related diseases like depression, restless syndrome, sleep and anxiety disorders (Clin. Neuropharmacol., 33, 55-60, 2010; J. Neurosci., 30 (48), 2010), 16284-16292; Parkinson Relat. Disord., 16 (6), 423-426, 2010; Expert Opinion Ther. Patents, 20(8), 987-1005, 2010; Current Opinion in Drug Discovery & Development, 13 (4), 466-480 ,2010 and references therein; Mov. Disorders, 25 (2), S305, 2010).

[0019] Known A_{2A} inhibitors are Istradefylline (KW-6002), Preladenant (SCH420814), SCH58261, CGS15943, Tozadenant, Vipadenant (V-2006), V-81444 (CPI-444, HTL-1071, PBF-509, Medi-9447, PNQ-370, ZM-241385, ASO-5854, ST-1535, ST-4206, DT1133 and DT-0926, which are in most cases developed for Parkinson's disease.

[0020] Adenosine A_{2B} receptors were cloned from rat hypothalamus (Rivkees and Reppert, 1992), human hippocampus (Pierce et al., 1992), and mouse mast cells (Marquardt et al., 1994), employing standard polymerase chain reaction techniques with degenerate oligonucleotide primers designed to recognize conserved regions of most G protein-coupled receptors. The human A_{2B} receptor shares 86 to 87% amino acid sequence homology with the rat and mouse A_{2B} receptors (Rivkees and Reppert, 1992; Pierce et al., 1992; Marquardt et al., 1994) and 45% amino acid sequence homology with human A_1 and A_{2A} receptors. As expected for closely related species, the rat and mouse A_{2B} receptors share 96% amino acid sequence homology. By comparison, the overall amino acid identity between A_1 receptors from various species is 87% (Palmer and Stiles, 1995). A_{2A} receptors share 90% of homology between species (Ongini and Fredholm, 1996), with most differences occurring in the 2nd extracellular loop and the long C-terminal domain (Palmer and Stiles, 1995). The lowest (72%) degree of identity between species is observed for A_3 receptor sequences (Palmer and Stiles, 1995).

[0021] The adenosine analog NECA remains the most potent A_{2B} agonist (Bruns, 1981; Feoktistov and Biaggioni, 1993, 1997; Brackett and Daly, 1994), with a concentration producing a half-maximal effect (EC_{50}) for stimulation of adenyl cyclase of approximately 2 μM). It is, however, nonselective and activates other adenosine receptors with even greater affinity, with an EC_{50} in the low nanomolar (A_1 and A_{2A}) or high nanomolar (A_3) range. The characterization of A_{2B} receptors, therefore, often relies on the lack of effectiveness of compounds that are potent and selective agonists of other receptor types. A_{2B} receptors have been characterized by a method of exclusion, i.e., by the lack of efficacy of agonists that are specific for other receptors. The A_{2A} selective agonist CGS-21680 (Webb et al., 1992), for example, has been useful in differentiating between A_{2A} and A_{2B} adenosine receptors (Hide et al., 1992; Chern et al., 1993; Feoktistov and Biaggioni, 1995; van der Ploeg et al., 1996). Both receptors are positively coupled to adenyl cyclase and are activated by the nonselective agonist NECA. CGS-21680 is virtually ineffective on A_{2B} receptors but is as potent as NECA in activating A_{2A} receptors, with an EC_{50} in the low nanomolar range for both agonists (Jarvis et al., 1989; Nakane and Chiba, 1990; Webb et al., 1992; Hide et al., 1992; Feoktistov and Biaggioni, 1993; Alexander et al., 1996). A_{2B} receptors have also a very low affinity for the A_1selective agonist R-PIA (Feoktistov and Biaggioni, 1993; Brackett and Daly, 1994) as well as for the A_3 selective agonist N^6-(3-iodobenzyl)-N-methyl-5'-carbamoyladenosine (IB-MECA) (Feoktistov and Biaggioni, 1997). The agonist profile NECA > R-PIA = IB-MECA > CGS-21680 was determined in human erythroleukemia (HEL) cells for A_{2B}-mediated cAMP accumulation. The difference between EC_{50} for NECA and the rest of the agonists is approximately 2 orders of magnitude.

Therefore, responses elicited by NECA at concentrations in the low micromolar range (1-10 μM), but not by R-PIA, IB-MECA or CGS-21680, are characteristic of A_{2B} receptors.

[0022] Whereas A_{2B} receptors have, in general, a lower affinity for agonists compared to other receptor subtypes, this is not true for antagonists. The structure activity relationship of adenosine antagonists on A_{2B} receptors has not been fully characterized, but at least some xanthines are as or more potent antagonists of A_{2B} receptor subtypes than of other subtypes. In particular, DPSPX (1,3-dipropyl-8-sulphophenylxanthine), DPCPX (1,3-diproyl-8c-yclopentylxanthine), DPX (1,3 diethylphenylxanthine), the antiasthmatic drug enprofylline (3-n-propylxanthine) and the non-xanthine compound 2,4-dioxobenzopteridine (alloxazine) have affinities in the mid to high nM range.

[0023] Other known A_{2B} inhibitors are ATL801, PSB-605, PSB-1115, ISAM-140, GS6201, MRS1706 and MRS1754.

[0024] It is disclosed herein that adenosine receptors play a non-redundant role in down-regulation of inflammation in vivo by acting as a physiological "STOP" (a termination mechanism) that can limit the immune response and thereby protect normal tissues form excessive immune damage during pathogenesis of different diseases.

[0025] A_{2A} receptor antagonists provide long term enhancement of immune responses by reducing T-cell mediated tolerance to antigenic stimuli, enhancing the induction of memory T cells and enhancing the efficacy of passive antibody administration for the treatment of cancer and infectious diseases while A_{2A} receptor agonists provide long term reduction of immune responses by enhancing T-cell mediated tolerance to antigenic stimuli, in particular to reduce use of immunosuppressive agents in certain conditions.

[0026] Immune modulation is a critical aspect of the treatment of a number of diseases and disorders. T cells in particularly play a vital role in fighting infections and have the capability to recognize and destroy cancer cells. Enhancing T cell mediated responses is a key component to enhancing responses to therapeutic agents. However, it is critical in immune modulation that any enhancement of an immune response is balanced against the need to prevent autoimmunity as well as chronic inflammation. Chronic inflammation and self-recognition by T cells is a major cause for the pathogenesis of systemic disorders such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. Furthermore, long term immunosuppression is required in preventing rejection of transplanted organs or grafts.

[0027] Tumor-induced immunosuppression is a major hurdle to the efficacy of current cancer therapies. Because of their remarkable clinical efficacy against a broader range of cancers, recent successes with immune checkpoint blockade inhibitors such as anti-CTLA-4 and anti-PD-1/PDL1 are revolutionizing cancer treatment.

[0028] Adenosine is one of the new promising immunosuppressive targets revealed in

preclinical studies. This metabolite is produced by the ectoenzyme CD73 expressed on host suppressor cells and tumor cells. Increased expression of CD73 correlates with poor prognosis in patients with a number of cancers, including colorectal cancer (Liu et al, J. Surgical Oncol, 2012), gastric cancer (Lu et al., World J. Gastroenterol., 2013), gallbladder cancer (Xiong et al., Cell and Tissue Res., 2014). Preclinical studies demonstrated that protumor effects of CD73 can be driven (at least in part) by adenosine-mediated immunosuppression. As disclosed above, adenosine binds to four known receptors A_1, A_{2A}, A_{2B}, and A_3, with the activation of A_{2A} and A_{2B} receptors known to suppress the effector functions of many immune cells, i.e. A_{2A} and A_{2B} receptors induce adenylate-cyclase-dependent accumulation of cAMP leading to immunosuppression. Since antagonizing A_1 and A_3 would counteract the desired effect and A_1 and A_3 agonists serve as potential cardioprotective agents, selectivity towards A_1 and A_3 needs to be achieved (Antonioli et al., Nat. rev. Cancer, 2013, Thiel et al., Microbes and Infection, 2003). In the microenvironment of the tumor, both A_{2A} and A_{2B} receptor activation has been demonstrated to suppress antitumor immunity and increase the spread of CD73 tumors. In addition, either A_{2A} or A_{2B} blockade with small molecule antagonists can reduce tumor metastasis. It has been found that blocking of A_{2A} receptor can overcome tumor escape mechanisms including both anergy and regulatory T cell induction caused by tumor cells and cause long-term tumor susceptibility to treatment. Ohta et al. demonstrated rejection of approximately 60% of established CL8-1 melanoma tumors in A_{2A} receptor-deficient mice compared to no rejection in normal mice (Ohta, et al.; PNAS 103 (35): 13132-7, 2006). In agreement, the investigators also showed improved inhibition of tumor growth, destruction of metastases and prevention of neovascularization by anti-tumor T cells after treatment with an A_{2A} receptor antagonist.

[0029] Tumors have been shown to evade immune destruction by impeding T cell activation through inhibition of co-stimulatory factors in the B7-CD28 and TNF families, as well as by attracting regulatory T cells, which inhibit anti-tumor T cell responses (Wang, Cancer. Semin. Cancer. Biol. 16: 73-79, 2006; Greenwald, et al., Ann. Rev. Immunol. 23: 515-48, 2005; Watts, Ann. Rev. Immunol. 23: 23-68, 2005; Sadum et al., Clin. Cane. Res. 13 (13): 4016-4025, 2007). Because A_{2A} receptor expression is increased in lymphocytes following activation, therapies that liberate lymphocyte effector responses, such as anti-CTLA-4 and anti-PD-1, may also increase the effects of A_{2A}-mediated immunosuppression. Immune checkpoint blockade in combination with A_{2A} or dual $A_{2A/2B}$ antagonists increase the magnitude of immune responses to tumors and metastasis. Accordingly, combination of A_{2A} inhibition with anti-PD-1 therapy enhances IFN-γ production by T-cells in a co-culture with MC38 tumor cells, improves mouse survival in 4T1 mammary tumor model and decreases tumor growth in AT-3ova^{dim} CD73^{+} tumors (Beavis et al., Cancer Immunol. Res., 2015; Mittal et al., Cancer Res., 2014).

[0030] Furthermore, preclinical studies demonstrated that A_{2B} inhibition leads to decreased tumor growth and extended survival of mice in Lewis lung carcinoma, MB49 bladder carcinoma, ortho 4T1 mammary carcinoma models (Ryzhov et al., 2009, Cekic et al., 2012) and the combination of A_{2B} inhibition with anti-PD-1 therapy reduces lung metastases of B16-

F10 melanoma tumors and improves mouse survival in the 4T1 mammary tumor model.

[0031] WO 03/050241 describes the methods to increase an immune response to an antigen, increasing vaccine efficacy or increasing an immune response to a tumor antigen or immune cell-mediated tumor destruction by administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors.

[0032] WO 2004/089942, WO 2005/000842 and WO 2006/008041 disclose benzothiazole derivatives, including Tozadenant, as A_{2A} inhibitors for the treatment of Parkinson's disease. WO 2004/092171 and WO 2005/028484 disclose similar thiazolopyridine and pyrazolopyrimidine derivatives also as A_{2A} inhibitors for the treatment of Parkinson's disease. However, these compounds do not show significant A_{2B} inhibitory activity and do only show good pharmacokinetic properties in the rat, the Parkison's disease animal model but not in the mouse, the cancer animal model. Furthermore, the compounds do not show that they are able to prevent immunosuppression and thus are able to support anti-tumor T cell induced inhibition of tumor growth, reduction or destruction of metastases and prevention of neovascularization.

[0033] Thus, there remains a need for therapies that provide long term enhancement of immune responses to specific antigens, particularly for the treatment and prevention of hyperproliferative and infectious diseases and disorders and thus the object of the present invention was to provide methods of treatment that allow simplified treatment protocols and enhance immune responses against certain antigens. It was a specific object of the invention to provide improved methods of preventing or treating hyperproliferative and infectious diseases and disorders in a host, especially to provide effective A_{2A} or dual $A_{2A/2B}$ antagonists for the treatment and prevention of such diseases.

Summary of the invention

[0034] Surprisingly, it has been found that the compounds according to the invention are highly effective inhibitors of the A_{2A} adenosine receptor or both the A_{2A} and A_{2B} adenosine receptors and at the same time have high selectivity over the A_1 and A_3 adenosine receptors, and thus the compounds of the present invention can be used for the treament of hyperproliferative diseases and disorders such as cancer and infectious diseases and disorders.

[0035] Particularly, in contrast to the known adenosine A_{2A} receptor antagonist Tozadenant and similar benzothiazole derivatives, the compounds of the present invention surprisingly show an A_{2A}/A_{2B} dual activity which is preferred for the treatment and/or prevention of hyperproliferative and infectious diseases and disorders as it is disclosed above or the compounds of the present invention show at least a high A_{2A} inhibitory activity together with the other surprising advantages disclosed herein leading to a high efficacy in the treatment and/or prevention of hyperproliferative and infectious diseases and disorders.

[0036] Additionally, in comparison with the known adenosine A_{2A} receptor antagonist Tozadenant and similar benzothiazole derivatives, the compounds of the present invention surprisingly show better pharmacokinetic properties in mouse as the animal model relevant for cancer, which is preferred for the treatment and/or prevention of hyperproliferative and infectious diseases and disorders as it is disclosed above.

[0037] Furthermore, as discussed above, adenosine in tumor microenvironment can inhibit T cell activity by signaling through A_{2A} receptors and suppress cytokine secretion by T cells. A_{2A} specific agonists like CGS-21680 or NECA, similar to adenosine, inhibit T cell cytokine secretion in vitro and in vivo. In contrast, potential A_{2A} antagonists or A_{2A}/A_{2B} dual antagonists can rescue T cells from this inhibition. In contrast to the known adenosine A_{2A} receptor antagonist Tozadenant, the compounds of the present invention show that they are able to rescue T cells from inhibition and are able to prevent the suppression of cyctokine secretion as induced by adenosine or A_{2A} specific agonists like CGS-2168, CGS-21680 or NECA, which is preferred for the treatment and/or prevention of hyperproliferative and infectious diseases and disorders as it is disclosed above. Therefore, the compounds of the present invention surprisingly are able to prevent immunosuppression and thus are able to support anti-tumor T cell induced inhibition of tumor growth, reduction or destruction of metastases and prevention of neovascularization.

[0038] The invention relates to a compound selected from the group consisting of:

1	(R)-3-Aminomethyl-pyrrolidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide
2	N-{4-methoxy-7-[4-(oxan-4-yloxy)phenyl]-[1,3]thiazolo[4,5-c]pyridin-2-yl}-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
3	(S)-3-Aminomethyl-pyrrolidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide
4	Cyclopropanecarboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide
6	N-(6-Fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-4-(1 H-tetrazol-5-yl)-benzamide
7	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide
9	N-[7-(1H-indol-6-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
10	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide
11	(5S)-N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide
12	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide
13	(5S)-N-{6-fluoro-4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-7-oxa-2-azaspiro[4.5]decane-2-carboxamide

14	3-Dimethylaminomethyl-bicyclo[1.1.1]pentane-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide
15	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
16	N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide
17	N-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-[(2-methoxyethyl)amino]-1,3-thiazole-5-carboxamide
18	(R)-2-Oxa-7-aza-spiro[4.4]nonane-7-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide
19	(5S)-N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c] pyrid i n-2-yl]-2-oxa-7-azaspi ro[4.4]nonane-7-carboxam ide
20	N-[6-Fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N', N'-dimethyl-terephthalamide
21	1-Imidazol-1-ylmethyl-cyclopropanecarboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
22	N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-(2-methoxyethyl)-1H-pyrazole-4-carboxamide
23	N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-methyl-1H-pyrazole-4-carboxamide
24	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
25	(S)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
26	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
27	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [6-fluoro-7-(4-fluoro-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
28	Cyclopropanecarboxylic acid [6-fluoro-4-methoxy-7-(tetrahydropyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
29	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-7-(4-fluoro-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
30	Cyclopropanecarboxylic acid [7-(3-ethylaminomethyl-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
31	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
32	1H-Imidazole-4-carboxylic acid (6-fluoro-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide
33	N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide
34	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide

35	(5S)-N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide
37	(R)-2-Oxa-7-aza-spiro[4.4]nonane-7-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
38	(5S)-N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide
39	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-aminophenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
40	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-oxo-cyclopent-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amide
41	Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide (2-hydroxy-ethyl)-methyl-amide
42	N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]cyclopropanecarboxamide
43	N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1H-imidazole-4-carboxamide
44	N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
45	N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxam ide
46	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(1-acetyl-1,2,3,6-tetrahydro-pyridin-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
47	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-thiophen-2-yl-thiazolo[4,5-c]pyridin-2-yl)-amide
48	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-furan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide
49	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-ethylaminomethyl-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
50	N-[6-Fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N'-(2-hydroxy-ethyl)-N'-methyl-terephthalamide
51	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-piperidin-1-yl-thiazolo[4,5-c]pyridin-2-yl)-amide
52	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-furan-3-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide
53	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(4-methyl-piperazin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
54	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methoxy-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amide
56	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(6-methyl-pyridazin-3-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
57	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-azetidin-1-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide
58	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-hydroxy-azetidin-1-

	yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
59	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-cyclohex-1-enyl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide
60	1H-Imidazole-4-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide
61	N4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N1,N1-dimethylbenzene-1,4-dicarboxamide
62	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-cyclohexyl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide
63	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(4,4-difluoro-cyclohex-1-enyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
64	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-thiopyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
65	1H-Imidazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
66	N-[4-methoxy-7-(4-methoxycyclohex-1-en-1-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
67	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(2-methyl-thiazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
68	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(1-pyridin-3-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
69	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(1-pyridin-2-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
71	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide
72	4-{[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}benzoic acid
73	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-[1,4]dioxan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide
74	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {7-[1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]-4-methoxy-thiazolo[4,5-c]pyridin-2-yl}-amide
75	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(1-pyridin-4-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
76	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(1-benzyl-1H-pyrazol-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
79	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(1-difluoromethyl-1H-pyrazol-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
80	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-difluoromethoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide
81	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-[(2-methoxyethyl)amino]-1,3-thiazole-5-carboxamide
82	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-

	[(1H-imidazol-1-yl)methyl]benzamide
83	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-[(1R)-1-acetamidoethyl]benzamide
84	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[1-(tetrahydro-pyran-2-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amide
85	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[1-(tetrahydro-pyran-4-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amide
86	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(1,1-dioxo-hexahydro-1l6-thiopyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
87	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[1-(tetrahydro-pyran-3-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amide
88	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)piperidine-1-carboxamide
89	3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(2-oxopyrrolidin-1-yl)phenyl]urea
90	N-[4-({[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}amino)phenyl]-2-(dimethylamino)acetamide
91	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(2,4-dioxo-1,3-thiazolidin-3-yl)piperidine-1-carboxamide
92	N-[4-({[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}amino)-2-methylphenyl]acetamide
93	N4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-hydroxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N1-(2-hydroxyethyl)-N1-methylbenzene-1,4-dicarboxamide
94	3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)phenyl]urea
95	3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]urea
96	N1-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N4,N4-dimethylpiperidine-1,4-dicarboxamide
97	[4-(4-Methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-ylcarbamoyl)-benzyl]-methyl-carbamic acid methyl ester
98	2,8-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
99	4-(2,5-Dioxo-pyrrolidin-1-yl)-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide
100	4-(2,5-Dioxo-pyrrolidin-1-yl)-piperidine-1-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
101	Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid (6-fluoro-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide (2-hydroxy-ethyl)-methylamide
102	2,7-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
103	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[2-(2-methoxy-ethoxy)-ethyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide

104	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[(R)-1-(tetrahydro-pyran-3-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide
105	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[(S)-1-(tetrahydro-pyran-3-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide
106	N 1-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]piperidine-1,4-dicarboxamide
107	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-hydroxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide
108	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide
109	4-({4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}carbamoyl)benzoic acid
110	N-{4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-4-(1H-1,2,3,4-tetrazol-5-yl)benzamide
111	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(4,4-difluoro-cyclohexyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
112	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methylamino-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amide
113	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(5-methyl-thiophen-2-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
114	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(5-methyl-furan-2-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
115	4-[(4-methoxy-7-{1-[(pyridin-3-yl)methyl]-1H-pyrazol-4-yl}-[1,3]thiazolo[4,5-c]pyridin-2-yl)carbamoyl]benzoic acid
116	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1H-pyrazole-4-carboxamide
117	N-{4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-1 H-pyrazole-4-carboxamide
118	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[(S)-1-(tetrahydro-pyran-2-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide
119	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[(R)-1-(tetrahydro-pyran-2-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide
121	(R)-2,7-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
122	(S)-2,7-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
123	Piperidine-1,4-dicarboxylic acid 4-dimethylamide 1-[(4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide]
124	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(2-amino-pyridin-4-yl)-4-

	methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
125	N-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-4-(4-methyl-piperazine-1-carbonyl)-benzamide
126	N-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-N'-(2-piperidin-1-yl-ethyl)-terephthalamide
127	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(2-methylamino-pyridin-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
128	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(5-methyl-cyclohex-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amide
129	N-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-4-(4-hydroxy-4-methyl-piperidine-1-carbonyl)-benzamide
130	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-fluoro-5-methanesulfonylamino-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
131	4-(2,5-Dioxo-imidazolidin-1-yl)-piperidine-1-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
132	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methyl-3,6-dihydro-2H-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
133	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-trifluoromethyl-piperidin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
134	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methoxy-piperidin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
135	Imidazo[1,2-a]pyridine-3-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
136	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(5-oxo-2,5-dihydro-1H-pyrrol-3-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide
137	4-(2,5-Dioxo-imidazolidin-1-yl)-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide
138	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(5-amino-2-fluoro-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
139	N-(2-Azetidin-1-yl-ethyl)-N'-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-terephthalamide
140	2-Pyridin-3-yl-1H-imidazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
141	N-{4-methoxy-7-[3-(trifluoromethyl)phenyl]-[1,3]thiazolo[4,5-c]pyridin-2-yl}-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
142	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(5-amino-6-fluoro-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
143	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(5-amino-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide
144	{4-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-ylcarbamoyl]-phenyl}-acetic acid
145	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-((S)-3-methyl-cyclohex-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amide

146	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-((R)-3-methyl-cyclohex-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amide

and physiologically acceptable salts, solvates, and stereoisomers thereof, including mixtures thereof in all ratios.

[0039] The compounds of the present invention fall under the general formula I,



I

wherein

R^1

is linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^5 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3,-OCO-, -NHCONH-, -NHCO-, $-NR^6SO_2R^7$-, -COO-, -CONH-,$-NCH_3CO$-, $-CONCH_3$-, -C=C- groups and/or -CH=CH- groups, and/or, in addition, 1-10 H atoms may be replaced by F and/or C!, or mono- or bicyclic cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^5 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, -OCO-,-NHCONH-, -NHCO-, $-NR^6SO_2R^7$-, -COO-, -CONH-, $-NCH_3CO$-,-$CONCH_3$-, -C=C- groups and/or by -CH=CH- groups and/or, in addition, 1-10 H atoms may be replaced by F and/or C!, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl, containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from N, O and S, which is unsubstituted or mono-, di- or trisubstituted by R^5,

R^2

is linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^5 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3,-OCO-, -NHCONH-, -NHCO-, $-NR^6SO_2R^7$-, -COO-, -CONH-,$-NCH_3CO$-, $-CONCH_3$-, -C=C- groups and/or -CH=CH- groups, and/or, in addition, 1-10 H atoms may be replaced by F and/or Cl, or cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by by R^5 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, -OCO-, -NHCONH-,-NHCO-, $-NR^6SO_2R^7$-, -COO-, -CONH-, $-NCH_3CO$-, $-CONCH_3$-,-C=C- groups and/or by -CH=CH- groups and/or, in addition, 1-11 H atoms may be replaced by F and/or C!, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl, containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from N, O

and S, which is unsubstituted or mono-, di- or trisubstituted by R^5,

R^3

is linear or branched alkyl or O-alkyl having 1-6 C atoms or cyclic alkyl having 3-6 C atoms, which is unsubstituted or mono-, di- or trisubstituted by H, =S, =NH, =O, OH, cyclic alkyl having 3-6 C atoms, COOH, Hal, NH_2, SO_2CH_3, SO_2NH_2, CN, $CONH_2$, $NHCOCH_3$, $NHCONH_2$ or NO_2,

R^4

is H, D, linear or branched alkyl having 1-6 C atoms, CN or Hal,

R^5

is H, R^6, =S, $=NR^6$, =O, OH, COOH, Hal, NH_2, SO_2CH_3, SO_2NH_2, CN, $CONH_2$, $NHCOCH_3$, $NHCONH_2$, NO_2, or linear or branched alkyl having 1-10 C atoms which is unsubstituted or mono-, di- or trisubstituted by R^6 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, -OCO-, -NHCONH-, -NHCO-,$-NR^6SO_2R^7$-, -COO-, -CONH-, $-NCH_3CO$-, $-CONCH_3$-, -C≡C- groups and/or-CH=CH- groups, and/or, in addition, 1-10 H atoms may be replaced by F and/or C!, or mono- or bicyclic cyclic alkyl having 3-7 C atoms which is unsubstituted or mono-, di- or trisubstituted by by R^6 and in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, -OCO-, -NHCONH-, -NHCO-, $-NR^6SO_2R^7$-, -COO-, -CONH-, $-NCH_3CO$-, $-CONCH_3$-, -C=C- groups and/or by-CH=CH- groups and/or, in addition, 1-10 H atoms may be replaced by F and/or C!, or mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl, containing 3 to 14 carbon atoms and 0-4 heteroatoms, independently selected from N, O and S, which is unsubstituted or mono-, di- or trisubstituted by R^6,

R^6, R^7

are independently of one another selected from the group consisting of H, =S, =NH, =O, OH, COOH, Hal, NH_2, SO_2CH_3, SO_2NH_2, CN, $CONH_2$, $NHCOCH_3$, $NHCONH_2$, NO_2 and linear or branched alkyl having 1-10 C atoms in which 1-4 C atoms may be replaced, independently of one another, by O, S, SO, SO_2, NH, NCH_3, -OCO-, -NHCONH-, -NHCO-,-COO-, -CONH-, $-NCH_3CO$-, $-CONCH_3$-, -C=C- groups and/or-CH=CH- groups, and/or, in addition, 1-10 H atoms may be replaced by F and/or Cl,

Hal

is F, Cl, Br, or I,

D

is deuterium

and physiologically acceptable salts, solvates, and stereoisomers thereof, including mixtures thereof in all ratios. Furthermore, the abbreviations below have the following meanings:

Boc

ter-butoxycarbonyl

CBZ

benzyloxycarbonyl

DNP

2,4-dinitrophenyl

FMOC

9-fluorenylmethoxycarbonyl

imi-DNP

2,4-dinitrophenyl in the 1-position of the imidazole ring

OMe

methyl ester

POA

phenoxyacetyl

DCCIdicyclohexylcarbodiimide

HOBt1-hydroxybenzotriazole

[0040] The invention further relates to a pharmaceutical preparation comprising the compound according to the present invention and/or one of its physiologically acceptable salts, solvates, and stereoisomers, including mixtures thereof in all ratios.

[0041] The invention also relates to a pharmaceutical preparation according to the invention of this type, comprising further excipients and/or adjuvants.

[0042] In addition, the invention relates to an above pharmaceutical preparation according to the invention, comprising at least one further medicament active compound.

[0043] The compound of the present invention can be used in its final non-salt form. On the other hand, the present invention also encompasses the use of pepstatin in the form of its pharmaceutically acceptable salts, which can be derived from various organic and inorganic bases by procedures known in the art. Pharmaceutically acceptable salt forms of pepstatin are for the most part prepared by conventional methods. If the compound of the present invention contains a carboxyl group, one of its suitable salts can be formed by reacting the compound of the present invention ith a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline-earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. The aluminium salts of pepstatin are likewise included.

[0044] Furthermore, the base salts of the compounds of the present invention include aluminium, ammonium, calcium, copper, iron(III), iron(II), lithium, magnesium, manganese(III), manganese(II), potassium, sodium and zinc salts, but this is not intended to represent a restriction.

[0045] Of the above-mentioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline-earth metal salts calcium and magnesium. Salts of the compounds of the present invention which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris-(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction.

[0046] As mentioned, the pharmaceutically acceptable base-addition salts of pepstatin are formed with metals or amines, such as alkali metals and alkaline-earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

[0047] The base-addition salts of the compounds of the present invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.

[0048] In view of that stated above, it can be seen that the term "pharmaceutically acceptable salt" in the present connection is taken to mean an active compound which comprises the compound of the present invention in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active compound compared with the free form of the active compound or any other salt form of the active compound used earlier. The pharmaceutically acceptable salt form of the active compound can also provide this active compound for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active compound with respect to its therapeutic efficacy in the body.

[0049] Solvates of the compound of the present invention are taken to mean adductions of inert solvent molecules pepstatin which form owing to their mutual attractive force. Solvates are, for example, hydrates, such as monohydrates or dihydrates, or alcoholates, i.e. addition compounds with alcohols, such as, for example, with methanol or ethanol.

[0050] All physiologically acceptable salts, solvates and stereoisomers of these compounds, including mixtures thereof in all ratios, are also in accordance with the invention.

[0051] Compounds of the present invention may contain one or more centres of chirality, so that all stereoisomers, enentiomers, diastereomers, etc., of the compounds of the present inventionare also claimed in the present invention.

[0052] The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and hydrates and solvates of these compounds.

[0053] Compounds of the present invention according to the invention may be chiral owing to their molecular structure and may accordingly occur in various enantiomeric forms. They may therefore be in racemic or optically active form. Since the pharmaceutical efficacy of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product, but also even the intermediates, may be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or already employed as such in the synthesis.

[0054] Suitable acid-addition salts are inorganic or organic salts of all physiologically or pharmacologically acceptable acids, for example halides, in particular hydrochlorides or hydrobromides, lactates, sulfates, citrates, tartrates, maleates, fumarates, oxalates, acetates, phosphates, methylsulfonates or p-toluenesulfonates.

[0055] Very particular preference is given to the hydrochlorides, the trifluoroacetates or the bistrifluoroacetates of the compounds according to the invention.

[0056] It is furthermore intended that a compound of the present invention includes isotope-labelled forms thereof. An isotope-labelled form of a compound of the present inventionis identical to this compound apart from the fact that one or more atoms of the compound have been replaced by an atom or atoms having an atomic mass or mass number which differs from the atomic mass or mass number of the atom which usually occurs naturally. Examples of isotopes which are readily commercially available and which can be incorporated into a compound of the present inventionby well-known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, for example ^{2}H, ^{3}H, ^{13}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F and ^{36}Cl, respectively. A compound of the present invention, a prodrug thereof or a pharmaceutically acceptable salt of either which contains one or more of the above-mentioned isotopes and/or other isotopes of other atoms is intended to be part of the present invention. An isotope-labelled compound of the present invention can be used in a number of beneficial ways. For example, an isotope-labelled compound of the present inventioninto which, for example, a radioisotope, such as ^{3}H or ^{14}C, has been incorporated is suitable for medicament and/or substrate tissue distribution assays. These radioisotopes, i.e. tritium (^{3}H) and carbon-14 (^{14}C), are particularly preferred owing to their simple preparation

and excellent detectability. Incorporation of heavier isotopes, for example deuterium (^2H), into a compound of the present inventionhas therapeutic advantages owing to the higher metabolic stability of this isotope-labelled compound. Higher metabolic stability translates directly into an increased in-vivo half-life or lower dosages, which under most circumstances would represent a preferred embodiment of the present invention. An isotope-labelled compound of the present inventioncan usually be prepared by carrying out the procedures disclosed in the synthesis schemes and the related description, in the example part and in the preparation part in the present text, replacing a non-isotope-labelled reactant with a readily available isotope-labelled reactant.

[0057] In order to manipulate the oxidative metabolism of the compound by way of the primary kinetic isotope effect, deuterium (^2H) can also be incorporated into a compound of the present invention. The primary kinetic isotope effect is a change in the rate of a chemical reaction that results from exchange of isotopic nuclei, which in turn is caused by the change in ground state energies necessary for covalent bond formation after this isotopic exchange. Exchange of a heavier isotope usually results in a lowering of the ground state energy for a chemical bond and thus causes a reduction in the rate in rate-limiting bond breakage. If the bond breakage occurs in or in the vicinity of a saddle-point region along the coordinate of a multi-product reaction, the product distribution ratios can be altered substantially. For explanation: if deuterium is bonded to a carbon atom in a non-exchangeable position, rate differences of k_M/k_D = 2-7 are typical. If this rate difference is successfully applied to a compound of the present inventionthat is susceptible to oxidation, the profile of this compound in vivo can thereby be drastically modified and result in improved pharmacokinetic properties.

[0058] When discovering and developing therapeutic agents, the person skilled in the art attempts to optimise pharmacokinetic parameters while retaining desirable in-vitro properties. It is reasonable to assume that many compounds with poor pharmacokinetic profiles are susceptible to oxidative metabolism. In-vitro liver microsomal assays currently available provide valuable information on the course of oxidative metabolism of this type, which in turn permits the rational design of deuterated compounds of the present invention with improved stability through resistance to such oxidative metabolism. Significant improvements in the pharmacokinetic profiles of the compounds of the present invention are thereby obtained and can be expressed quantitatively in terms of increases in the in-vivo half-life (T/2), concentration at maximum therapeutic effect (C_{max}), area under the dose response curve (AUC), and F; and in terms of reduced clearance, dose and costs of materials. The following is intended to illustrate the above: a compound of the present invention which has multiple potential sites of attack for oxidative metabolism, for example benzylic hydrogen atoms and hydrogen atoms bonded to a nitrogen atom, is prepared as a series of analogues in which various combinations of hydrogen atoms are replaced by deuterium atoms, so that some, most or all of these hydrogen atoms have been replaced by deuterium atoms. Half-life determinations enable favourable and accurate determination of the extent to which the improvement in resistance to oxidative metabolism has improved. In this way, it is determined that the half-life of the parent compound can be extended by up to 100% as the result of deuterium-hydrogen exchange of this type.

[0059] The replacement of hydrogen by deuterium in a compound of the present inventioncan also be used to achieve a favourable modification of the metabolite spectrum of the starting compound in order to diminish or eliminate undesired toxic metabolites. For example, if a toxic metabolite arises through oxidative carbon-hydrogen (C-H) bond cleavage, it can reasonably be assumed that the deuterated analogue will greatly diminish or eliminate production of the undesired metabolite, even if the particular oxidation is not a rate-determining step. Further information on the state of the art with respect to deuterium-hydrogen exchange is given, for example in Hanzlik et al., J. Org. Chem. 55, 3992-3997, 1990, Reider et al., J. Org. Chem. 52, 3326-3334, 1987, Foster, Adv. Drug Res. 14, 1-40, 1985, Gillette et al., Biochemistry 33(10), 2927-2937, 1994, and Jarman et al., Carcinogenesis 16(4), 683-688, 1993.

[0060] The invention also relates to mixtures of the compounds of the present invention according to the invention, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000. These are particularly preferably mixtures of two stereoisomeric compounds. However, preference is also given to mixtures of two or more compounds of the present invention.

[0061] In addition, the description relates to a process for the preparation of the compounds of the present invention, characterized in that

1. a) a compound of the formula II undergoes a reduction to give a compound of formula III, a compound of formula III is reacted with a compound of formula IV at elevated temperature to give a compound of formula V, a compound of formula V is converted to a compound of the formula VI employing the use of catalyst and base, a compound of formula VI is converted to a compound of the formula VII by bromination, a compound of the formula VII is converted to a compound of the formula VIII under essentially basic conditions and a compound of the formula VIII is reacted with a compound of the formula IX under standard amidation or carbamide formation conditions to give a compound of the formula I,





2. b) a compound of the formula V is reacted with a compound of the formula X under Suzuki-type reaction conditions to give a compound of the formula VI, a compound of formula VI is converted to a compound of the formula VII by bromination, a compound of formula VII is converted to a compound of the formula VIII under essentially basic conditions and a compound of the formula VIII is reacted with a compound of the formula IX under standard amidation or carbamide formation conditions to give a compound of the formula I,



3. c) a compound of the formula XII is iodinated to give a compound of the formula XIII, a compound of formula XIII is converted to a compound of the formula XIV by treatment with base and an electrophile, a compound of formula XIV is converted to a compound of the formula XV by reduction, a compound of formula XV is reacted with a compound of formula IV at elevated temperature to give a compound of the formula XVI, a

compound of formula XVI is converted under catalytic conditions to a compound of the formula XVII, a compound of the formula XVII is converted to a compound of the formula VIII under basic conditions and a compound of the formula VIII is reacted with a compound of the formula IX under standard amidation or carbamide formation conditions to give a compound of the formula I,



4. d) the base of a compound of the present invention is converted into one of its salts by treatment with an acid, or
5. e) an acid of a compound of the present invention is converted into one of its salts by treatment with a base.

[0062] It is also possible to carry out the reactions stepwise in each case and to modify the sequence of the linking reactions of the building blocks with adaptation of the protecting-group concept.

[0063] The starting materials or starting compounds are generally known. If they are novel, they can be prepared by methods known per se.

[0064] If desired, the starting materials can also be formed in situ by not isolating them from

the reaction mixture, but instead immediately converting them further into the compounds of the present invention.

[0065] The compounds of the present invention are preferably obtained by liberating them from their functional derivatives by solvolysis, in particular by hydrolysis, or by hydrogenolysis. Preferred starting materials for the solvolysis or hydrogenolysis are those which contain correspondingly protected amino, carboxyl and/or hydroxyl groups instead of one or more free amino, carboxyl and/or hydroxyl groups, preferably those which carry an amino-protecting group instead of an H atom which is connected to an N atom. Preference is furthermore given to starting materials which carry a hydroxyl-protecting group instead of the H atom of a hydroxyl group. Preference is also given to starting materials which carry a protected carboxyl group instead of a free carboxyl group. It is also possible for a plurality of identical or different protected amino, carboxyl and/or hydroxyl groups to be present in the molecule of the starting material. If the protecting groups present are different from one another, they can in many cases be cleaved off selectively.

[0066] The term "amino-protecting group" is generally known and relates to groups which are suitable for protecting (blocking) an amino group against chemical reactions, but which can easily be removed after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are, in particular, unsubstituted or substituted acyl groups, furthermore unsubstituted or substituted aryl (for example 2,4-dinitophenyl) or aralkyl groups (for example benzyl, 4-nitrobenzyl, triphenylmethyl). Since the amino-protecting groups are removed after the desired reaction or reaction sequence, their type and size is, in addition, not crucial, but preference is given to those having 1-20, in particular 1-8, C atoms. The term "acyl group" is to be understood in the broadest sense in connection with the present process. It encompasses acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids and, in particular, alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups. Examples of such acyl groups are alkanoyl, such as acteyl, propionyl, buturyl, aralkanoyl, such as phenylacetyl, aroyl, such as benzoyl or toluyl, aryoxyaklkanoyl, such as phenoxyacetyl, alkyoxycarbonyyl, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycaronyl, aralkoxycarbonyl. such as CBZ, 4-methoxybenzyloxycarbonyl or FMOC. Preferred acyl groups are CBZ, FMOC, benzyl and acetyl.

[0067] The term "acid-protecting group" or "carboxyl-protecting group" is likewise generally known and relates to groups which are suitable for protecting a -COOH group against chemical reactions, but which can easily be removed after the desired chemical reaction has been carried out elsewhere in the molecule. The use of esters instead of the free acids, for example of substituted and unsubstituted alkyl esters (such as methyl, ethyl, tert-butyl and substituted derivatives thereof), of substituted and unsubstituted benzyl esters or silyl esters, is typical. The type and size of the acid-protecting groups is not crucial, but preference is given to those having 1-20, in particular 1-10, C atoms.

[0068] The term "hydroxyl-protecting group" is likewise generally known and relates to groups which are suitable for protecting a hydroxyl group against chemical reactions, but which can

easily be removed after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the above-mentioned unsubstituted or substituted aryl, aralkyl or acyl groups, furthermore also alkyl groups. Their type and size of the hydroxyl-protecting groups is not crucial, but preference is given to those having 1-20, in particular 1-10, C atoms. Examples of hyrdoxyl-protecting groups are, inter alia, benzyl, p-nitrobenzoyl, p-toluenesulfonyl and acetyl, where benzyl and acetyl are preferred.

[0069] Further typical examples of amino-, acid- and hydroxyl-protecting groups are found, for example, in "Greene's Protective Groups in Organic Synthesis", fourth edition, Wiley-Interscience, 2007.

[0070] The functional derivatives of the compounds of the present invention to be used as starting materials can be prepared by known methods of amino-acid and peptide synthesis, as described, for example, in the said standard works and patent applications.

[0071] The compounds of the present invention are liberated from their functional derivatives, depending on the protecting group used, for example, with the aid of strong acids, advantageously using trifluoroacetic acid or perchloric acid, but also using other strong inorganic acids, such as hydrochloric acid or sulfuric acid, strong organic acids, such as trichloroacetic acid, or sulfonic acids, such as benzoyl- or p-toluenesulfonic acid. The presence of an additional inert solvent and/or a catalyst is possible but is not always necessary.

[0072] Depending on the respective synthetic route, the starting materials can optionally be reacted in the presence of an inert solvent.

[0073] Suitable inert solvents are, for example, heptane, hexane, petroleum ether, DMSO, benzene, toluene, xylene, trichloroethylene-, 1,2-dichloroethanecarbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether (preferably for substitution on the indole nitrogen), tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethy-l ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); nitriles, such as acetonitrile; esters, such as ethyl acetate, carboxylic acids or acid anhydrides, such as, for example, such as acetic acid or acetic anhydride, nitro compounds, such as nitromethane or nitrobenzene, optionally also mixtures of the said solvents with one another or mixtures with water.

[0074] The amount of solvent is not crucial; 10 g to 500 g of solvent can preferably be added per g of the compound of the present inventionto be reacted.

[0075] It may be advantageous to add an acid-binding agent, for example an alkali metal or alkaline-earth metal hydroxide, carbonate or bicarbonate or other alkali or alkaline-earth metal salts of weak acids, preferably a potassium, sodium or calcium salt, or to add an organic base, such as, for example, on triethylamine, dimethylamine, pyridine or quinoline, or an excess of

the amine component.

[0076] The resultant compounds according to the invention can be separated from the corresponding solution in which they are prepared (for example by centrifugation and washing) and can be stored in another composition after separation, or they can remain directly in the preparation solution. The resultant compounds according to the invention can also be taken up in desired solvents for the particular use.

[0077] The reaction duration depends on the reaction conditions selected. In general, the reaction duration is 0.5 hour to 10 days, preferably 1 to 24 hours. On use of a microwave, the reaction time can be reduced to values of 1 to 60 minutes.

[0078] The compounds of the present invention and also the starting materials for their preparation are, in addition, prepared by known methods, as described in the literature (for example in standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), for example under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants known per se, which are not described here in greater detail.

[0079] Conventional work-up steps, such as, for example, addition of water to the reaction mixture and extraction, enable the compounds to be obtained after removal of the solvent. It may be advantageous, for further purification of the product, to follow this with a distillation or crystallisation or to carry out a chromatographic purification.

[0080] An acid of the present inventioncan be converted into the associated addition salt using a base, for example by reaction of equivalent amounts of the acid and base in an inert solvent, such as ethanol, and inclusive evaporation. Suitable bases for this reaction are, in particular, those which give physiologically acceptable salts. Thus, the acid of the present inventioncan be converted into the corresponding metal salt, in particular alkali or alkaline-earth metal salt, using a base (for example sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate) or into the corresponding ammonium salt. Organic bases which give physiologically acceptable salts, such as, for example, ethanolamine, are also suitable for this reaction.

[0081] On the other hand, a base of the present inventioncan be converted into the associated acid-addition salt using an acid, for example by reaction of equivalent amounts of the base and acid in an inert solvent, such as ethanol, with subsequent evaporation. Suitable acids for this reaction are, in particular, those which give physiologically acceptable salts. Thus, it is possible to use inorganic acids, for example sulfuric acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic, mono- or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethanesulfonic acid,

ethanedisulfonic acid, 2-hydroxysulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenemom- and disulfonic acids or laurylsulfuric acid. Salts with physiologically unacceptable acids, for example picrates, can be used for the isolation and/or purification of the compounds of the present invention.

[0082] It has been found that the compounds of the present invention are well tolerated and have valuable pharmacological properties.

[0083] Since adenosine receptors, such as A_{2A} and A_{2B}, are shown to down-regulate the immune response during inflammation and protect tissues from immune damage, inhibition of signaling through adenosine receptors can be used to intensify and prolong the immune response.

[0084] Methods are provided herein to increase an immune response. In one example, the method increases desirable and targeted tissue damage, such as damage of a tumor, for example cancer. Disclosed herein are methods of inhibiting one or more processes conducive to the production of extracellular adenosine and adenosine-triggered signaling through adenosine receptors. For example, enhancement of an immune response, local tissue inflammation, and targeted tissue destruction is accomplished by: inhibiting or reducing the adenosine-producing local tissue hypoxia; by degrading (or rendering inactive) accumulated extracellular adenosine; by preventing or decreasing expression of adenosine receptors on immune cells; and or by inhibiting/antagonizing signaling by adenosine ligands through adenosine receptors. The results disclosed herein demonstrate that by in vivo administration of agents that disrupt the "hypoxia -> adenosine accumulation -> immunosuppressive adenosine receptor signaling to immune cells" pathway in subjects suffering from various diseases (e.g. cancer and sepsis) can result in in vivo treatment of tumors or improved immunization.

[0085] In one example, the method includes administering one or more inhibitors of extracellular adenosine and or adenosine receptor inhibitors, such as an adenosine receptor antagonist. To increase the efficacy of a vaccine, one or more adenosine receptor inhibitors and/or inhibitors of extracellular adenosine can be administered in conjunction with the vaccine. In one example, one or more adenosine receptor inhibitors or inhibitors of extracellular adenosine are administered to increase an immune response/inflammation. In another example, a method is provided to achieve targeted tissue damage, such as for tumor destruction.

[0086] The invention therefore furthermore relates to the use of compounds according to the invention for the preparation of a medicament for the treatment and/or prophylaxis of diseases which are caused, promoted and/or propagated by adenosine or other A_{2A} and/or A_{2B} receptor agonists.

[0087] The invention thus also relates, in particular, to a medicament comprising at least one compound according to the invention and/or one of its physiologically acceptable salts, solvates, and stereoisomers, including mixtures thereof in all ratios, for use in the treatment

and/or prophylaxis of physiological and/or pathophysiological states.

[0088] Particular preference is given, in particular, to physiological and/or pathophysiological states which are connected to adenosine A_{2A} and/or A_{2B} receptors.

[0089] Physiological and/or pathophysiological states are taken to mean physiological and/or pathophysiological states which are medically relevant, such as, for example, diseases or illnesses and medical disorders, complaints, symptoms or complications and the like, in particular diseases.

[0090] The invention furthermore relates to a medicament comprising at least one compound according to the invention and/or one of its physiologically acceptable salts, solvates, and stereoisomers, including mixtures thereof in all ratios, for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states selected from the group consisting of hyperproliferative and infectious diseases and disorders.

[0091] The invention further relates to a medicament comprising at least one compound according to the invention and/or one of its physiologically acceptable salts, solvates, and stereoisomers, including mixtures thereof in all ratios, for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states selected from the group consisting of hyperproliferative and infectious diseases and disorders, wherein the hyperproliferative disease or disorder is cancer.

[0092] The invention thus particularly preferably relates to a medicament comprising at least one compound according to the invention and/or one of its physiologically acceptable salts, solvates, and stereoisomers, including mixtures thereof in all ratios, wherein the cancer is selected from the group consisting of acute and chronic lymphocytic leukemia, acute granulocytic leukemia, adrenal cortex cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, cervical hyperplasia, cervical cancer, chorio cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, colon cancer, endometrial ccancer, esophageal cancer, essential thrombocytosis, genitourinary carcinoma, glioma, glioblastoma, hairv cell leukemia. head and neck carcinoma. Hodokin's disease. Kaoosi's sarcoma, lung carcinoma, lymphoma, malignant carcinoid carcinoma, malignant hypercalcemia, malignant melanoma, malignant pancreatic insulinoma, medullary thyroid carcinoma, melanoma, multiple myeloma, mycosis fungoides, myeloid and lymphocytic leukemia, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, osteogenic sarcoma, ovarian carcinoma, pancreatic carcinoma, polycythemia vera, primary brain carcinoma, primary macroglobulinemia, prostatic cancer, renal cell cancer, rhabdomyosarcoma, skin cancer, small-cell lung cancer, soft-tissue sarcoma, squamous cell cancer, stomach cancer, testicular cancer, thyroid cancer and Wilms' tumor.

[0093] The invention further preferably relates to a medicament comprising at least one compound according to the invention and/or one of its physiologically acceptable salts, solvates, and stereoisomers, including mixtures thereof in all ratios, for use in the treatment

and/or prophylaxis of physiological and/or pathophysiological states selected from the group consisting of hyperproliferative and infectious diseases and disorders, wherein the hyperproliferative disease or disorder is selected from the group consisting of age-related macular degeneration, Crohn's disease, cirrhosis, chronic inflammatory-related disorders, proliferative diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, granulomatosis, immune hyperproliferation associated with organ or tissue transplantation and an immunoproliferative disease or disorder selected from the group comnsisting of inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE), vascular hyperproliferation secondary to retinal hypoxia and vasculitis.

[0094] The invention further preferably relates to a medicament comprising at least one compound according to the invention and/or one of its physiologically acceptable salts, solvates, and stereoisomers, including mixtures thereof in all ratios, for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states selected from the group consisting of hyperproliferative and infectious diseases and disorders, wherein the infectious disease or disorder is selected from the group consisting of

1. a) virally induced infectious diseases which are caused by retroviruses, hepadnaviruses, herpesviruses, flaviviridae and/or adenoviruses wherein the retroviruses are selected from lentiviruses or oncoretroviruses, wherein the lentivirus is selected from the group consisting of HIV-1, HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV and EIAV and the oncoretrovirus is selected from the group consisting of HTLV-I, HTLV-II and BLV, the hepadnavirus is selected from the group consisting of HBV, GSHV and WHV, the herpesivirus is selected from the group from the group consisting of HSV I, HSV II, EBV, VZV, HCMV or HHV 8 and the flaviviridae is selected from the group consisting of HCV, West nile and Yellow Fever,
2. b) bacterial infectious diseases which are caused by Gram-positive bacteria wherein the Gram-positive bacteria are selected from the group consisting of methicillin-susceptible and methicillin-resistant staphylococci (including Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, and coagulase-negative staphylococci), glycopeptides-intermediate susceptible Staphylococcus aureus (GISA), penicillin-susceptible and penicillin-resistant streptococci (including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sanguis and Streptococci Group C (GCS), Streptococci Group G (GGS) and viridans streptococci), enterococci (including vancomycinsusceptible and vancomycin-resistant strains such as Enterococcus faecalis and Enterococcus faecium), Clostridium difficile, listeria monocytogenes, Corynebacterium jeikeium, Chlamydia spp (including C. pneumoniae) and Mycobacterium tuberculosis,
3. c) bacterial infectious diseases which are caused by Gram-negative bacteria wherein the Gram-negative bacteria are selected from the group consisting of the Genus Enterobacteriacae, including Escherichia spp. (including Escherichia coli), Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia spp., Proteus spp., Providencia spp., Salmonella spp., Shigella spp., the genus Pseudomonas (including P. aeruginosa), Moraxella spp. (including M. catarrhalis), Haemophilus spp. and Neisseria spp.,

4. d) infectious diseases induced by intracellular active parasites selected from the group consisting of phylum Apicomplexa, or Sarcomastigophora (including Trypanosoma, Plasmodia, Leishmania, Babesia or Theileria), Cryptosporidia, Sacrocystida, Amoebia, Coccidia and Trichomonadia.

[0095] It is intended that the medicaments disclosed above include a corresponding use of the compounds according to the invention for the preparation of a medicament for the treatment and/or prophylaxis of the above physiological and/or pathophysiological states.

[0096] The compounds according to the invention preferably exhibit an advantageous biological activity which can easily be demonstrated in enzyme assays and animal experiments, as described in the examples. In such enzyme-based assays, the compounds according to the invention preferably exhibit and cause an inhibiting effect, which is usually documented by IC_{50} values in a suitable range, preferably in the micromolar range and more preferably in the nanomolar range.

[0097] The compounds according to the invention can be administered to humans or animals, in particular mammals, such as apes, dogs, cats, rats or mice, and can be used in the therapeutic treatment of the human or animal body and in the combating of the above-mentioned diseases. They can furthermore be used as diagnostic agents or as reagents.

[0098] Furthermore, compounds according to the invention can be used for the isolation and investigation of the activity or expression of adenosine A_{2A} and/or A_{2B} receptors. In addition, they are particularly suitable for use in diagnostic methods for diseases in connection with disturbed adenosine A_{2A} and/or A_{2B} receptor activity. The invention therefore furthermore relates to the use of the compounds according to the invention for the isolation and investigation of the activity or expression of adenosine A_{2A} and/or A_{2B} receptors or as binders and inhibitors of adenosine A_{2A} and/or A_{2B} receptors.

[0099] For diagnostic purposes, the compounds according to the invention can, for example, be radioactively labelled. Examples of radioactive labels are ^{3}H, ^{14}C, ^{231}I and ^{125}I. A preferred labelling method is the iodogen method (Fraker et al., 1978). In addition, the compounds according to the invention can be labelled by enzymes, fluorophores and chemophores. Examples of enzymes are alkaline phosphatase, β-galactosidase and glucose oxidase, an example of a fluorophore is fluorescein, an example of a chemophore is luminol, and automated detection systems, for example for fluorescent colorations. are described, for example, in US 4.125.828 and US 4,207,554.

[0100] The compounds of the present invention can be used for the preparation of pharmaceutical preparations, in particular by non-chemical methods. In this case, they are brought into a suitable dosage form together with at least one solid, liquid and/or semi-liquid excipient or adjuvant and optionally in combination with one or more further active

compound(s).

[0101] The invention therefore furthermore relates to pharmaceutical preparations comprising at least one compound of the present inventionand/or physiologically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios. In particular, the invention also relates to pharmaceutical preparations which comprise further excipients and/or adjuvants, and also to pharmaceutical preparations which comprise at least one further medicament active compound.

[0102] In particular, the invention also relates to a process for the preparation of a pharmaceutical preparation, characterised in that a compound of the present inventionand/or one of its physiologically acceptable salts, solvates and stereoisomers, including mixtures thereof in all ratios, is brought into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant and optionally with a further medicament active compound.

[0103] The pharmaceutical preparations according to the invention can be used as medicaments in human or veterinary medicine. The patient or host can belong to any mammal species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cattle, dogs, cats, etc. Animal models are of interest for experimental investigations, where they provide a model for the treatment of a human disease.

[0104] Suitable carrier substances are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical administration and do not react with the novel compounds, for example water, vegetable oils (such as sunflower oil or cod-liver oil), benzyl alcohols, polyethylene glycols, gelatine, carbohydrates, such as lactose or starch, magnesium stearate, talc, lanolin or Vaseline. Owing to his expert knowledge, the person skilled in the art is familiar with which adjuvants are suitable for the desired medicament formulation. Besides solvents, for example water, physiological saline solution or alcohols, such as, for example, ethanol, propanol or glycerol, sugar solutions, such as glucose or mannitol solutions, or a mixture of the said solvents, gel formers, tablet assistants and other active-ingredient carriers, it is also possible to use, for example, lubricants, stabilisers and/or wetting agents, emulsifiers, salts for influencing the osmotic pressure, antioxidants, dispersants, antifoams, buffer substances, flavours and/or aromas or flavour correctants, preservatives, solubilisers or dyes. If desired, preparations or medicaments according to the invention may comprise one or more further active compounds, for example one or more vitamins.

[0105] If desired, preparations or medicaments according to the invention may comprise one or more further active compounds and/or one or more action enhancers (adjuvants).

[0106] The terms "pharmaceutical formulation" and "pharmaceutical preparation" are used as synonyms for the purposes of the present invention.

[0107] As used here, "pharmaceutically tolerated" relates to medicaments, precipitation reagents, excipients, adjuvants, stabilisers, solvents and other agents which facilitate the administration of the pharmaceutical preparations obtained therefrom to a mammal without

undesired physiological side effects, such as, for example, nausea, dizziness, digestion problems or the like.

[0108] In pharmaceutical preparations for parenteral administration, there is a requirement for isotonicity, euhydration and tolerability and safety of the formulation (low toxicity), of the adjuvants employed and of the primary packaging. Surprisingly, the compounds according to the invention preferably have the advantage that direct use is possible and further purification steps for the removal of toxicologically unacceptable agents, such as, for example, high concentrations of organic solvents or other toxicologically unacceptable adjuvants, are thus unnecessary before use of the compounds according to the invention in pharmaceutical formulations.

[0109] The invention particularly preferably also relates to pharmaceutical preparations comprising at least one compound according to the invention in precipitated non-crystalline, precipitated crystalline or in dissolved or suspended form, and optionally excipients and/or adjuvants and/or further pharmaceutical active compounds.

[0110] The compounds according to the invention preferably enable the preparation of highly concentrated formulations without unfavourable, undesired aggregation of the compounds according to the invention occurring. Thus, ready-to-use solutions having a high active-ingredient content can be prepared with the aid of compounds according to the invention with aqueous solvents or in aqueous media.

[0111] The compounds and/or physiologically acceptable salts and solvates thereof can also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations.

[0112] Aqueous preparations can be prepared by dissolving or suspending compounds according to the invention in an aqueous solution and optionally adding adjuvants. To this end, defined volumes of stock solutions comprising the said further adjuvants in defined concentration are advantageously added to a solution or suspension having a defined concentration of compounds according to the invention, and the mixture is optionally diluted with water to the pre-calculated concentration. Alternatively, the adjuvants can be added in solid form. The amounts of stock solutions and/or water which are necessary in each case can subsequently be added to the aqueous solution or suspension obtained. Compounds according to the invention can also advantageously be dissolved or suspended directly in a solution comprising all further adjuvants.

[0113] The solutions or suspensions comprising compounds according to the invention and having a pH of 4 to 10, preferably having a pH of 5 to 9, and an osmolality of 250 to 350 mOsmol/kg can advantageously be prepared. The pharmaceutical preparation can thus be administered directly substantially without pain intravenously, intra-arterially, intra-articularly, subcutaneously or percutaneously. In addition, the preparation may also be added to infusion solutions, such as, for example, glucose solution, isotonic saline solution or Ringer's solution,

which may also contain further active compounds, thus also enabling relatively large amounts of active compound to be administered.

[0114] Pharmaceutical preparations according to the invention may also comprise mixtures of a plurality of compounds according to the invention.

[0115] The preparations according to the invention are physiologically well tolerated, easy to prepare, can be dispensed precisely and are preferably stable with respect to assay, decomposition products and aggregates throughout storage and transport and during multiple freezing and thawing processes. They can preferably be stored in a stable manner over a period of at least three months to two years at refrigerator temperature (2-8°C) and at room temperature (23-27°C) and 60% relative atmospheric humidity (R.H.).

[0116] For example, the compounds according to the invention can be stored in a stable manner by drying and when necessary converted into a ready-to-use pharmaceutical preparation by dissolution or suspension. Possible drying methods are, for example, without being restricted to these examples, nitrogen-gas drying, vacuum-oven drying, lyophilisation, washing with organic solvents and subsequent air drying, liquid-bed drying, fluidised-bed drying, spray drying, roller drying, layer drying, air drying at room temperature and further methods.

[0117] The term "effective amount" denotes the amount of a medicament or of a pharmaceutical active compound which causes in a tissue, system, animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician.

[0118] In addition, the term "therapeutically effective amount" denotes an amount which, compared with a corresponding subject who has not received this amount, has the following consequence: improved treatment, healing, prevention or elimination of a disease, syndrome, disease state, complaint, disorder or prevention of side effects or also a reduction in the progress of a disease, complaint or disorder. The term "therapeutically effective amount" also encompasses the amounts which are effective for increasing normal physiological function.

[0119] On use of preparations or medicaments according to the invention, the compounds according to the invention and/or physiologically acceptable salts and solvates thereof are generally used analogously to known, commercially available preparations or preparations, preferably in dosages of between 0.1 and 500 mg, in particular 5 and 300 mg, per use unit. The daily dose is preferably between 0.001 and 250 mg/kg, in particular 0.01 and 100 mg/kg, of body weight. The preparation can be administered one or more times per day, for example two, three or four times per day. However, the individual dose for a patient depends on a large number of individual factors, such as, for example, on the efficacy of the particular compound used, on the age, body weight, general state of health, sex, nutrition, on the time and method of administration, on the excretion rate, on the combination with other medicaments and on the severity and duration of the particular disease.

[0120] A measure of the uptake of a medicament active compound in an organism is its bioavailability. If the medicament active compound is delivered to the organism intravenously in the form of an injection solution, its absolute bioavailability, i.e. the proportion of the pharmaceutical which reaches the systemic blood, i.e. the major circulation, in unchanged form, is 100%. In the case of oral administration of a therapeutic active compound, the active compound is generally in the form of a solid in the formulation and must therefore first be dissolved in order that it is able to overcome the entry barriers, for example the gastrointestinal tract, the oral mucous membrane, nasal membranes or the skin, in particular the stratum corneum, or can be absorbed by the body. Data on the pharmacokinetics, i.e. on the bioavailability, can be obtained analogously to the method of J. Shaffer et al., J. Pharm. Sciences, 88 (1999), 313-318.

[0121] Furthermore, medicaments of this type can be prepared by means of one of the processes generally known in the pharmaceutical art.

[0122] Medicaments can be adapted for administration via any desired suitable route, for example by the oral (including buccal or sublingual), rectal, pulmonary, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal and in particular intra-articular) routes. Medicaments of this type can be prepared by means of all processes known in the pharmaceutical art by, for example, combining the active compound with the excipient(s) or adjuvant(s).

[0123] Parenteral administration is preferably suitable for administration of the medicaments according to the invention. In the case of parenteral administration, intra-articular administration is particularly preferred.

[0124] The invention thus preferably also relates to the use of a pharmaceutical preparation according to the invention for intra-articular administration in the treatment and/or prophylaxis of physiological and/or pathophysiological states selected from the group consisting of osteoarthritis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.

[0125] Intra-articular administration has the advantage that the compound according to the invention can be administered directly into the synovial fluid in the vicinity of the joint cartilage and is also able to diffuse from there into the cartilage tissue. Pharmaceutical preparations according to the invention can thus also be injected directly into the joint gap and thus develop their action directly at the site of action as intended. The compounds according to the invention are also suitable for the preparation of medicaments to be administered parenterally having slow, sustained and/or controlled release of active compound. They are thus also suitable for the preparation of delayed-release formulations, which are advantageous for the patient since administration is only necessary at relatively large time intervals.

[0126] The medicaments adapted to parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood or synovial fluid of the

recipient to be treated; as well as aqueous and non-aqueous sterile suspensions, which can comprise suspension media and thickeners. The formulations can be delivered in single-dose or multi-dose containers, for example sealed ampoules and vials, and stored in the freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary. Injection solutions and suspensions prepared in accordance with the formulation can be prepared from sterile powders, granules and tablets.

[0127] The compounds according to the invention can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.

[0128] The compounds according to the invention can also be coupled to soluble polymers as targeted medicament excipients. Such polymers can encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds according to the invention can furthermore be coupled to a class of biodegradable polymers which are suitable for achieving slow release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, polylactic-co-glycolic acid, polymers, such as conjugates between dextran and methacrylates, polyphosphoesters, various polysaccharides and polyamines and poly-ε-caprolactone, albumin, chitosan, collagen or modified gelatine and crosslinked or amphipathic block copolymers of hydrogels.

[0129] Suitable for enteral administration (oral or rectal) are, in particular, tablets, dragees, capsules, syrups, juices, drops or suppositories, and suitable for topical use are ointments, creams, pastes, lotions, gels, sprays, foams, aerosols, solutions (for example solutions in alcohols, such as ethanol or isopropanol, acetonitrile, DMF, dimethylacetamide, 1,2-propanediol or mixtures thereof with one another and/or with water) or powders. Also particularly suitable for topical uses are liposomal preparations.

[0130] In the case of formulation to give an ointment, the active compound can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active compound can be formulated to a cream with an oil-in-water cream base or a water-in-oil base.

[0131] Medicaments adapted to transdermal administration can be delivered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active compound can be supplied from the plaster by means of iontophoresis, as described in general terms in Pharmaceutical Research, 3 (6), 318 (1986).

[0132] It goes without saying that, besides the constituents particularly mentioned above, the medicaments according to the invention may also comprise other agents usual in the art with respect to the particular type of pharmaceutical formulation.

[0133] The invention also relates to a set (kit) consisting of separate packs of

1. a) an effective amount of a compound of the present inventionand/or physiologically acceptable salts, solvates, and stereoisomers thereof, including mixtures thereof in all ratios, and
2. b) an effective amount of a further medicament active compound.

[0134] The set comprises suitable containers, such as boxes or cartons, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules each containing an effective amount of a compound of the present inventionand/or pharmaceutically acceptable salts, solvates, and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active compound in dissolved or lyophilised form.

[0135] Furthermore, the medicaments according to the invention can be used in order to provide additive or synergistic effects in certain known therapies and/or can be used in order to restore the efficacy of certain existing therapies.

[0136] Besides the compounds according to the invention, the pharmaceutical preparations according to the invention may also comprise further medicament active compounds, for example for use in the treatment of cancer, other anti-tumor medicaments. For the treatment of the other diseases mentioned, the pharmaceutical preparations according to the invention may also, besides the compounds according to the invention, comprise further medicament active compounds which are known to the person skilled in the art in the treatment thereof. In one principal embodiment, methods are provided for enhancing an immune response in a host in need thereof. The immune response can be enhanced by reducing T cell tolerance, including by increasing IFN-γ release, by decreasing regulatory T cell production or activation, or by increasing antigen-specific memory T cell production in a host. In one embodiment, the method comprises administering a compound of the present invention to a host in combination or alternation with an antibody. In particular subembodiments, the antibody is a therapeutic antibody. In one particular embodiment, a method of enhancing efficacy of passive antibody therapy is provided comprising administering a compound of the present invention in combination or alternation with one or more passive antibodies. This method can enhance the efficacy of antibody therapy for treatment of abnormal cell proliferative disorders such as cancer, or can enhance the efficacy of therapy in the treatment or prevention of infectious diseases. The compound of the present invention can be administered in combination or alternation with antibodies such as rituximab, herceptin or erbitux, for example.

[0137] In another principal embodiment, a method of treating or preventing abnormal cell proliferation is provided comprising administering a compound of the present invention to a host in need thereof substantially in the absence of another anti-cancer agent.

[0138] Methods of treatment described herein do however not form part of the invention.

[0139] In another principal embodiment, a method of treating or preventing abnormal cell proliferation in a host in need thereof is provided, comprising administering a first a compound of the present invention substantially in combination with a first anti-cancer agent to the host and subsequently administering a second A_{2A} and/or A_{2B} receptor antagonist. In one subembodiment, the second antagonist is administered substantially in the absence of another anti-cancer agent. In another principal embodiment, a method of treating or preventing abnormal cell proliferation in a host in need thereof is provided, comprising administering a compound of the present invention substantially in combination with a first anti-cancer agent to the host and subsequently administering a second anti-cancer agent in the absence of the antagonist.

[0140] Thus, the cancer treatment disclosed here can be carried out as therapy with a compound of the present invention or in combination with an operation, irradiation or chemotherapy. Chemotherapy of this type can include the use of one or more active compounds of the following categories of antitumour active compounds:

1. (i) antiproliferative/antineoplastic/DNA-damaging active compounds and combinations thereof, as used in medical oncology, such as alkylating active compounds (for example cis-platin, parboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines, such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin) ; antimitotic active compounds (for example vinca alkaloids, such as vincristine, vinblastine, vindesine and vinorelbine, and taxoids, such as taxol and taxotere) ; topoisomerase inhibitors (for example epipodophyllotoxins, such as etoposide and teniposide, amsacrine, topotecan, irinotecan and camptothecin) and celldifferentiating active compounds (for example all-trans-retinoic acid, 13-cis-retinoic acid and fenretinide);
2. (ii) cytostatic active compounds, such as anti-oestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor regulators (for example fulvestrant), anti-androgens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progesterones (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5α-reductase, such as finasteride;
3. (iii) active compounds which inhibit cancer invasion including for example metalloproteinase inhibitors, like marimastat, and inhibitors of urokinase plasminogen activator receptor function;
4. (iv) inhibitors of growth factor function, for example growth factor antibodies, growth factor receptor antibodies, for example the anti-erbb2 antibody trastuzumab [Herceptin™] and the anti-erbbl antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors, such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6- (3-morpholinopropoxy)

quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033), for example inhibitors of the platelet-derived growth factor family and, for example, inhibitors of the hepatocyte growth factor family;

5. (v) anti-angiogenic active compounds, such as bevacizumab, angiostatin, endostatin, linomide, batimastat, captopril, cartilage derived inhibitor, genistein, interleukin 12, lavendustin, medroxypregesterone acetate, recombinant human platelet factor 4, tecogalan, thrombospondin, TNP-470, anti-VEGF monoclonal antibody, soluble VEGF-receptor chimaeric protein, anti-VEGF receptor antibodies, anti-PDGF receptors, inhibitors of integrins, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, antisense oligonucleotides, antisense oligodexoynucleotides, siRNAs, anti-VEGF aptamers, pigment epithelium derived factor and compounds which have been published in the international patent applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354);
6. (vi) vessel-destroying agents, such as combretastatin A4 and compounds which have been published in the international patent applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;
7. (vii) antisense therapies, for example those directed to the targets mentioned above, such as ISIS 2503, an anti-Ras antisense;
8. (viii) gene therapy approaches, including, for example, approaches for replacement of abnormal, modified genes, such as abnormal p53 or abnormal BRCA1 or BRCA2, GDEPT approaches (gene-directed enzyme pro-drug therapy), such as those which use cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme, and approaches which increase the tolerance of a patient to chemotherapy or radiotherapy, such as multi-drug resistance therapy; and
9. (ix) immunotherapy approaches, including, for example, ex-vivo and in-vivo approaches for increasing the immunogenicity of tumour cells of a patient, such as transfection with cytokines, such as interleukin 2, interleukin 4 or granulocyte macrophage colony stimulating factor, approaches for decreasing T-cell anergy, approaches using transfected immune cells, such as cytokine-transfected dendritic cells, approaches for use of cytokine-transfected tumour cells and approaches for use of anti-idiotypic antibodies
10. (x) chemotherapeutic agents including foor example abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anastrozole, arsenic trioxide, asparaginase, BCG live, bevaceizumab, bexarotene, bleomycin, bortezomib, busulfan, calusterone, camptothecin, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cinacalcet, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, daunorubicin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone, epirubicin, epoetin alfa, estramustine, etoposide, exemestane, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant and gemcitabine.

[0141] The medicaments from table 1 can preferably, but not exclusively, be combined with the compounds of the present invention.

Table 1		
Alkylating active compounds	Cyclophosphamide	Lomustine
	Busulfan	Procarbazine
	Ifosfamide	Altretamine
	Melphalan	Estramustine phosphate
	Hexamethylmelamine	Mechloroethamine
	Thiotepa	Streptozocin
	chloroambucil	Temozolomide
	Dacarbazine	Semustine
	Carmustine	
Platinum active compounds	Cisplatin	Carboplatin
	Oxaliplatin	ZD-0473 (AnorMED)
	Spiroplatin	Lobaplatin (Aetema)
	Carboxyphthalatoplatinum	Satraplatin (Johnson Matthey)
	Tetraplatin	
	Ormiplatin	BBR-3464
	Iproplatin	(Hoffrnann-La Roche)
		SM-11355 (Sumitomo)
		AP-5280 (Access)
Antimetabolites	Azacytidine	Tomudex
	Gemcitabine	Trimetrexate
	Capecitabine	Deoxycoformycin
	5-Fluorouracil	Fludarabine
	Floxuridine	Pentostatin
	2-Chlorodesoxyadenosine	Raltitrexed
	6-Mercaptopurine	Hydroxyurea
	6-Thioguanine	Decitabine (SuperGen)
	Cytarabine	Clofarabine (Bioenvision)
	2-Fluorodesoxycytidine	Irofulven (MGI Pharrna)
	Methotrexate	DMDC (Hoffmann-La Roche)
	I datrexate	Ethynylcytidine (Taiho)

Table 1		
Topoisomerase inhibitors	Amsacrine	Rubitecan (SuperGen)
	Epirubicin	Exatecan mesylate (Daiichi)
	Etoposide	Quinamed (ChemGenex)
	Teniposide or mitoxantrone	Gimatecan (Sigma- Tau)
	Irinotecan (CPT-11)	Diflomotecan (Beaufour-Ipsen)
	7-ethyl-10-hydroxycamptothecin	TAS-103 (Taiho)
	Topotecan	Elsamitrucin (Spectrum)
	Dexrazoxanet (TopoTarget)	J-107088 (Merck & Co)
	Pixantrone (Novuspharrna)	BNP-1350 (BioNumerik)
	Rebeccamycin analogue (Exelixis)	CKD-602 (Chong Kun Dang)
	BBR-3576 (Novuspharrna)	KW-2170 (Kyowa Hakko)
Antitumour antibiotics	Dactinomycin (Actinomycin D)	Amonafide
		Azonafide
	Doxorubicin (Adriamycin)	Anthrapyrazole
	Deoxyrubicin	Oxantrazole
	Valrubicin	Losoxantrone
	Daunorubicin (Daunomycin)	Bleomycin sulfate (Blenoxan)
	Epirubicin	Bleomycinic acid
	Therarubicin	Bleomycin A
	Idarubicin	Bleomycin B
	Rubidazon	Mitomycin C
	Plicamycinp	MEN-10755 (Menarini)
	Porfiromycin	GPX-100 (Gem
	Cyanomorpholinodoxorubicin	Pharmaceuticals)
	Mitoxantron (Novantron)	
Antimitotic active compounds	Paclitaxel	SB 408075
	Docetaxel	(GlaxoSmithKline)
	Colchicine	E7010 (Abbott)

Table 1		
	Vinblastine	PG-TXL (Cell Therapeutics)
	Vincristine	IDN 5109 (Bayer)
	Vinorelbine	A 105972 (Abbott)
	Vindesine	A 204197 (Abbott)
	Dolastatin 10 (NCI)	LU 223651 (BASF)
	Rhizoxin (Fujisawa)	D 24851 (ASTA Medica)
	Mivobulin (Warner-Lambert)	ER-86526 (Eisai)
	Cemadotin (BASF)	Combretastatin A4 (BMS)
	RPR 109881A (Aventis)	Isohomohalichondrin-B (PharmaMar)
	TXD 258 (Aventis)	
	Epothilone B (Novartis)	ZD 6126 (AstraZeneca)
	T 900607 (Tularik)	PEG-Paclitaxel (Enzon)
	T 138067 (Tularik)	AZ10992 (Asahi)
	Cryptophycin 52 (Eli Lilly)	!DN-5109 (Indena)
	Vinflunine (Fabre)	AVLB (Prescient
	Auristatin PE (Teikoku Hormone)	NeuroPharma)
		Azaepothilon B (BMS)
	BMS 247550 (BMS)	BNP- 7787 (BioNumerik)
	BMS 184476 (BMS)	CA-4-prodrug (OXiGENE)
	BMS 188797 (BMS)	Dolastatin-10 (NrH)
	Taxoprexin (Protarga)	CA-4 (OXiGENE)
Aromatase inhibitors	Aminoglutethimide	Exemestan
	Letrozole	Atamestan (BioMedicines)
	Anastrazole	YM-511 (Yamanouchi)
	Formestan	
Thymidylate Synthase inhibitors	Pemetrexed (Eli Lilly)	Nolatrexed (Eximias)
	ZD-9331 (BTG)	CoFactor™ (BioKeys)
DNA antagonists	Trabectedin (PharmaMar)	Mafosfamide (Baxter

Table 1		
	Glufosfamide (Baxter International)	International)
	Albumin + 32P	Apaziquone (Spectrum Pharmaceuticals)
	(isotope solutions)	O6-benzylguanine (Paligent)
	Thymectacin (NewBiotics)	
	Edotreotid (Novartis)	
Farnesyl transferase inhibitors	Arglabin (NuOncology Labs)	Tipifarnib (Johnson & Johnson)
	Lonafarnib (Schering-Plough)	
	BAY-43-9006 (Bayer)	Perillyl alcohol (DOR BioPharma)
Pump inhibitors	CBT-1 (CBA Pharma)	Zosuquidar trihydrochloride (Eli Lilly)
	Tariquidar (Xenova)	
	MS-209 (Schering AG)	Biricodar dicitrate (Vertex)
Histone acetyl transferase inhibitors	Tacedinaline (Pfizer)	Pivaloyloxymethyl butyrate (Titan)
	SAHA (Aton Pharma)	
	MS-275 (Schering AG)	Depsipeptide (Fujisawa)
Metalloproteinase inhibitors	Neovastat (Aeterna Laboratories)	CMT -3 (CollaGenex)
		BMS-275291 (Celltech)
Ribonucleoside reductase	Marimastat (British Biotech)	Tezacitabine (Aventis)
	Gallium maltolate (Titan)	Didox (Molecules for Health)
inhibitors	Triapin (Vion)	
TNF-alpha agonists / antagonists	Virulizin (Lorus Therapeutics)	Revimid (Celgene)
	CDC-394 (Celgene)	
Endothelin-A receptor antagonists	Atrasentan (Abbot)	YM-598 (Yamanouchi)
	ZD-4054 (AstraZeneca)	
Retinoic acid receptor agonists	Fenretinide (Johnson & Johnson)	Alitretinoin (Ligand)

Table 1		
	LGD-1550 (ligand)	
Immunomodulators	Interferon	Dexosome therapy (Anosys)
	Oncophage (Antigenics)	Pentrix (Australian Cancer Technology)
	GMK (Progenics)	
	Adenocarcinoma vaccine	JSF-154 (Tragen)
	(Biomira)	Cancer vaccine (Intercell)
	CTP-37 (AVI BioPharma)	Norelin (Biostar)
	JRX-2 (Immuno-Rx)	BLP-25 (Biomira)
	PEP-005 (Peplin Biotech)	MGV (Progenies)
	Synchrovax vaccines (CTL	!3-Alethin (Dovetail)
	Immuno)	CLL-Thera (Vasogen)
	Melanoma vaccines (CTL Immuno)	
	p21-RAS vaccine (GemVax)	
Hormonal and antihormonal active compounds	Oestrogens	Prednisone
	Conjugated oestrogens	Methylprednisolone
	Ethynyloestradiol	Prednisolone
	Chlorotrianisene	Aminoglutethimide
	Idenestrol	Leuprolide
	Hydroxyprogesterone	Goserelin
	caproate	Leuporelin
	Medroxyprogesterone	Bicalutamide
	Testosterone	Flutamide
	Testosterone propionate	Octreotide
	Fluoxymesterone	Nilutamide
	Methyltestosterone	Mitotan
	Diethylstilbestrol	P-04 (Novogen)
	Megestrol	2-Methoxyoestradiol (En_-
	Tamoxifen	treMed)
	Toremofin	Arzoxifen (Eli Lilly)
	Dexamethasone	
Photodynamic active	Talaporfin (Light Sciences)	Pd

Table 1		
compounds	Theralux (Theratechnologies)	bacteriopheophorbide (Yeda)
	Motexafin-Gadolinium	Lutetium texaphyrin
	(Pharmacyclics)	(Pharmacyclics)
		Hypericin
Tyrosine kinase inhibitors	Imatinib (Novartis)	Kahalide F (PharmaMar)
	Leflunomide(Sugen/Pharmacia	CEP- 701 (Cephalon)
	ZDI839 (AstraZeneca)	CEP-751 (Cephalon)
	Erlotinib (Oncogene Science)	MLN518 (Millenium)
	Canertjnib (Pfizer)	PKC412 (Novartis)
	Squalamine (Genaera)	Phenoxodiol O
	SU5416 (Pharmacia)	Trastuzumab (Genentech)
	SU6668 (Pharmacia)	C225 (ImClone)
	ZD4190 (AstraZeneca)	rhu-Mab (Genentech)
	ZD6474 (AstraZeneca)	MDX-H210 (Medarex)
	Vatalanib (Novartis)	2C4 (Genentech)
	PKI166 (Novartis)	MDX-447 (Medarex)
	GW2016 (GlaxoSmithKline)	ABX-EGF (Abgenix)
	EKB-509 (Wyeth)	IMC-1C11 (ImClone)
	EKB-569 (Wyeth)	
Various other active compounds	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo)	BCX-1777 (PNP inhibitor, BioCryst)
	Tocladesine (cyclic AMP agonist, Ribapharm)	Ranpirnase (ribonuclease stimulant, Alfacell)
	Alvocidib (CDK inhibitor, Aventis)	Galarubicin (RNA synthesis inhibitor, Dong-A)
	CV-247 (COX-2 inhibitor, Ivy Medical)	Tirapazamine (reducing agent, SRI International)
	P54 (COX-2 inhibitor, Phytopharm)	N-Acetylcysteine (reducing agent, Zambon)
	CapCell™ (CYP450	
	stimulant, Bavarian Nordic) GCS-IOO (gal3 antagonist, GlycoGenesys)	R-Flurbiprofen (NF-kappaB inhibitor, Encore)

Table 1		
		3CPA (NF-kappaB inhibitor, Active Biotech)
	G17DT immunogen (gastrin inhibitor, Aphton)	Seocalcitol (vitamin D receptor agonist, Leo)
	Efaproxiral (oxygenator, Allos Therapeutics)	131-I-TM-601 (DNA antagonist, TransMolecular)
	PI-88 (heparanase inhibitor, Progen)	
	Tesmilifen (histamine antagonist, YM BioSciences)	Eflornithin (ODC inhibitor,ILEX Oncology)
	Histamine (histamine H2 receptor agonist, Maxim)	Minodronic acid (osteoclast inhibitor, Yamanouchi)
	Tiazofurin (IMPDH inhibitor, Ribapharm)	Indisulam (p53 stimulant, Eisai)
	Cilengitide (integrin antagonist, Merck KGaA)	Aplidin (PPT inhibitor, PharmaMar)
	SR-31747 (IL-1 antagonist, Sanofi-Synthelabo)	Rituximab (CD20 antibody, Genentech)
	CCI-779 (mTOR kinase inhibitor, Wyeth)	Gemtuzumab (CD33 antibody, Wyeth Ayerst)
	Exisulind (PDE-V inhibitor, Cell Pathways)	PG2 (haematopoiesis promoter, Pharmagenesis)
	CP-461 (PDE-V inhibitor, Cell Pathways)	Immunol™ (triclosan mouthwash, Endo)
	AG-2037 (GART inhibitor, Pfizer)	Triacetyluridine (uridine prodrug, Wellstat)
	WX-UK1 (plasminogen activator inhibitor, Wilex)	SN-4071 (sarcoma agent, Signature BioScience)
	PBI-1402 (PMN stimulant, ProMetic LifeSciences)	TransMID-107™ (immunotoxin, KS Biomedix)
	Bortezomib (proteasome inhibitor, Millennium)	PCK-3145 (apoptosis promoter, Procyon)
	SRL-172 (T-cell stimulant, SR Pharma)	Doranidazole (apoptosis promoter, Pola)
	TLK-286 (glutathione-S transferase inhibitor, Telik)	CHS-828 (cytotoxic agent, Leo)
	PT-100 (growth factor agonist, Point Therapeutics)	trans-Retinoic acid (differentiator, NIH)
	Midostaurin (PKC inhibitor,	MX6 (apoptosis

Table 1		
	Novartis)	promoter, MAXIA)
	Bryostatin-1 (PKC stimulant, GPC Biotech)	Apomine (apoptosis promoter, ILEX Oncology)
	CDA-II (apoptosis promoter, Everlife)	Urocidin (apoptosis promoter, Bioniche)
	SDX-101 (apoptosis promoter, Salmedix)	Ro-31-7453 (apoptosis promoter, La Roche)
	Ceflatonin (apoptosis promoter, ChemGenex)	Brostallicin (apoptosis promoter, Pharmacia)

[0142] Even without further embodiments, it is assumed that a person skilled in the art will be able to use the above description in the broadest scope. The preferred embodiments should therefore merely be regarded as descriptive disclosure which is limited only by the appendant claims.

[0143] The following examples are thus intended to explain the invention without limiting it. Unless indicated otherwise, per cent data denote per cent by weight. All temperatures are indicated in degrees Celsius. "Conventional work-up": water is added if necessary, the pH is adjusted, if necessary, to values between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate, filtered and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation.

[0144] Rf values on silica gel; mass spectrometry: EI (electron impact ionisation): M^+, FAB (fast atom bombardment): $(M+H)^+$, THF (tetrahydrofuran), NMP (N-methlpyrrolidone), DMSO (dimethyl sulfoxide), EA (ethyl acetate), MeOH (methanol), TLC (thin-layer chromatography)

List of Abbreviations

[0145]

AUC

Area under the plasma drug concentration-time curve

C_{max}

Maximum plasma concentration

CL

Clearance

CV

Coefficient of variation

CYP

Cytochrome P450

DMSO

Dimethyl sulfoxide

F

Bioavailability

f_a

Fraction absorbed

iv

Intravenous

LC-MS/MS

Liquid chromatography tandem mass spectrometry

LLOQ

Lower limit of quantification

NC

Not calculated

ND

Not determined

PEG

Polyethylene glycol

Pgp

Permeability glycoprotein

PK

Pharmacokinetic(s)

po

Per os (oral)

$t_{1/2}$

Half-life

t_{max}

Time at which maximum plasma concentration of drug is reached

UPLC

Ultra performance liquid chromatography

V_{ss}

Volume of distribution (at steady state)

v/v

Volume to volume

Example 1: Examples of compounds of the present invention

[0146] The invention especially relates to the compounds 1-4, 6, 7, 9-35, 37-54, 56-69, 71-77,

79-119, and 121-146 of table 2 and physiologically acceptable salts, solvates, and stereoisomers thereof including mixtures thereof in all ratios. The compound numbers 5, 8, 36, 55, 70, 78, 120 and 147-174 are merely reference examples and do not form part of the invention.

Table 2 - examples of the invention and reference examples

No.	Structure	IUPAC-Name	MW	[M+H]+1
1		(R)-3-Aminomethylpyrrolidine-1-carboxylic acid (4-methoxy-7-phenylthiazolo[4,5-c]pyridin-2-yl)-amide	383,47	384
2		N-{4-methoxy-7-[4-(oxan-4-yloxy)phenyl]-[1,3]thiazolo[4,5-c]pyridin-2-yl}-8-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	524,64	526
3		(S)-3-Aminomethylpyrrolidine-1-carboxylic acid (4-methoxy-7-phenylthiazolo[4,5-c]pyridin-2-yl)-amide	383,47	384
4		Cyclopropanecar boxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	352,39	353
5		4-Methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-ylamine	265,34	266
6		N-(6-Fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-4-(1H-tetrazol-5-yl)-benzamide	456,46	457

No.	Structure	IUPAC-Name	MW	[M+H]+1
7		7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	451,52	453
8		7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-ylamine	263,32	264
9		N-[7-(1H-indol-6-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	463,56	465
10		(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	451,52	453
11		(5S)-N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	451,52	453
12		(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	442,51	444
13		(5S)-N-{6-fluoro-4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-7-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	442,51	444

No.	Structure	IUPAC-Name	MW	[M+H]+1
14		3-Dimethylaminomethyl-bicyclo[1.1.1]pentane-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	417,53	419
15		7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	430,53	432
16		N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nona ne-7-carboxamide	437,49	438
17		N-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-[(2-methoxyethyl)amino]-1,3-thiazole-5-carboxamide	449,55	451
18		(R)-2-Oxa-7-aza-spiro[4.4]nonane-7-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	437,49	438
19		(5S)-N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nona ne-7-carboxamide	437,49	438
20		N-[6-Fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N',N'-dimethyl-terephthalamide	458,51	460

No.	Structure	IUPAC-Name	MW	[M+H]+1
21		1-Imidazol-1-ylmethyl-cyclopropanecarb oxylic acid [6-fluoro-4-methoxy-7-(tetrahydropyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	431,49	432
22		N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-(2-methoxyethyl)-1H-pyrazole-4-carboxamide	435,48	436
23		N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-methyl-1H-pyrazole-4-carboxamide	391,43	392
24		(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	430,53	432
25		(S)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	430,53	432
26		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	450,53	452
27		4-Hydroxy-4-methyl-piperidine-1-carboxylic acid [6-fluoro-7-(4-fluoro-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	434,47	435

No.	Structure	IUPAC-Name	MW	[M+H]+1
28		Cyclopropanecarboxylic acid [6-fluoro-4-methoxy-7-(tetrahydropyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	351,40	352
29		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-7-(4-fluoro-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	460,50	462
30		Cyclopropanecarboxylic acid [7-(3-ethylaminomethyl -phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	382,49	383
31		7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	450,53	452
32		1H-Imidazole-4-carboxylic acid (6-fluoro-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	369,38	370
33		N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nona ne-7-carboxamide	436,51	438
34		(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-	450,53	452

No.	Structure	IUPAC-Name	MW	[M+H]+1
		yl]-amide		
35		(5S)-N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	450,53	452
36		1-Methyl-1H-pyrazole-4-carboxylic acid [4-methoxy-7-(2,2,2-trifluoro-ethoxy)-thiazolo[4,5-c]pyridin-2-yl]-amide	387,34	388
37		(R)-2-Oxa-7-aza-spiro[4.4]nonane-7-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	436,51	438
38		(5S)-N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nona ne-7-carboxamide	436,51	438
39		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-aminophenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	439,54	441
40		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-oxo-cyclopent-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	428,51	430
41		Bicyclo[1.1.1]pent ane-1,3-dicarboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-	478,54	480

No.	Structure	IUPAC-Name	MW	[M+H]+1
		yl]-amide (2-hydroxyethyl)-methylamide		
42		N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]cyclopropanecarboxamide	317,37	318
43		N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1H-imidazole-4-carboxamide	343,37	344
44		N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	416,50	417
45		N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	416,50	417
46		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(1-acetyl-1,2,3,6-tetrahydro-pyridin-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	471,58	473
47		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-thiophen-2-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	430,55	432

No.	Structure	IUPAC-Name	MW	[M+H]+1
48		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-furan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	414,48	415
49		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-ethylaminomethyl - phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	481,62	483
50		N-[6-Fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N'-(2-hydroxy-ethyl)-N'-methyl-terephthalamide	488,54	490
51		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-piperidin-1-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	431,56	433
52		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-furan-3-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	414,48	415
53		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(4-methyl-piperazin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	446,57	448
54		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methoxy-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	454,55	456

No.	Structure	IUPAC-Name	MW	[M+H]+1
55		N-{6-cyano-4-nethoxy-1,3]thiazolo[4,5-c]pyridin-2-yl}-1-2-methoxyethyl)-1H-pyrazole-4-carboxamide	358,38	359
56		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(6-methyl-pyridazin-3-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	440,53	442
57		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-azetidin-1-yl-4-methoxythiazolo[4,5-c]pyridin-2-yl)-amide	403,50	405
58		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-hydroxy-azetidin-1-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	419,50	421
59		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-cyclohex-1-enyl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	428,55	430
60		1H-Imidazole-4-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	351,39	352
61		N4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N1,N1-dimethylbenzene-1,4-dicarboxamide	438,51	440

No.	Structure	IUPAC-Name	MW	[M+H]+1
62		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-cyclohexyl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	430,57	432
63		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(4,4-difluoro-cyclohex-1-enyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	464,53	466
64		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-thiopyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	446,59	448
65		1H-Imidazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	357,39	358
66		N-[4-methoxy-7-(4-methoxycyclohex-1-en-1-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	458,58	460
67		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(2-methyl-thiazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	445,57	447
68		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(1-pyridin-3-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-	505,60	507

No.	Structure	IUPAC-Name	MW	[M+H]+1
		c]pyridin-2-yl]-amide		
69		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(1-pyridin-2-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	505,60	507
70		(5R)-N-[4-methoxy-7-(4-methoxycyclohex-1-en-1-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	458,58	460
71		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide	434,48	435
72		4-{[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}ben zoic acid	411,44	412
73		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-[1,4]dioxan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	434,51	436
74		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {7-[1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]-4-methoxy-thiazolo[4,5-c]pyridin-2-yl}-amide	478,52	480
75		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(1-pyridin-4-ylmethyl-1H-pyrazol-4-	505,60	507

No.	Structure	IUPAC-Name	MW	[M+H]+1
		yl)-thiazolo[4,5-c]pyridin-2-yl]-amide		
76		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(1-benzyl-1H-pyrazol-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	504,61	506
77		(5S)-N-[4-methoxy-7-(4-methoxycyclohex-1-en-1-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	458,58	460
78		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(6-oxo-1,6-dihydro-pyridin-3-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	441,51	443
79		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(1-difluoromethyl-1H-pyrazol-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	464,49	465
80		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-difluoromethoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	460,50	462
81		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-[(2-methoxyethyl)ami no]-1,3-thiazole-5-carboxamide	447,54	449
82		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-	447,52	449

No.	Structure	IUPAC-Name	MW	[M+H]+1
		c]pyridin-2-yl]-4-[(1H-imidazol-1-yl)methyl]benzami de		
83		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-[(1R)-1-acetamidoethyl]benzamide	452,53	454
84		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[1-(tetrahydro-pyran-2-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amide	512,63	514
85		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[1-(tetrahydro-pyran-4-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amide	512,63	514
86		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(1,1-dioxo-hexahydro-1l6-thiopyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	480,61	482
87		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[1-(tetrahydro-pyran-3-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amide	512,63	514
88		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)piperidine-1-	469,52	471

No.	Structure	IUPAC-Name	MW	[M+H]+1
		carboxamide		
89		3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(2-oxopyrrolidin-1-yl)phenyl]urea	465,53	467
90		N-[4-({[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}amino)phenyl]-2-(dimethylamino)acetamide	482,56	484
91		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(2,4-dioxo-1,3-thiazolidin-3-yl)piperidine-1-carboxamide	489,57	491
92		N-[4-({[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}amino)-2-methylphenyl]acetamide	453,52	455
93		N4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-hydroxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N 1-(2-hydroxyethyl)-N1-methylbenzene-1,4-dicarboxamide	454,50	456
94		3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)phenyl]urea	478,53	480
95		3-[7-(3,6-dihydro-2H-	467,50	469

No.	Structure	IUPAC-Name	MW	[M+H]+1
		pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]urea		
96		N1-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N4, N4-dimethylpiperidine -1,4-dicarboxamide	445,54	447
97		[4-(4-Methoxy-7-phenylthiazolo[4,5-c]pyridin-2-ylcarbamoyl)-benzyl]-methyl-carbamic acid methyl ester	462,53	464
98		2,8-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	429,54	431
99		4-(2,5-Dioxo-pyrrolidin-1-yl)-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	465,53	467
100		4-(2,5-Dioxo-pyrrolidin-1-yl)-piperidine-1-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	471,54	473
101		Bicyclo[1.1.1]pent ane-1,3-dicarboxylic acid (6-fluoro-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide (2-hydroxyethyl)-methylamide	470,52	472

No.	Structure	IUPAC-Name	MW	[M+H]+1
102		2,7-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	429,54	431
103		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[2-(2-methoxy-ethoxy)-ethyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide	516,62	518
104		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[(R)-1-(tetrahydropyran-3-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide	512,63	514
105		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[(S)-1-(tetrahydropyran-3-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide	512,63	514
106		N 1-[7-(3, 6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]piperidine-1,4-dicarboxamide	417,49	418
107		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-hydroxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nona ne-7-carboxamide	402,47	403
108		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-	416,50	417

No.	Structure	IUPAC-Name	MW	[M+H]+1
		c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nona ne-7-carboxamide		
109		4-({4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}carbamoyl)ben zoic acid	405,43	406
110		N-{4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-4-(1H-1,2,3,4-tetrazol-5-yl)benzamide	429,46	430
111		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(4,4-difluoro-cyclohexyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	466,55	468
112		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methylaminophenyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	453,56	455
113		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(5-methyl-thiophen-2-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	444,58	446
114		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(5-methyl-furan-2-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	428,51	430
115		4-[(4-methoxy-7-{1-[(pyridin-3-	486,51	488

No.	Structure	IUPAC-Name	MW	[M+H]+1
		yl)methyl]-1H-pyrazol-4-yl}-[1,3]thiazolo[4,5-c]pyridin-2-yl)carbamoyl]ben zoic acid		
116		N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1H-pyrazole-4-carboxamide	357,39	358
117		N-{4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-1H-pyrazole-4-carboxamide	351,39	352
118		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[(S)-1-(tetrahydropyran-2-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide	512,63	514
119		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{1-[(R)-1-(tetrahydropyran-2-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amide	512,63	514
120		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-methanesulfonyla mino-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	517,63	519
121		(R)-2,7-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-	429,54	431

No.	Structure	IUPAC-Name	MW	[M+H]+1
		yl]-amide		
122		(S)-2,7-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	429,54	431
123		Piperidine-1,4-dicarboxylic acid 4-dimethylamide 1-[(4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide]	439,54	441
124		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(2-amino-pyridin-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	440,53	442
125		N-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-4-(4-methylpiperazine-1-carbonyl)-benzamide	493,59	495
126		N-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-N'-(2-piperidin-1-yl-ethyl)-terephthalamide	521,64	523
127		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(2-methylamino-pyridin-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	454,55	456
128		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(5-methyl-cyclohex-1-enyl)-	442,58	444

No.	Structure	IUPAC-Name	MW	[M+H]+1
		thiazolo[4,5-c]pyridin-2-yl]-amide		
129		N-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-4-(4-hydroxy-4-methyl-piperidine-1-carbonyl)-benzamide	508,60	510
130		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-fluoro-5-methanesulfonyla mino-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	535,62	537
131		4-(2,5-Dioxo-imidazolidin-1-yl)-piperidine-1-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	472,52	474
132		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methyl-3,6-dihydro-2H-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	444,55	446
133		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-trifluoromethyl-piperidin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	499,56	501
134		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methoxy-piperidin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	461,58	463
135		Imidazo[1,2-a]pyridine-3-carboxylic acid [7-	407,45	408

No.	Structure	IUPAC-Name	MW	[M+H]+1
		(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide		
136		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(5-oxo-2,5-dihydro-1H-pyrrol-3-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	429,50	430
137		4-(2,5-Dioxo-imidazolidin-1-yl)-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	466,52	468
138		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(5-amino-2-fluoro-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	458,52	460
139		N-(2-Azetidin-1-yl-ethyl)-N'-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-terephthalamide	493,59	495
140		2-Pyridin-3-yl-1H-imidazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	434,48	435
141		N-{4-methoxy-7-[3-(trifluoromethyl) ph enyl]-[1,3]thiazolo[4,5-c]pyridin-2-yl}-8-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	492,52	494
142		8-Oxa-2-aza-	458,52	460

No.	Structure	IUPAC-Name	MW	[M+H]+1
		spiro[4.5]decane-2-carboxylic acid [7-(5-amino-6-fluoro-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide		
143		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(5-amino-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	440,53	442
144		{4-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-ylcarbamoyl]-phenyl}-acetic acid	425,46	426
145		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-((S)-3-methyl-cyclohex-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	442,58	444
146		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-((R)-3-methyl-cyclohex-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	442,58	444
147		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[3-(1-methyl-1H-pyrazol-4-yloxy)-phenyl]-thiazolo[4,5-c]pyridin-2-yl}-amide amide	520,61	522
148		4-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-ylcarbamoyl]-thiazole-2-carboxylic acid	418,45	419

No.	Structure	IUPAC-Name	MW	[M+H]+1
149		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(4-fluoro-3-hydroxy-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	458,51	460
150		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(2-fluoro-5-hydroxy-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	458,51	460
151		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid ((R)-7-[1,4]dioxan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	434,51	436
152		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid ((S)-7-[1,4]dioxan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	434,51	436
153		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-hydroxyphenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	440,52	442
154		{4-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-ylcarbamoyl]-thiazol-2-yl}-acetic acid	432,48	433
155		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(6-aminomethyl-2-methyl-pyrimidin-4-yl)-4-	469,57	471

No.	Structure	IUPAC-Name	MW	[M+H]+1
		methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide		
156		1-Phenyl-1H-pyrazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	433,49	434
157		1-Pyridin-4-yl-1H-pyrazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	434,48	435
158		1-(1H-Imidazol-2-ylmethyl)-1H-pyrazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	437,48	438
159		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[3-(3,3,3-trifluoro-propylamino)-phenyl]-thiazolo[4,5-c]pyridin-2-yl}-amide	535,59	537
160		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[3-(pyridin-3-yloxy)-phenyl]-thiazolo[4,5-c]pyridin-2-yl}-amide	517,61	519
161		N-(7-[1,4]Dioxan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-terephthalamic acid	415,42	416
162		2-Pyridin-2-yl-1H-imidazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-	434,48	435

No.	Structure	IUPAC-Name	MW	[M+H]+1
		thiazolo[4,5-c]pyridin-2-yl]-amide		
163		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {4-methoxy-7-[1-(1-methyl-1-phenyl-ethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amide	532,67	534
164		N-(7-[1,4]Dioxan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-4-(1H-tetrazol-5-yl)-benzamide	439,45	440
165		2-Pyridin-4-yl-1H-imidazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	434,48	435
166		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-{3-[(oxazol-4-ylmethyl)-amino]-phenyl}-thiazolo[4,5-c]pyridin-2-yl)-amide	520,61	522
167		{4-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-ylcarbamoyl]-benzyl}-methyl-carbamic acid methyl ester	468,53	470
168		5-[7-(3,6-Dihydro-2H-pyran-4-yl)-4-methoxy thiazolo[4,5-c]pyridin-2-ylcarbamoyl]-1H-imidazole-2-carboxylic acid	401,40	402
169		N-((R)-7-[1,4]Dioxan-2-yl-4-methoxy-	415,42	416

No.	Structure	IUPAC-Name	MW	[M+H]+1
		thiazolo[4,5-c]pyridin-2-yl)-terephthalamic acid		
170		N-((S)-7-[1,4]Dioxan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-terephthalamic acid	415,42	416
171		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-iodo-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	474,32	475
172		8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(2-cyano-pyridin-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	450,52	452
173		(5R)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-(2H3)methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	433,54	435
174		(5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-(2H3)methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]deca ne-2-carboxamide	433,54	435

Table 3 - NMR profiles of the examples and reference examples

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
1	1H NMR (400 MHz, DMSO,ppm) :7.97 (s, 1H), 7.70-7.66 (m, 2H), 7.58-7.51 (m, 2H), 7.47-7.41 (m, 1H), 4.02 (s, 3H), 3.55 (s, 3H),3.31(s,2H), 2.60 (d, J = 6.9 Hz, 1H), 2.22 (s, 1H), 1.96 (s, 1H), 1.64 (s, H).
2	1H NMR (400 MHz, DMSO-d6)11.34 (s,1H), 7.97 (s,1H), 7.68-7.54 (m,2H), 7.25-7.08 (m, 2H), 4.65 (dq, J=8.3, 4.2,3.8 Hz,1H), 4.02 (s,3H), 3.87 (dt, J=11.5, 4.4 Hz, 2H), 3.81-3.39 (m,10H), 2.08-1.72 (m, 4H), 1.62 (dtd, J =13.1, 9.1,4.1 Hz, 2H), 1.49 (d, J = 5.7 Hz, 4H).
3	1H NMR (400 MHz, DMSO,ppm) :7.97 (s, 1H), 7.70-7.66 (m, 2H), 7.58-7.51 (m, 2H), 7.47-7.41 (m, 1H), 4.02 (s, 3H), 3.55 (s, 3H),3.31(s,2H), 2.60 (d, J = 6.9 Hz, 1H), 2.22 (s, 1H), 1.96 (s, 1H), 1.64 (s, H).
4	(400MHz,DMSO,ppm):12.89(s,1H),3.96(s,3H),3.73-3.70(m,4H),3.06-3.05(m,4H),1.98-1.92(m,1H),1.01-0.99(m,4H).
5	1HNMR(400MHz,DMSO,ppm):7.64(s,3H),4.02-3.92(m,2H),3.89(s,3H),3.46(m,2H),2.77(m,1H), 1.87-1.69(m,4H).
6	(400MHz,DMSO,ppm):13.26(s,1H),8.27(d,J=8.4,2H),8.19(d,J=8.4,2H),3.99(s,3H),3.78-3.75(m,4H),3.11-3.10(m,4H).
7	(400MHz,DMSO,ppm):11.30(s,1H),3.93(s,3H),3.73-3.71(m,4H),3.61-3.23(m,8H),3.16-3.14(m,4H),1.82-1.53(m,6H).
8	(400MHz,DMSO,ppm):7.78(s,1H),7.67-7.63(m,2H),6.11(s,1H),4.25-4.24(m,2H),3.92-3.82(m,5H),3.32-3.30(m,2H).
9	1H NMR (400 MHz, DMSO,ppm) : 11.32 (d, J = 10.5 Hz, 2H), 8.04 (s, 1H), 7.70-7.68 (d, J = 8.1 Hz, 2H), 7.45-7.43 (t, J = 2.7 Hz, 1H), 7.32-7.30 (dd, J = 8.1, 1.7 Hz, 1H), 6.51 (t, J = 2.5 Hz, 1H), 4.04 (s, 3H), 3.71-3.39 (m, 7H), 3.31 (s, 1H), 1.82 (m, 2H), 1.50 (t, J = 5.4 Hz, 4H).
10	(400MHz,DMSO,ppm):11.30(s,1H),3.93(s,3H),3.73-3.71(m,4H),3.61-3.46(m,6H),3.41-3.38(m,1H), 3.32-3.29(m,1H),3.20-3.17(m,4H),1.84-1.49(m,6H).
11	(400MHz,DMSO,ppm):11.30(s,1H),3.93(s,3H),3.73-3.71(m,4H),3.61-3.46(m,6H),3.41-3.38(m,1H), 3.32-3.29(m,1H),3.18-3.17(m,4H), 1.81-1.48(m,6H).
13	1H NMR (400 MHz, DMSO-d6,ppm) : 11.37 (s, 1H), 7.61-7.58 (m, 2H), 7.56 - 7.52 (m, 2H), 7.50 - 7.44 (m, 1H), 4.02 (s, 3H), 3.67 - 3.36 (m, 6H), 3.32 - 3.26 (m, 2H), 1.88 - 1.46 (m, 6H).
14	1H NMR (400 MHz, CD3OD-d4):7.63 (s, 1H), 4.07 (s, 3H), 3.89 (d, J = 4.8 Hz, 4H), 3.18 ? 3.14 (m, 4H), 2.54 (s, 2H), 2.32 (s, 6H), 2.20 (s, 6H).
15	1H NMR (300MHz, DMSO,ppm):11.37(s,1H),7.95(s,1H),6.25(s,1H),4.30-4.29(m,2H),3.99(s,3H),3.89(t,J=5.4Hz,2H),3.61-3.29(m,8H),2.55-2.51(m,2H),1.82-1.54(m,6H).

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
16	1H NMR (400MHz,DMSO,ppm):11.32(s,1H),3.93(s,3H),3.80-3.72(m,6H),3.58-3.29(m,6H),3.06-3.05(m,4H), 1.92-1.84(m,4H).
17	(400MHz,DMSO,ppm):12.97(s,1H),8.69(s,1H),8.31(s,1H),7.88(s,1H),4.02-4.00(m,5H),3.55-3.32(m,6H),3.29(s,3H),3.01-2.99(m,1H),1.93-1.79(m,4H).
18	1H NMR (400MHz,DMSO,ppm):11.33(s,1H),3.94(s,3H),3.80-3.72(m,6H),3.58-3.30(m,6H),3.06-3.05(m,4H), 1.91-1.82(m,4H).
19	1H NMR (400MHz,DMSO,ppm):11.33(s,1H),3.94(s,3H),3.82-3.71(m,6H),3.61-3.30(m,6H),3.06-3.05(m,4H), 1.91-1.82(m,4H).
20	1H NMR (400 MHz, DMSO, ppm) : 13.32 (s, 1H), 8.20 ? 8.18 (d, J = 8.0 Hz, 2H), 7.59 ? 7.57 (d, J = 7.9 Hz, 2H), 4.02 - 3.99 (m, 5H), 3.54 ? 3.52 (t, J = 11.6 Hz, 2H), 3.21 ? 3.15 (m, 1H), 3.01 (s, 3H), 2.91(s, 3H), 2.12 ? 2.04 (m, 2H), 1.70 ? 1.67 (m, 2H).
21	1H NMR (400 MHz, DMSO-d6, ppm) : 12.41 (s, 1H) 7.69 (s, 1H), 7.21 (s, 1H), 6.86 (s, 1H), 4.37 (s, 2H), 4.01 - 3.98 (m, 5H), 3.48 (t, J = 11.6 Hz, 2H), 3.20 - 3.12 (m, 1H) , 2.02 (d, J = 11.4 Hz, 2H), 1.64 (d, J = 13.1 Hz, 2H), 1.47 (s, 2H), 1.22 (s, 2H).
22	1H NMR (400 MHz, DMSO-d6) 12.90 (s, 1H), 8.54 (s, 1H), 8.23 (s, 1H), 4.35 (t, J = 5.2 Hz, 2H), 3.98 (s, 5H), 3.71 (t, J = 5.1 Hz, 2H), 3.50 (t, J = 11.6 Hz, 2H), 3.25 (d, J = 0.9 Hz, 3H), 3.20-3.08 (m, 1H), 2.05 (d, J = 13.5 Hz, 2H), 1.68 (d, J = 12.8 Hz, 2H).
23	1H NMR (400 MHz, DMSO, ppm) : 12.90 (s, 1H), 8.50 (s, 1H), 8.20 (s, 1H), 4.01 - 3.98 (m, 5H), 3.92 (s, 3H), 3.53 - 3.48 (m, 2H), 3.20 - 3.13 (m, 1H), 2.10 - 2.01 (m, 2H), 1.68 - 1.65 (d, J = 12.7 Hz, 2H).
24	1H NMR (400MHz, DMSO, ppm): 11.35 (s,1H), 7.94 (s,1H), 6.24 (s, 1H), 4.29-4.28 (m,2H), 3.99 (s,3H), 3.88-3.85 (m, 2H), 3.49-3.29 (m,8H), 2.55-2.50 (m,2H), 1.83-1.53 (m,6H).
25	1H NMR (400MHz, DMSO-d6, ppm): 11.35 (s,1H), 7.94 (s,1H), 6.24 (s,1H), 4.29-4.28 (m,2H), 3.99 (s,3H), 3.88-3.85 (m, 2H), 3.61-3.29 (m,8H), 2.55-2.50 (m,2H), 1.83-1.53 (m,6H).
26	1H NMR (400MHz,DMSO-d6,ppm):11.31(s,1H),3.99-3.94(m,5H),3.61-3.45(m,10H),3.12(t,J=12.4Hz,1H),2.03(q,J=12.5Hz,2H),1.82(s,2H),1.65-1.62(m,2H),1.50(s,4H).
27	(400MHz,DMSO-d6,ppm):11.52(s,1H),7.67-7.64(m,2H),7.41-7.36(m,2H),4.40(s,1H),4.02(s,3H),3.83-3.80(m,2H),3.28-3.25(m,2H),1.46-1.41(m,4H),1.13(s,3H).
28	1H NMR (400 MHz, DMSO-d6)12.93 (s, 1H), 4.08-3.91 (m, 5H), 3.47 (t, J=11.6 Hz, 2H), 3.19-3.06 (m, 1H), 2.13-1.89 (m, 3H), 1.64 (d, J=13.0 Hz, 2H), 1.09-0.88 (m, 4H)
29	1H NMR (400MHz,DMSO-d6,ppm):11.37(s,1H),7.67-7.64(m,2H),7.41-7.37(m,2H),4.02(s,3H),3.61-3.32(m,8H),1.86-

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
	1.71(m,2H),1.49(s,4H).
30	1H NMR (300 MHz, DMSO-d6, ppm) 8.02 (s, 1H), 7.60 (s, 1H), 7.52 - 7.33 (m, 3H), 4.02 (s, 3H), 3.74 (s, 2H), 2.57 - 2.50 (m, 2H), 1.92 (d, J = 4.7 Hz, 1H), 1.06 - 0.96 (m, 3H), 0.96 - 0.86 (m, 4H).
31	1H NMR (400 MHz, DMSO-d6)11.34 (s, 1H), 4.05 ? 3.89 (m, 5H), 3.70 ? 3.36 (m, 8H), 3.29 (s, 2H), 3.12 (t, J = 12.3 Hz, 1H), 2.11 ? 1.95 (m, 1H), 1.60 (m, J = 35.5, 12.5 Hz, 6H).
32	1H NMR (400 MHz, DMSO-d6, ppm) : 12.81 (s, 1H) 8.11 (s, 1H), 7.89 (s, 1H), 7.64 (d, J = 7.6 Hz, 2H), 7.57 (t, J = 7.5 Hz, 2H), 7.49 (t, J = 7.4 Hz, 1H), 4.05 (s, 3H).
33	1H NMR (400MHz,DMSO-d6,ppm):11.37(s,1H),3.99-3.94(m,5H),3.80-3.76(m,2H),3.58-3.48(m,8H),3.20-3.12(m,1H),2.05-2.04(m,2H),2.02-1.85(m,4H),1.70-1.60(m,2H).
34	1H NMR (400 MHz, DMSO-d6) 11.34 (s, 1H), 3.94 (s, 5H), 3.69-3.36 (m, 8H), 3.30-3.25 (m, 1H), 3.12 (s, 2H), 2.06 -1.93 (m, 2H), 1.74-1.39 (m, 8H).
35	1H NMR (400 MHz, DMSO-d6)11.34 (s, 1H), 3.94 (s, 5H), 3.69-3.36 (m, 8H), 3.30-3.25 (m, 1H), 3.12 (s, 2H), 2.06-1.93 (m, 2H), 1.74-1.39 (m, 8H).
36	1H NMR (300 MHz, DMSO-d6): 8.85 (s, 1H), 8.24 (s, 1H), 7.75 (d, J = 9.8 Hz, 1H), 6.89 (s, 1H), 4.70 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H), 3.72 (s, 3H).
37	HNMR (400MHz,DMSO-d6,ppm):11.37(s,1H),3.99-3.94(m,5H),3.80-3.76(m,2H),3.58-3.48(m,8H),3.16-3.10(m,1H),2.04-1.84(m,6H),1.70-1.60(m,2H).
38	HNMR (400MHz,DMSO-d6,ppm):11.37(s,1H),3.99-3.94(m,5H),3.80-3.76(m,2H),3.58-3.48(m,8H),3.16-3.10(m,1H),2.08-1.85(m,6H),1.70-1.60(m,2H).
39	1H NMR (400 MHz, DMSO-d6, ppm) : 11.31 (s, 1H), 7.93 (s, 1H), 7.16 (t, J = 7.8 Hz, 1H), 6.84 (t, J = 2.0 Hz, 1H), 6.78 - 6.73 (m, 1H), 6.66 - 6.59 (m, 1H), 5.30 (s, 2H), 4.02 (s, 3H), 3.69 - 3.44 (m, 4H), 1.81 (s, 2H), 1.50 (t, J = 5.4 Hz, 4H).
40	1H NMR (400 MHz, DMSO-d6, ppm) : 11.48 (s, 1H), 8.38 (d, J = 4.5 Hz, 1H), 6.50 (s, 1H), 4.06 (d, J = 1.1 Hz, 3H), 3.69 - 3.43 (m, 8H), 3.31 (s, 2H), 3.20 (s, 2H), 1.83 (s, 2H), 1.50 (t, J = 5.4 Hz, 4H).
41	1H NMR (400MHz, DMSO-d6, ppm): 12.81 (s, 1H), 4.84-4.66 (m, 1H), 4.00-3.96 (m, 5H), 3.53-3.46 (m, 5H), 3.31-3.30 (m, 1H), 3.18-3.09 (m, 2H), 2.82 (s, 2H), 2.50-2.40 (m, 6H), 2.07-1.94 (m, 2H), 1.65 (d, J = 12.8 Hz, 2H).
42	1H NMR (500 MHz, DMSO-d6) d 13.02 (s, 1H), 7.87 (s, 1H), 6.38-6.36 (m, 1H), 5.06 - 5.02 (m, 2H), 4.82 - 4.79 (m, 2H), 4.03 (s, 3H), 2.03 - 1.95 (m, 1H), 1.03 - 0.93 (m, 4H).

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.

No.	NMR
43	1H NMR (500 MHz, DMSO-d6) d 12.89 - 12.74 (m, 1H), 11.94 - 11.87 (m, 1H), 8.49 - 8.46 (m, 1H), 8.31 - 8.29 (m, 1H), 7.92 (s, 1H), 6.46 - 6.43 (m, 1H), 5.09 - 5.05 (m, 2H), 4.86 - 4.82 (m, 2H), 4.05 (s, 3H).
44	1H NMR (500 MHz, DMSO-d6) d 11.43 - 11.34 (m, 1H), 7.81 (s, 1H), 6.37 - 6.35 (m, 1H), 5.06 - 5.02 (m, 2H), 4.83 - 4.79 (m, 2H), 4.01 (s, 3H), 3.68 - 3.27 (m, 8H), 1.92 - 1.73 (m, 2H), 1.54 - 1.48 (m, 4H).
45	1H NMR (400 MHz, DMSO-d6) d 11.45 - 11.36 (m, 1H), 7.81 (s, 1H), 6.38 - 6.35 (m, 1H), 5.06 - 5.02 (m, 2H), 4.83 - 4.79 (m, 2H), 4.01 (s, 3H), 3.68 - 3.44 (m, 4H), 3.44 - 3.38 (m, 1H), 3.34 - 3.29 (m, 1H), 3.29 - 3.11 (m, 2H), 1.91 - 1.47 (m, 6H).
46	1H NMR (400 MHz, DMSO-d6, ppm) : 11.32 (s, 1H), 7.91 (d, J = 5.6 Hz, 1H), 6.17 (s, 1H), 4.18 (d, J = 24.9 Hz, 2H), 3.99 (s, 3H), 3.77 - 3.39 (m, 10H), 2.64 - 2.53 (m, 2H), 2.07 (d, J = 13.3 Hz, 3H), 1.81 (s, 2H), 1.50 (t, J = 5.4 Hz, 4H).
47	1H NMR (400MHz, DMSO-d6, ppm): 11.42 (s, 1H), 8.21 (s, 1H), 7.69 (d, J = 4.0 Hz, 1H), 7.53 (d, J = 2.8 Hz, 1H), 7.25 (dd, J = 5.2, 3.6 Hz, 1H), 4.03 (s, 3H), 3.62-3.29 (m, 8H), 1.83 (s, 2H), 1.51 (s, 4H).
48	1H NMR (400MHz, DMSO-d6, ppm): 11.38 (s, 1H), 8.36 (s, 1H), 7.90 (d, J = 1.2 Hz, 1H), 6.96 (d, J = 3.2 Hz, 1H), 6.71 (dd, J = 3.2, 2.0 Hz, 1H), 4.03 (s, 3H), 3.62-3.29 (m, 8H), 1.86-1.82 (m, 2H), 1.51 (s, 4H).
49	1H NMR (400 MHz, DMSO-d6, ppm) : 7.99 (s, 1H), 7.63 (d, J = 1.8 Hz, 1H), 7.56 - 7.43 (m, 2H), 7.40 (dt, J = 7.6, 1.5 Hz, 1H), 4.03 (s, 3H), 3.80 (s, 2H), 3.71 - 3.45 (m, 8H), 2.58 (q, J = 7.1 Hz, 2H), 1.80 (s, 2H), 1.49 (t, J = 5.4 Hz, 4H), 1.05 (t, J = 7.1 Hz, 3H).
50	1H NMR (400 MHz, DMSO-d6)13.31 (s, 1H), 8.18 (t, J = 8.8 Hz, 2H), 7.57 (d, J=7.6 Hz, 2H), 4.83 (s, 1H), 4.00 (s, 5H), 3.64 (d, J=5.9 Hz, 1H), 3.52 (t, J=11.6 Hz, 4H), 3.30-3.12 (m, 2H), 2.97 (d, J=27.7 Hz, 3H), 2.08 (q, J=12.2 Hz, 2H), 1.69 (d, J=12.8 Hz, 2H).
51	1H NMR (400 MHz, DMSO-d6, ppm) : 11.27 (s, 1H), 7.53 (s, 1H), 3.93 (s, 3H), 3.74 - 3.39 (m, 8H), 3.03 (t, J = 5.3 Hz, 4H), 1.82 (s, 2H), 1.69 (t, J = 5.5 Hz, 4H), 1.61 - 1.45 (m, 6H).
52	1H NMR (400MHz, DMSO-d6, ppm): 11.38 (s, 1H), 8.16 (s, 1H), 8.10 (s, 1H), 7.87 (s, 1H), 7.03 (s, 1H), 4.01 (s, 3H), 3.62-3.29 (m, 8H), 1.83 (s, 2H), 1.51 (s, 4H)
53	1H NMR (400 MHz, CDOH-d4, ppm) : 7.58-7.56 (m, 1H), 4.06 (s, 3H), 3.82 - 3.58 (m, 6H), 3.47 (s, 2H), 3.20 (s, 4H), 2.69 (s, 4H), 2.40 (s, 3H), 1.96 (s, 2H), 1.65 (t, J = 5.4 Hz, 4H).
54	1H NMR (300 MHz, DMSO-d6): 11.38 (s, 1H), 8.06 (s, 1H), 7.47-7.45 (m, 1H), 7.22-7.21 (m, 2H), 7.04 (dd, J = 8.3, 2.6 Hz, 1H), 4.04 (s, 3H), 3.84 (s, 3H), 3.58-3.33 (m, 8H), 1.82 (s, 2H), 1.51 (s, 4H).
55	1H NMR (400 MHz, DMSO-d6, ppm) : 8.50 (s, 1H), 8.31 (d, J = 6.4 Hz, 1H), 8.18 (s, 1H), 4.33 (t, J = 5.2 Hz, 2H), 4.03 (d, J = 3.0 Hz, 3H), 3.71 (t, J = 5.1 Hz, 2H), 3.25 (s, 3H).

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
56	1H NMR (400 MHz, DMSO-d6, ppm) : 11.19 (s, 1H), 8.76 (s, 1H), 8.45 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 8.9 Hz, 1H), 4.08 (s, 3H), 3.74 - 3.39 (m, 8H), 2.69 (s, 3H), 1.83 (s, 2H), 1.53 (t, J = 5.5 Hz, 4H).
57	1H NMR (400 MHz, DMSO-d6, ppm) : 11.25 (s, 1H), 7.06 (s, 1H), 3.99 - 3.81 (m, 7H), 3.70 - 3.42 (m, 8H), 2.35 - 2.26 (m, 2H), 1.80 (s, 2H), 1.49 (t, J = 5.4 Hz, 4H).
58	1H NMR (400 MHz, DMSO-d6, ppm) : 11.28 (s, 1H), 7.09 (s, 1H), 5.69 (d, J = 6.6 Hz, 1H), 4.57 (q, J = 6.1 Hz, 1H), 4.19 - 4.12 (m, 2H), 3.89 (s, 3H), 3.69 - 3.45 (m, 10H), 1.82 (s, 2H), 1.49 (t, J = 5.4 Hz, 4H).
59	1H NMR (400 MHz, DMSO-d6, ppm) : 11.28 (s, 1H), 7.86 (s, 1H), 6.15 (s, 1H), 3.97 (s, 3H), 3.67 - 3.43 (m, 8H), 2.46 - 2.40 (m, 2H), 2.26 - 2.20 (m, 2H), 1.88 - 1.71 (m, 4H), 1.69 - 1.62 (m, 2H), 1.49 (t, J = 5.4 Hz, 4H).
60	1H NMR (400 MHz, DMSO-d6, ppm) : 12.83 (s, 1H), 8.12 (d, J = 17.3 Hz, 2H), 7.91 (s, 1H), 7.72 (d, J = 7.6 Hz, 2H), 7.58 (t, J = 7.6 Hz, 2H), 7.48 (t, J = 7.5 Hz, 1H), 4.07 (s, 3H).
61	1H NMR (700 MHz, DMSO-d6) delta 13.36 - 13.29 (m, 1H), 8.21 - 8.18 (m, 2H), 8.05 (s, 1H), 7.60 - 7.57 (m, 2H), 6.33 - 6.31 (m, 1H), 4.32 (q, J = 2.8 Hz, 2H), 4.04 (s, 3H), 3.89 (t, J = 5.4 Hz, 2H), 3.03 - 2.88 (m, 6H), 2.61 - 2.57 (m, 2H).
62	1H NMR (400 MHz, DMSO-d6, ppm) : 11.28 (s, 1H), 7.75 (s, 1H), 3.94 (s, 3H), 3.62 (s, 2H), 3.56-3.42 (m, 5H), 2.69 - 2.60 (m, 1H), 1.94 - 1.70 (m, 7H), 1.68 - 1.34 (m, 8H), 1.32-1.20 (m, 1H).
63	HNMR (400 MHz, DMSO, ppm): 11.34 (s, 1H), 7.92 (s, 1H), 6.03 (s, 1H), 3.99 (s, 3H), 3.62-3.33 (m, 8H), 2.85-2.67 (m, 4H), 2.28-2.18(m, 2H), 1.81-1.77 (m, 2H), 1.60-1.40 (m, 4H) .
64	1H NMR (400 MHz, DMSO-d6, ppm) : 11.31 (s, 1H), 7.86 (d, J = 1.5 Hz, 1H), 6.28 (s, 1H), 3.98 (s, 3H), 3.73 - 3.40 (m, 8H), 3.35 (d, J = 3.3 Hz, 2H), 2.88 (t, J = 5.7 Hz, 2H), 2.68 (s, 2H), 1.83 (s, 2H), 1.50 (t, J = 5.4 Hz, 4H).
65	1H NMR (400 MHz, DMSO-d6, ppm): 13.19-13.10 (m, 1H), 12.27-12.18 (m, 1H), 8.15 (s, 1H), 8.01 (s, 1H), 7.90 (s, 1H), 6.29(s, 1H), 4.32-4.32 (m, 2H), 4.02 (s, 3H), 3.90-3.87 (m, 2H), 2.58-2.57 (m, 2H).
67	1H NMR (400 MHz, DMSO-d6, ppm) : 11.20 (s, 1H), 8.51 (s, 1H), 8.04 (d, J = 1.3 Hz, 1H), 4.03 (s, 3H), 3.69 - 3.43 (m, 8H), 2.78 (s, 3H), 1.82 (s, 2H), 1.51 (t, J = 5.4 Hz, 4H).
68	1H NMR (400 MHz, DMSO-d6, ppm) : 11.38 (s, 1H), 8.58 (d, J = 2.3 Hz, 1H), 8.52 (dd, J = 4.8, 1.6 Hz, 1H), 8.38 (s, 1H), 8.15 (s, 1H), 7.98 (s, 1H), 7.72 (dt, J = 7.9, 2.0 Hz, 1H), 7.40 (dd, J = 7.9, 4.8 Hz, 1H), 5.50 (s, 2H), 3.99 (s, 3H), 3.69 - 3.42 (m, 8H), 1.81 (d, J = 26.9 Hz, 2H), 1.50 (t, J = 5.2 Hz, 4H).

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
69	1H NMR (400 MHz, DMSO-d6)11.32 (s, 1H), 8.55 (dt, J = 5.0, 1.4 Hz, 1H), 8.36 (s, 1H), 8.18 (s, 1H), 7.99 (d, J = 0.8 Hz, 1H), 7.80 (td, J = 7.7, 1.8 Hz, 1H), 7.36 ? 7.30 (m, 1H), 7.13 (d, J = 7.9 Hz, 1H), 5.55 (s, 2H), 4.00 (s, 3H), 3.76 ? 3.38 (m, 8H), 1.84 (s, 2H), 1.50 (s, 4H).
70	1H NMR (400 MHz, DMSO-d6) delta 11.30 - 11.24 (m, 1H), 7.87 (s, 1H), 6.06 - 6.02 (m, 1H), 3.98 (s, 3H), 3.66 - 3.43 (m, 5H), 3.43 - 3.12 (m, 4H), 3.31 (s, 3H), 2.62 - 1.47 (m, 12H).
71	1H NMR (400 MHz, DMSO-d6) delta 13.56 -13.16 (m, 1H), 9.00 (d, J = 1.2 Hz, 1H), 8.40 - 8.36 (m, 2H), 8.19 - 8.14 (m, 2H), 8.06 (s, 1H), 8.05 (d, J = 1.2 Hz, 1H), 6.34 - 6.31 (m, 1H), 4.35 - 4.31 (m, 2H), 4.05 (s, 3H), 3.90 (t, J = 5.4 Hz, 2H), 2.63 - 2.57 (m, 2H).
73	1H NMR (400 MHz, DMSO-d6, ppm): 11.25 (s, 1H), 7.84 (s, 1H), 4.82-4.79 (m, 1H), 3.96-3.92 (m, 4H), 3.84-3.78 (m, 3H), 3.66-3.49 (m, 10H), 1.83-1.70 (m, 2H), 1.51-1.48 (m, 4H).
74	1H NMR (400 MHz, DMSO-d6, ppm) : 11.39 (s, 1H), 8.26 (s, 1H), 8.17 (s, 1H), 8.04 (d, J = 0.8 Hz, 1H), 6.43 (tt, J = 54.9, 3.8 Hz, 1H), 4.75 (td, J = 15.1, 3.8 Hz, 2H), 4.01 (s, 3H), 3.71 - 3.40 (m, 8H), 1.84 (s, 2H), 1.51 (t, J = 5.4 Hz, 4H).
75	1H NMR (400 MHz, DMSO-d6, ppm) : 11.38 (s, 1H), 8.56 - 8.53 (m, 2H), 8.38 (d, J = 0.9 Hz, 1H), 8.18 (s, 1H), 8.03 (d, J = 0.9 Hz, 1H), 7.21 - 7.17 (m, 2H), 5.53 (s, 2H), 4.00 (s, 3H), 3.70 - 3.42 (m, 8H), 1.83 (s, 2H), 1.50 (t, J = 5.2 Hz, 4H).
76	1H NMR (400 MHz, DMSO-d6, ppm): 11.37 (s, 1H), 8.32 (s, 1H), 8.15 (s, 1H), 7.96 (s, 1H), 7.41 - 7.23 (m, 5H), 5.45 (s, 2H), 3.99 (s, 3H), 3.68 - 3.42 (m, 8H), 1.81 (d, J = 25.8 Hz, 2H), 1.50 (t, J = 5.2 Hz, 4H).
77	1H NMR (400 MHz, DMSO-d6) delta 11.30 - 11.24 (m, 1H), 7.86 (s, 1H), 6.06 - 6.02 (m, 1H), 3.98 (s, 3H), 3.67 - 3.43 (m, 5H), 3.43 - 3.11 (m, 4H), 3.31 (s, 3H), 2.62 - 1.46 (m, 12H).
78	1H NMR (300 MHz, DMSO-d6, ppm): 11.95 (s, 1H), 11.41 (s, 1H), 7.95 (s, 1H), 7.80-7.69 (m, 2H), 6.53 (d, J = 9.6 Hz, 1H), 4.01 (s, 3H), 3.62-3.49 (m, 8H), 1.95-1.70 (m, 2H), 1.65-1.40(m, 4H).
79	HNMR(400MHz,DMSO,ppm):11.45(s,1H),8.67(s,1H),8.32-8.24(m,1H),8.09-7.75 (m,2H),4.02(s,3H),3.63-3.30(m,8H),1.86-1.79(m,2H),1.51(s,4H)
80	1H NMR (400 MHz, DMSO-d6)11.57 (s, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.89 (s, 1H), 7.72 (d, J = 7.9 Hz, 2H), 7.54 (dt, J = 32.6, 7.5 Hz, 3H), 3.52 (s, 7H), 3.30 (s, 1H), 1.81 (d, J = 38.2 Hz, 2H), 1.50 (s, 4H).
82	1H NMR (400 MHz, DMSO-d6) d 14.88 - 14.65 (m, 1H), 13.30 (s, 1H), 9.39 - 9.36 (m, 1H), 8.22 - 8.18 (m, 2H), 8.06 (s, 1H), 7.87 - 7.85 (m, 1H), 7.76 - 7.74 (m, 1H), 7.61 - 7.58 (m, 2H), 6.33 - 6.30 (m, 1H), 5.60 - 5.56 (m, 2H), 4.32 (q, J = 2.7 Hz, 2H), 4.04 (s, 3H), 3.89 (t, J = 5.4 Hz, 2H), 2.62 - 2.56 (m, 2H).
83	1H NMR (400 MHz, DMSO-d6) delta 13.19 (s, 1H), 8.41 (d, J = 7.8

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
	Hz, 1H), 8.14 - 8.08 (m, 2H), 8.05 (s, 1H), 7.51 - 7.46 (m, 2H), 6.34 - 6.31 (m, 1H), 4.96 (quint, J = 7.2 Hz, 1H), 4.32 (q, J = 2.7 Hz, 2H), 4.04 (s, 3H), 3.89 (t, J = 5.4 Hz, 2H), 2.62 - 2.56 (m, 2H), 1.86 (s, 3H), 1.36 (d, J = 7.0 Hz, 3H).
84	1H NMR (400MHz,DMSO,ppm):8.15-8.12(m,3H),7.91(s,1H),4.21-4.19(m,2H),3.99(s,3H),3.52-3.51(m,9H),3.33(m,2H),2.50-2.49(m,3H),1.50-1.46(m,9H).
85	1H NMR (400MHz,DMSO,ppm):11.38(s,1H),8.17-8.14(m,2H),7.92(s,1H),4.12-3.99(m,2H),3.85-3.82(m,3H),3.62(s,2H),3.52-3.49(m,8H),3.30-3.20(m,2H),2.13-2.08(m,1H),1.86(s,2H),1.80-1.79(m,4H),1.51-1.42(m,2H),1.29(s,2H).
87	1H NMR (400MHz,DMSO,ppm): 11.41(s, 1H), 8.17 - 8.15 (m, 2H), 7.92 (s, 1H), 4.12 (s, 2H),3.99(s, 3H), 3.75-3.18(m, 12H), 2.15(s, 1H), 1.95-1.28 (m, 10H).
88	1H NMR (500 MHz, DMSO-d6) delta 12.02 - 11.09 (m, 1H), 7.94 (s, 1H), 6.97 (s, 2H), 6.26 - 6.24 (m, 1H), 4.36 - 4.30 (m, 2H), 4.29 (q, J = 2.8 Hz, 2H), 4.15 - 4.07 (m, 1H), 4.00 (s, 3H), 3.87 (t, J = 5.4 Hz, 2H), 2.99 - 2.91 (m, 2H), 2.58 - 2.54 (m, 2H), 2.10 - 2.00 (m, 2H), 1.71 - 1.65 (m, 2H).
89	1H NMR (400 MHz, DMSO-d6) delta 11.57 - 10.66 (m, 1H), 9.51 (s, 1H), 7.96 (s, 1H), 7.65 - 7.60 (m, 2H), 7.52 - 7.47 (m, 2H), 6.27 - 6.25 (m, 1H), 4.30 (q, J = 2.7 Hz, 2H), 4.01 (s, 3H), 3.88 (t, J = 5.4 Hz, 2H), 3.82 (t, J = 7.0 Hz, 2H), 2.59 - 2.53 (m, 2H), 2.50 - 2.45 (m, 2H), 2.10 - 2.02 (m, 2H).
90	1H NMR (400 MHz, DMSO-d6) delta 10.74 -10.71 (m, 1H), 10.06-10.02 (m, 1H), 9.99 - 9.89 (m, 1H), 7.96 (s, 1H), 7.60 - 7.56 (m, 2H), 7.52 - 7.47 (m, 2H), 6.27 - 6.24 (m, 1H), 4.30 (q, J = 2.8 Hz, 2H), 4.15 - 4.11 (m, 2H), 4.01 (s, 3H), 3.88 (t, J = 5.4 Hz, 2H), 2.91 - 2.86 (m, 6H), 2.59 - 2.53 (m, 2H).
91	1H NMR (400 MHz, DMSO-d6) delta 11.76 - 11.45 (m, 1H), 7.98-7.92 (m, 1H), 6.29 - 6.14 (m, 1H), 4.38 - 4.23 (m, 5H), 4.17 - 4.12 (m, 2H), 4.02 - 3.96 (m, 3H), 3.91 - 3.83 (m, 2H), 3.01 - 2.88 (m, 2H), 2.59 - 2.52 (m, 2H), 2.24 - 2.09 (m, 2H), 1.71 - 1.59 (m, 2H).
92	1H NMR (400 MHz, DMSO-d6) d 11.48 - 10.98 (m, 1H), 9.54 (s, 1H), 9.26 (s, 1H), 7.97 (s, 1H), 7.38 (d, J = 2.4 Hz, 1H), 7.31 (d, J = 8.6 Hz, 1H), 7.26 (dd, J = 8.6, 2.5 Hz, 1H), 6.29 - 6.25 (m, 1H), 4.32 - 4.29 (m, 2H), 4.01 (s, 3H), 3.88 (t, J = 5.4 Hz, 2H), 2.60 - 2.54 (m, 2H), 2.19 (s, 3H), 2.04 (s, 3H).
94	1H NMR (500 MHz, DMSO-d6) d 11.95 - 11.08 (m, 1H), 10.05 (s, 1H), 7.97 (s, 1H), 7.66 - 7.59 (m, 4H), 6.28 - 6.26 (m, 1H), 5.56 - 5.55 (m, 1H), 4.31 (q, J = 2.8 Hz, 2H), 4.02 (s, 3H), 3.88 (t, J = 5.4 Hz, 2H), 2.59 - 2.54 (m, 2H), 2.20 (s, 3H).
95	1H NMR (400 MHz, DMSO-d6) d 11.35 - 11.02 (m, 1H), 9.51 (s, 1H),

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
	7.97 (s, 1H), 7.57 - 7.50 (m, 4H), 6.29 - 6.25 (m, 1H), 4.47 - 4.40 (m, 2H), 4.32 - 4.29 (m, 2H), 4.09 - 4.03 (m, 2H), 4.01 (s, 3H), 3.90 - 3.85 (m, 2H), 2.60 - 2.54 (m, 2H).
96	1H NMR (400 MHz, DMSO-d6) d 11.79 - 11.47 (m, 1H), 7.95 (s, 1H), 6.27 - 6.23 (m, 1H), 4.31 - 4.28 (m, 2H), 4.26 - 4.23 (m, 2H), 4.00 (s, 3H), 3.87 (t, J = 5.4 Hz, 2H), 3.04 (s, 3H), 3.02 - 2.86 (m, 3H), 2.81 (s, 3H), 2.58 - 2.52 (m, 2H), 1.72 - 1.62 (m, 2H), 1.52 - 1.39 (m, 2H).
97	1H NMR (400 MHz, DMSO-d6) 13.25 (s, 1H), 8.14 (d, J = 8.8 Hz, 3H), 7.73 (d, J = 7.4 Hz, 2H), 7.58 (t, J = 7.5 Hz, 2H), 7.48 (t, J = 7.4 Hz, 1H), 7.39 (s, 2H), 4.52 (s, 2H), 4.08 (d, J = 1.1 Hz, 3H), 3.64 (d, J = 9.6 Hz, 3H), 2.85 (s, 3H).
98	1H NMR (400 MHz, Methanol-d4, ppm): 7.86 (s, 1H), 6.26 (s, 1H), 4.37-4.35 (m, 2H), 4.09 (s, 3H), 4.01-3.96 (m, 2H), 3.62 (s, 2H), 3.49-3.44(m, 2H), 2.99-2.86(m, 4H), 2.63-2.61 (m, 2H), 2.00-1.92 (m, 2H), 1.70-1.65 (m, 4H).
99	1H NMR (400MHz,DMSO,ppm):11.68(s, 1H), 8.04(s, 1H), 7.71-7.69(m, 2H), 7.57-7.54(m, 2H), 7.47-7.46(m, 1H), 4.33-4.30(m, 2H), 4.04-4.01(m, 4H), 2.99-2.98(m, 2H),2.58-2.49(m, 4H), 2.16-2.14(m, 2H), 1.58-1.56(m, 2H).
100	1H NMR (400MHz,DMSO,ppm):11.62(s, 1H), 7.93(s, 1H), 6.25(s, 1H), 4.29-4.28(m, 5H), 3.98(s, 3H), 3.88-3.85(m, 2H), 2.92(s, 2H), 2.58-2.49(m, 6H), 2.16-2.14(m, 2H), 1.58-1.55(m, 2H).
101	1H NMR (400MHz,DMSO,ppm):7.62-7.60(m,2H),7.57-7.56(m,2H),7.54-7.48(m, 1H),4.04-3.44(m,4H),3.33-3.30(m,4H),3.08(s,1H),2.81(s,2H),2.51-2.37(m,6H), 1.23(s, 1H).
102	1H NMR (400 MHz, Methanol-d4, ppm): 7.88 (s, 1H), 6.25 (s, 1H), 4.37-4.36 (m, 2H), 4.09 (s, 3H), 3.99-3.96 (m, 2H), 3.62-3.60 (m, 2H), 3.53-3.50(m, 1H), 3.37-3.34(m, 1H), 2.92-2.76(m, 4H), 2.63-2.61 (m, 2H), 1.98-1.91 (m, 2H), 1.71-1.69 (m, 4H).
103	1H NMR (400 MHz, DMSO-d6, ppm): 11.37 (s, 1H), 8.17-8.13 (m, 2H), 7.92 (s, 1H), 4.37-4.35 (m, 2H), 4.00 (s, 3H), 3.83-3.80 (m, 2H), 3.62-3.50 (m, 9H), 3.44-3.42 (m, 3H),3.21 (s, 3H), 1.90-1.70 (m, 2H), 1.51-1.48 (m, 4H).
104	1H NMR (400 MHz, Methanol-d4, ppm): 8.08 (s, 2H), 7.93 (s, 1H), 4.18-4.16 (m, 2H), 4.12 (s, 3H), 3.83-3.75 (m, 4H), 3.72-3.62 (m, 4H), 3.53-3.47 (m, 3H), 3.32-3.29 (m, 1H), 2.26-2.24 (m, 1H), 1.97-1.80 (m, 2H), 1.73-1.71 (m, 1H), 1.67-1.64 (m, 1H), 1.63-1.60 (m, 5H), 1.40-1.36 (m, 1H).
105	1H NMR (400 MHz, Methanol-d4, ppm): 8.09 (s, 2H), 7.93 (s, 1H), 4.19-4.16 (m, 2H), 4.12 (s, 3H), 3.84-3.75 (m, 4H), 3.72-3.62 (m, 4H), 3.53-3.48 (m, 3H), 3.32-3.29 (m, 1H), 2.26-2.24 (m, 1H), 1.97-1.80 (m, 2H), 1.74-1.71 (m, 1H), 1.67-1.64 (m, 1H), 1.62-1.60 (m, 5H), 1.40-1.36 (m, 1H).

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
106	1H NMR (700 MHz, DMSO-d6) d 11.55 - 11.50 (m, 1H), 7.94 (s, 1H), 7.30 - 7.27 (m, 1H), 6.82 - 6.79 (m, 1H), 6.26 - 6.24 (m, 1H), 4.29 (q, J = 2.7 Hz, 2H), 4.22 - 4.17 (m, 2H), 3.99 (s, 3H), 3.87 (t, J = 5.5 Hz, 2H), 2.95 - 2.88 (m, 2H), 2.57 - 2.54 (m, 2H), 2.37 - 2.32 (m, 1H), 1.76 - 1.72 (m, 2H), 1.50 - 1.43 (m, 2H).
107	1H NMR (400 MHz, DMSO-d6) d 11.37 - 11.30 (m, 1H), 7.94 (s, 1H), 6.25 - 6.23 (m, 1H), 4.29 (q, J = 2.7 Hz, 2H), 3.99 (s, 3H), 3.87 (t, J = 5.4 Hz, 2H), 3.81 - 3.76 (m, 2H), 3.59 - 3.52 (m, 4H), 3.47 - 3.38 (m, 2H), 2.58 - 2.53 (m, 2H), 1.97 - 1.88 (m, 2H), 1.91 - 1.82 (m, 2H).
108	1H NMR (400 MHz, DMSO-d6) d 11.37 - 11.30 (m, 1H), 7.94 (s, 1H), 6.25 - 6.23 (m, 1H), 4.29 (q, J = 2.7 Hz, 2H), 3.99 (s, 3H), 3.87 (t, J = 5.4 Hz, 2H), 3.81 - 3.76 (m, 2H), 3.59 - 3.52 (m, 4H), 3.47 - 3.38 (m, 2H), 2.58 - 2.53 (m, 2H), 1.97 - 1.88 (m, 2H), 1.91 - 1.82 (m, 2H).
109	1H NMR (400 MHz, DMSO-d6) d 13.46-13.40 (m, 1H), 13.40-13.23 (m, 1H), 8.26 - 8.21 (m, 2H), 8.15 (s, 1H), 8.11 -8.07 (m, 2H), 7.76 - 7.72 (m, 2H), 7.62 - 7.56 (m, 2H), 7.52 - 7.46 (m, 1H), 4.09 (s, 3H).
110	1H NMR (500 MHz, DMSO-d6) d 13.46 - 13.31 (m, 1H), 8.37 - 8.33 (m, 1H), 8.24 - 8.18 (m, 2H), 8.16 - 8.14 (m, 1H), 7.76 - 7.73 (m, 2H), 7.63 - 7.56 (m, 3H), 7.52 - 7.47 (m, 1H), 4.12 - 4.08 (m, 3H).
112	1H NMR (400 MHz, DMSO-d6) 11.32 (s, 1H), 7.98 (s, 1H), 7.23 (t, J = 7.8 Hz, 1H), 6.92 ? 6.73 (m, 2H), 6.60 (d, J = 8.9 Hz, 1H), 5.90 (d, J = 5.2 Hz, 1H), 4.02 (s, 3H), 3.71 ? 3.38 (m,7H), 3.32 (s, 1H), 2.72 (d, J = 5.0 Hz, 3H), 1.83 (s, 2H), 1.50 (s, 4H)
113	1H NMR (400 MHz, DMSO-d6)11.41 (s, 1H), 8.13 (s, 1H), 7.30 (d, J = 3.6 Hz, 1H), 6.92 (d, J = 3.5 Hz, 1H), 4.01 (s, 3H), 3.57 (d, J = 47.7 Hz, 7H), 2.52 (s, 3H), 1.84 (s, 2H), 1.51 (s, 4H).
115	1H NMR (500 MHz, DMSO-d6) d 13.52 - 13.20 (m, 2H), 8.61 - 8.60 (m, 1H), 8.53 (dd, J = 4.8, 1.7 Hz, 1H), 8.47 - 8.45 (m, 1H), 8.27 - 8.24 (m, 3H), 8.11 - 8.08 (m, 2H), 8.03 (d, J = 0.8 Hz, 1H), 7.74 (dt, J = 7.9, 2.0 Hz, 1H), 7.43 - 7.39 (m, 1H), 5.53 (s, 2H), 4.05 (s, 3H).
116	1H NMR (400 MHz, DMSO-d6) d 13.97 - 12.99 (m, 1H), 12.85 (s, 1H), 8.57 - 8.27 (m, 2H), 8.01 (s, 1H), 6.31 - 6.27 (m, 1H), 4.31 (q, J = 2.8 Hz, 2H), 4.06 - 4.01 (m, 3H), 3.89 (t, J = 5.4 Hz, 2H), 2.61 - 2.55 (m, 2H).
117	1H NMR (500 MHz, DMSO-d6) delta 13.50 - 13.46 (m, 1H), 12.89 - 12.87 (m, 1H), 8.61 - 8.58 (m, 1H), 8.25 - 8.21 (m, 1H), 8.11 (s, 1H), 7.74 - 7.71 (m, 2H), 7.60 - 7.56 (m, 2H), 7.50 - 7.46 (m, 1H), 4.08 (s, 3H).
118	1H NMR (400MHz,DMSO,ppm):11.96(s,1H),8.14-8.11(m,2H),7.91(s,1H),4.21-4.00(m,2H),3.87-3.85(m,3H),3.73-3.67(m,1H),3.62(s,3H),3.52-3.50(m,4H),3.34-3.31 (m,3H), 1.80(S,3H), 1.78(S,1H), 1.60-1.50(m,7H), 1.46-1.42(m, 1H)
119	1H NMR (400MHz,DMSO,ppm):11.96(s,1H),8.14-

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
	8.11(m,2H),7.91(s,1H),4.21-4.00(m,2H),3.87-3.85(m,3H),3.73-3.67(m,1H),3.62(s,3H),3.52-3.50(m,4H),3.34-3.31(m,3H),1.80(S,3H),1.78(S,1H), 1.60-1.50(m,7H),1.46-1.42(m,1H)
120	1H NMR (400 MHz, DMSO-d6, ppm): 11.37 (s, 1H), 10.01 (s, 1H), 8.01 (s, 1H), 7.53-7.49 (m, 2H), 7.41-7.39 (m, 1H), 7.29-7.27 (m, 1H), 4.04 (s, 3H), 3.62-3.45 (m, 8H), 3.08 (s, 3H), 1.90-1.70 (m, 2H), 1.51-1.48 (m, 4H).
121	1H NMR (400 MHz, Methanol-d4, ppm): 7.88 (s, 1H), 6.26 (s, 1H), 4.37-4.36 (m, 2H), 4.09 (s, 3H), 3.98-3.96 (m, 2H), 3.62-3.60 (m, 2H), 3.52-3.50(m, 1H), 3.36-3.33(m, 1H), 2.89-2.72(m, 4H), 2.63-2.61 (m, 2H), 1.98-1.91 (m, 2H), 1.71-1.69 (m, 4H).
122	1H NMR (400 MHz, Methanol-d4, ppm): 7.88 (s, 1H), 6.26 (s, 1H), 4.37-4.36 (m, 2H), 4.09 (s, 3H), 3.98-3.96 (m, 2H), 3.62-3.60 (m, 2H), 3.52-3.50(m, 1H), 3.36-3.33(m, 1H), 2.89-2.72(m, 4H), 2.63-2.61 (m, 2H), 1.98-1.91 (m, 2H), 1.71-1.61 (m, 4H).
123	1H NMR (400 MHz, DMSO-d6, ppm): 11.57(s, 1H), 8.03 (s, 1H), 7.70-7.68 (m, 2H), 7.57-7.53 (m, 2H), 7.47-7.44 (m, 1H), 4.23-4.20 (m, 2H), 4.04 (s, 3H), 3.04 (s, 3H), 2.99-2.88 (m, 3H), 2.81 (s, 3H), 1.68-1.66 (m, 2H), 1.50-1.46 (m, 2H).
124	1H NMR (400MHz,DMSO,ppm):11.398(s,1H),8.05-8.02(m,2H),6.78-6.73(m,2H),6.19(s,2H),4.03-3.97(m,3H),3.53-3.31(m,8H),1.50-1.49(m,6H).
126	1H NMR (400MHz,DMSO,ppm):8.66 (s, 1H), 8.24-8.22 (d, J = 8.5 Hz, 2H), 8.04 ? 7.98 (m, 3H), 6.33 ? 6.32 (m, 1H), 4.33-4.32 (m, J = 2.8 Hz, 2H), 4.04-3.90 (m, 3H), 3.89 (t, J = 5.4 Hz, 2H), 3.46-3.31(d, J = 6.5 Hz, 2H), 2.67-2.50 (m, J = 1.8 Hz, 8H), 2.33-1.42(d, J = 5.7 Hz, 7H)
127	1H NMR (400 MHz, DMSO, ppm): 11.395 (s, 1H), 8.11-8.07 (m, 2H), 6.78-6.70(m, 3H), 4.03 (s, 3H), 3.62-3.31 (m, 8H), 2.50-2.49 (m, 3H), 1.81-1.79(m, 2H), 1.50 (s, 4H).
129	1H NMR (400MHz,DMSO,ppm):13.31(s,1H), 8.21-8.19(m,2H), 8.05(s,1H), 7.57-7.55(m,2H), 6.32(s,1H), 4.44(s,1H), 4.34-4.32(m,2H), 4.04(s,5H), 3.91-3.88(m,2H), 3.31(s,2H), 2.60-2.59(m,2H), 1.60-1.58(m,4H), 1.162(s,3H).
130	1H NMR (400MHz, DMSO, ppm): 11.40 (s, 1H), 11.32 (s, 1H), 8.05 (s, 1H), 7.34 (s, 1H), 7.23-7.21 (m, 1H), 7.09-7.06 (m, 1H), 4.04 (s, 3H), 3.53-3.31 (m, 8H), 3.14 (s, 3H), 1.86-1.81 (m, 2H), 1.60-1.50 (m, 4H).
131	(400MHz, DMSO, ppm):11.6(s,1H), 8.03(s,1H), 7.95(s,1H), 6.25(s,1H), 4.33-4.29(m,4H), 4.05-4.00(m,4H), 3.88-3.85(m,4H), 2.96-2.90(m,2H), 2.55(s,2H), 2.18-2.14(m,2H), 1.64-1.61(m,2H).
132	1H NMR (400 MHz, DMSO-d6, ppm): 7.92 (s, 2H), 6.14 (s, 1H), 4.27-4.25 (m, 2H), 4.01 (s, 3H), 3.95-3.94 (m, 3H), 3.87-3.84 (m, 2H),

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
	3.63-3.50 (m, 6H), 3.45-3.40 (m, 2H), 3.28-3.27 (m, 1H), 1.87-1.75 (m, 2H), 1.60-1.44 (m, 4H).
133	(400MHz,DMSO,ppm):11.292(s,1H), 7.62(s,1H), 3.94(s,3H), 3.65-3.31(m,10H), 2.84-2.75(m,3H), 2.03-1.99(m, 1H), 1.90-1.69(m,4H), 1.51-1.47(m,5H).
134	(400MHz,DMSO,ppm):11.27(s,1H), 7.56(s,1H), 3.93(s,3H), 3.62-3.53(m,2H), 3.52-3.39(m,8H), 3.38-3.31(m,3H), 3.24-3.21(m,1H), 2.74-2.68(m,2H), 2.09-1.99(m,1H), 1.98-1.78(m,3H), 1.77-1.45(m,5H), 1.41-1.1.25(m,1H).
135	(400 MHz, DMSO-d6)9.59 (d, J = 6.9 Hz, 1H), 8.79 (s, 1H), 7.98 (s, 1H), 7.81 (d, J = 9.0 Hz, 1H), 7.58 (d, J = 14.9, 7.2 Hz, 1H), 7.23 (t, J = 6.9 Hz, 1H), 6.31 (s, 1H), 4.33 (q, J = 2.8 Hz, 2H), 4.02 (s, 3H), 3.94 ? 3.84 (m, 2H), 2.58 (s, 2H).
136	(400MHz , DMSO, ppm) : 11.44-11.39 ,(m , 1H), 8.28-8.19 (m , 2H) , 6.30 (s , 1H) , 4.54 (s, 2H) , 4.03 (s , 3H) , 3.62-3.32 (m , 8H) , 1.89-1.76 (m , 2H) , 1.50-0.86 (m , 4H).
137	(400MHz,DMSO,ppm):11.64(s,1H), 8.03(s,2H), 7.71-7.69(m,2H), 7.57-7.54(m,2H), 7.47-7.44(m,1H), 4.34-4.30(m,2H), 4.04(s,4H), 3.85(s,2H), 2.95-2.89(m,2H), 2.30-2.13(m,2H), 1.63-1.61(m,2H).
138	1H NMR (400 MHz, DMSO-d6) 11.39 (s, 1H), 7.95 (d, J = 1.5 Hz, 1H), 7.56 (t, J = 2.5 Hz, 1H), 7.28 (m, J = 8.6, 2.9 Hz, 1H), 5.46 (s, 2H), 4.04 (s, 3H), 3.80 ? 3.39 (m, 8H), 1.86 (d, J = 38.0 Hz, 2H), 1.50 (s, 4H).
139	(400MHz,DMSO,ppm):8.57(m,1H)?8.23-8.21(m,2H)?7.96-7.94(m,3H)?6.32(s,1H)?4.33(s,2H)?4.02-3.88(m,5H)?3.31-3.23(m,6H)?2.67-2.51(m,4H)?2.03-2.01(m,2H).
140	HNMR15 (400MHz , DMSO , ppm) : 9.21-9.206 ,(m , 1H), 8.61-8.43 (m, 1H) , 8.09-7.95 (m , 1H) , 7 .61-7.58 (m, 1H) , 6.32 (s , 1H) , 4.89-4.83 (m , 1H) , 4.13-3.40 (m , 1H) , 3.62-3.21 (m , 2H) , 3.15-3.00 (m, 5H), 2.87-2.65 (m , 2H)
141	(400MHz , DMSO , ppm) : 11.408 ,(s , 1H) , 8.11-8.00 (m , 1H) , 7.99 (s , 2H), 7 .82-7.78 (m, 2H), 4.05 (s , 3H) , 3.62-3.31 (m , 7H) , 1.85-1.83 (m, 2H), 1.51-1.23 (m , 4H).
142	(400MHz , DMSO , ppm) : 11.39(s , 1H) , 7.98 (s , 1H) , 7.57-7.56 (m , 1H) , 7.43-7.40 (s, 1H) , 5.73(s , 2H) , 4.03 (s , 3H) , 3.61-3.31 (m , 8H), 2.07-1.77 (m, 2H), 1.50 (s, 4H) .
143	(400MHz,DMSO,ppm):11.38(s,1H), 8.00-7.99(m,3H), 7.19-7.17(m,1H), 5.58(s,2H), 4.03(s,3H), 3.61-3.31(m,8H), 1.99-1.78(m,2H), 1.50(s,4H).
144	(400MHz , DMSO , ppm) : 8.10-8.08 ,(m , 2H) , 7.96 (s , 1H) , 7.41-7.39 (m , 2H) , 6.31 (s, 1H) , 4.33 -4.31(m , 2H) , 4.04-4.01 (m , 3H) , 3.90-3.87 (m , 2H) , 3.64-3.31 (m , 2H) , 2.54-2.32 (m , 2H) .

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
145	1H NMR (400 MHz, DMSO-d6, ppm): 11.26 (s, 1H), 7.86 (s, 1H), 6.00 (s, 1H), 3.97 (s, 3H), 3.65-3.62 (m, 2H), 3.52-3.31 (m, 6H), 2.40-2.33 (m, 3H), 1.90-1.76 (m, 4H), 1.71-1.70 (m, 1H), 1.66-1.50 (m, 4H), 1.30-1.20 (m, 1H), 1.10-1.02 (m, 3H).
146	1H NMR (400 MHz, DMSO-d6, ppm): 11.26 (s, 1H), 7.85 (s, 1H), 6.00 (s, 1H), 3.97 (s, 3H), 3.65-3.62 (m, 2H), 3.52-3.31 (m, 6H), 2.40-2.33 (m, 3H), 1.87-1.82 (m, 4H), 1.68-1.64 (m, 1H), 1.51-1.48 (m, 4H), 1.30-1.20 (m, 1H), 1.10-1.02 (m, 3H).
147	(400MHz,DMSO,ppm):11.37(s,1H), 8.02(s,1H), 7.80(s,1H), 7.54-7.29(m,4H), 7.06-7.04(m,1H), 4.03(s,3H), 3.83(s,3H), 3.62-3.49(m,8H), 1.83-1.81(m,2H), 1.50(s,4H).
148	1H NMR (400 MHz, DMSO-d6) ? 12.66 (s, 1H), 8.78 (s, 1H), 8.05 (s, 1H), 7.63-6.98(m, 1H), 6.31 (s, 1H), 4.32 (s, 2H), 4.03 (s, 3H), 3.89 (s, 2H), 2.59 (s, 2H).
149	(400MHz,DMSO,ppm):11.34-11.33(m,1H), 10.19(s,1H), 7.95(s,1 H), 7.32-7.24(m,2H), 7.09-7.05(m,1H), 4.02(s,3H), 3.62-3.31(m,8H), 1.81(s,2H), 1.50(s,4H).
150	(400MHz,DMSO,ppm):11.36(s,1H), 9.67(s,1H), 7.93(s,1H), 7.21-7.17(m,1H), 6.94-6.91(m,1H), 6.87-6.84(m,1H), 4.04(s,3H), 3.61-3.49(m,8H), 1.84-1.80(m,2H),1.50(s,4H).
151	1H NMR (400 MHz, DMSO-d6, ppm): 11.25 (s, 1H), 7.84 (s, 1H), 4.82-4.79 (m, 1H), 3.96-3.92 (m, 4H), 3.84-3.78 (m, 3H), 3.66-3.49 (m, 10H), 1.83-1.70 (m, 2H), 1.51-1.48 (m, 4H).
152	1H NMR (400 MHz, DMSO-d6, ppm): 11.25 (s, 1H), 7.84 (s, 1H), 4.82-4.79 (m, 1H), 3.96-3.92 (m, 4H), 3.84-3.78 (m, 3H), 3.66-3.49 (m, 10H), 1.83-1.70 (m, 2H), 1.51-1.48 (m, 4H).
153	(400MHz, DMSO , ppm) : 11.310(s , 1H) , 9.70 (s , 1H) , 7.98 (s , 1H) , 7.34-7.31 (m, 1H) , 7.09-7.06 (m , 2H) , 6.85-6.82 (m , 1H) , 4.03 (s , 3H) , 3.65-3.23 (m , 8H) , 1.82 (s , 2H) , 1.51-1.49 (s , 4H).
154	1H NMR (300 MHz, DMSO-d6) ? 8.28 (s, 1H), 7.87 (s, 1H), 7.05 (s, 2H), 6.28 (s, 1H), 4.30 (d, J = 2.8 Hz, 2H), 3.98 (s, 3H), 3.87 (t, J = 5.4 Hz, 2H), 2.70 (s, 2H), 2.56 (s, 2H).
155	1H NMR (400MHz, DMSO-d6, ppm): 11.06 (s, 1H), 8.63-8.62(m, 2H), 7.29 (s, 1H), 6.91 (s, 1H), 4.05 (s, 3H), 3.63-3.29 (m, 8H), 2.86-2.85 (m, 3H), 2.49-2.47 (m, 2H), 1.82-1.74 (m, 2H), 1.51-1.44 (m, 4H).
156	1H NMR (300 MHz, DMSO-d6) ? 9.24 (s, 1H), 8.46 (s, 1H), 8.00 (s, 1H), 7.91 ? 7.81 (m, 2H), 7.56 (dd, J = 8.6, 7.2 Hz, 2H), 7.45 ? 7.35 (m, 1H), 6.32 ? 6.24 (m, 1H), 4.30 (q, J = 2.8 Hz, 2H), 4.02 (s, 3H), 3.87 (t, J = 5.4 Hz, 2H), 2.62 ? 2.52 (m, 2H).
157	1H NMR (300 MHz, DMSO-d6) ? 13.12 (s, 1H), 9.46 (s, 1H), 8.72 (d, J = 5.2 Hz, 2H), 8.58 (s, 1H), 8.13 ? 7.79 (m, 3H), 6.27 (s, 1H), 4.30 (s, 2H), 4.15 ? 3.72 (m, 5H), 2.56 (s, 2H).

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
158	1H NMR (300 MHz, DMSO-d6) ? 12.92 (s, 1H), 12.21 (s, 1H), 8.55 (s, 1H), 8.20 (s, 1H), 7.99 (s, 1H), 7.12 (s, 1H), 6.89 (s, 1H), 6.33 ? 6.19 (m, 1H), 5.40 (s, 2H), 4.30 (q, J = 2.8 Hz, 2H), 4.01 (s, 3H), 3.87 (t, J = 5.4 Hz, 2H), 2.56 (s, 2H).
159	(400MHz , DMSO , ppm) : 11.310(s , 1H) ,7.986(s , 1H) , 7.27-7.24 (m, 1H) , 6.85-6.83 (m , 2H) , 6.67-6.65(m , 1H) , 6.03-6.00 (m ,1H) ,4.023 (s, 3H), 3.61 (s, 2H), 3.53-3.50 (m , 5H), 3.40-3.31 (m, 3H) , 2.63-2.52 (m, 2H), 2.50-1.82 (m, 6H) .
160	(400MHz,DMSO,ppm):11.37(s,1H),8.48-8.47(m,1H),8.41-8.40(m,1H),8.04(s,1H),7.60-7.58(m,2H),7.57-7.49(m,2H),7.38-7.37(m,1H),7.11-7.09(m, 1H),4.03(s,3H),3.63-3.62(m,2H),3.52-3.49(m,6H), 1.82-1.80(s,2H), 1.50(s,4H).
161	1H NMR (400 MHz, DMSO-d6) 8.22 (d, J = 8.2 Hz, 2H), 8.06 (d, J = 8.4 Hz, 2H), 7.93 (s, 1H), 4.88 (d, J = 10.1, 2.9 Hz, 1H), 4.01 (s, 4H), 3.94 ? 3.77 (m, 3H), 3.75 ? 3.48 (m, 2H).
162	(400MHz , DMSO, ppm): 13.6-13.5(m , 1H) ,12.46-12.43(m , 1H) , 8.67-8.66 (m , 1H) , 8.25-8.23 (m , 2H) , 8.17-7.96(m , 2H) , 7.48-7.45 (m, 1H) , 6.31 (s, 1H) , 4.33-4.32 (m , 2H) , 4.03 (s , 3H) , 3.91-3.88 (m , 2H) , 2.67-2.50 (m , 2H) .
163	(400MHz,DMSO,ppm):11.37(s,1H),8.31(s,1H),8.17(s,1H),7.95(s,1H), 7.33-7.24(m,3H),7.06-7.04(m,2H),4.00(s,3H),3.62-3.32(m,8H),2.12-1.99(s,6H),1.99-1.75(s,2H),1.65-1.35(s,4H),1.35-1.10(s,3H),0.99-0.75(s,1H).
164	1H NMR (400 MHz, DMSO-d6) 13.27 (s, 1H), 8.32 (d, J = 8.4 Hz, 2H), 8.20 (d, J = 8.3 Hz, 2H), 7.97 (d, J = 0.7 Hz, 1H), 7.08 (s, 1H), 4.90 (dd, J = 9.9, 3.0 Hz, 1H), 4.03 (s, 4H), 3.94 ? 3.79 (m, 3H), 3.68 (td, J = 11.6, 2.7 Hz, 1H), 3.59 (dd, J = 11.6, 10.2 Hz, 1H).
165	(400MHz , DMSO , ppm) : 8.80-8.02(m, 2H) ,7.58(m , 1H) , 6.30 (s , 3H) , 4.68 (s, 1H), 4.33-4.28(m , 2H), 4.10-3.48 (m ,3H) ,3.30-3.12 (m, 2H), 2.89-2.42 (m, 2H) .
166	(400MHz , DMSO, ppm): 11.29(s, 1H) ,8.32(s , 1H) , 8.01-7.94 (m , 2H) , 7.24-7.20 (m , 1H) , 6.91-6.83(m , 2H) , 6.69 (s ,1H) ,6.29-6.26 (m, 1H) , 4.22-4.21 (m , 2H), 4.02 (s ,3H) ,3.62-3.30 (m , 8H) , 1.81-1.78 (m, 2H), 1.81-1.50 (m , 4H).
167	1H NMR (400 MHz, DMSO-d6) ? 8.15 (d, J = 8.2 Hz, 2H), 8.04 (s, 1H), 7.42 (s, 2H), 6.32 (s, 1H), 4.52 (s, 2H), 4.32 (q, J = 2.8 Hz, 2H), 4.04 (s, 3H), 3.89 (t, J = 5.4 Hz, 2H), 3.65 (s, 3H), 2.85 (s, 3H), 2.59 (s, 2H).
168	(400MHz,DMSO,ppm): 8.01(s,1H),7.94(s,1H),6.29(s,1H),4.32(s,2H),4.02(s,3H),3.90(m,2H),2.65-2.54(m,2H).
169	1H NMR (400 MHz, DMSO-d6) 8.22 (d, J = 8.2 Hz, 2H), 8.06 (d, J = 8.4 Hz, 2H), 7.93 (s, 1H), 4.88 (d, J = 10.1, 2.9 Hz, 1H), 4.01 (s, 4H),

The Nos. recited herein corresponds to the numbering of the compounds disclosed in table 2.	
No.	**NMR**
	3.94 ? 3.77 (m, 3H), 3.75 ? 3.48 (m, 2H).
170	1H NMR (400 MHz, DMSO-d6) 8.22 (d, J = 8.2 Hz, 2H), 8.06 (d, J = 8.4 Hz, 2H), 7.93 (s, 1H), 4.88 (d, J = 10.1, 2.9 Hz, 1H), 4.01 (s, 4H), 3.94 ? 3.77 (m, 3H), 3.75 ? 3.48 (m, 2H).
171	1H NMR (400MHz, DMSO-d6, ppm): 11.44 (s, 1H), 8.09 (s, 1H), 3.97 (s, 3H), 3.62-3.29 (m, 8H), 1.83-1.80 (m, 2H), 1.60-1.50 (m, 6H).
172	(400MHz,DMSO,ppm): 11.49(s,1H),8.89(m,1H),8.39(s,1H),8.29(s,1H),8.06(m,1H),7.80-7.22(m,3H),4.07-4.04(m,3H),3.62-3.32(m,8H),1.98-1.83(s,2H),1.61-1.45(m,4H), 1.28-1.15(m, 1H).
173	1H NMR (400 MHz, DMSO-d6) 11.32 (s, 1H), 7.93 (s, 1H), 6.23 (tt, J = 2.9, 1.4 Hz, 1H), 4.29 (q, J = 2.8 Hz, 2H), 3.86 (t, J = 5.4 Hz, 2H), 3.73 ? 3.35 (m, 6H), 3.32 (s, 1H), 3.19 (s, 1H), 2.55 (dh, J = 6.0, 3.4, 2.7 Hz, 2H), 1.82 (s, 1H), 1.72 ? 1.45 (m, 5H)
174	1H NMR (400 MHz, DMSO-d6) 11.32 (s, 1H), 7.93 (s, 1H), 6.23 (tt, J = 2.9, 1.4 Hz, 1H), 4.29 (q, J = 2.8 Hz, 2H), 3.86 (t, J = 5.4 Hz, 2H), 3.73 ? 3.35 (m, 6H), 3.32 (s, 1H), 3.19 (s, 1H), 2.55 (dh, J = 6.0, 3.4, 2.7 Hz, 2H), 1.82 (s, 1H), 1.72 ? 1.45 (m, 5H).

Example 2: Preparation of the compounds of the present invention and analytical methods

[0147] All solvents used were commercially available and used without further purification. Reactions were typically run using anhydrous solvents under an inert atmosphere of nitrogen. Flash column chromatography was generally carried out using Silica gel 60 (0.035-0.070 mm particle size).

[0148] All NMR experiments were recorded either on Bruker Mercury Plus 400 NMR Spectrometer equipped with a Bruker 400 BBFO probe at 400 MHz for proton NMR or on Bruker Mercury Plus 300 NMR Spectrometer equipped with a Bruker 300 BBFO probe at 300 MHz for proton NMR. All deuterated solvents contained typically 0.03% to 0.05% v/v tetramethylsilane, which was used as the reference signal (set at δ = 0.00 for both ^{1}H and ^{13}C).

[0149] LC-MS analyses were performed on a SHIMADZU LC-MS machine consisting of an UFLC 20-AD system and LCMS 2020 MS detector. The column used was a Shim-pack XR-ODS, 2.2 µm, 3.0 × 50 mm. A linear gradient was applied, starting at 95 % A (A: 0.05% TFA in water) and ending at 100% B (B: 0.05% TFA in acetonitrile) over 2.2 min with a total run time of 3.6 min. The column temperature was at 40°C with the flow rate at 1.0 mL/min. The Diode Array detector was scanned from 200-400 nm. The mass spectrometer was equipped with an

electro spray ion source (ES) operated in a positive or negative mode. The mass spectrometer was scanned between *m/z* 90-900 with a scan time of 0.6 s. If not otherwise stated.

1. (5R)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide 24 and (5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide 25

[0150]



a. 4-chloro-5-iodo-3-nitropyridin-2-ol

[0151] Into a 250-mL round-bottom flask was placed 4-chloro-3-nitropyridin-2-ol (10.0 g, 54.4 mmol, 95%), N-Iod-succinimid (NIS, 14.2 g, 59.9 mmol, 95%) in acetonitrile (115 mL). The solution was stirred for 1 h overnight at 80°C in an oil bath. The mixture was concentrated and the precipitate formed collected by filtration. The residue was washed with twice with petrol ether (500 mL) dried under vacuum at 60°C overnight. This resulted in 4-chloro-5-iodo-3-nitropyridin-2-ol (16.5 g, 97.9%, 97% purity) as a yellow solid. MS: *m/z* = 300.9 $[M+H]^+$.

b. 4-chloro-5-iodo-2-methoxy-3-nitropyridine

[0152] Into a 500-mL round-bottom flask was placed 4-chloro-5-iodo-3-nitropyridin-2-ol (16.5 g, 53.3 mmol, 97%), Ag_2CO_3 (15.5 g, 53.3 mmol, 95%) in toluene (310 mL). To this suspension CH_3I (15.9 g, 107 mmol, 95%) was added at 50°C and the mixture was stirred at 80°C for 4 h.

The precipitate was collected by filtration and discarded. The filtrate was evaporated to dryness under vacuum and the residue purified by silica gel chromatography with ethyl acetate/petroleum ether (15:85). This resulted in 4-chloro-5-iodo-2-methoxy-3-nitropyridine (9.90 g, 52.6%, 89% purity) as a light yellow solid. MS: *m/z* = 315.5 $[M+H]^+$.

c. 4-chloro-5-iodo-2-methoxypyridin-3-amine

[0153] Into a 250-mL 3-necked round-bottom flask was placed 4-chloro-5-iodo-2-methoxy-3-nitropyridine (9.90 g, 28.0 mmol, 89%), iron (16.5 g, 281 mmol, 95%) and NH_4Cl (9.40 g, 174 mmol, 99%) in ethanol (152 mL) and water (30 mL). The mixture was stirred for 2 h at 80°C in an oil bath. The reaction mixture was filtered over Celite, washed with ethanol and the mother liquor was concentrated to dryness. The residue was stirred for 30 min. with 100 ml water at 60°dried in vacuo. This resulted in 4-chloro-5-iodo-2-methoxypyridin-3-amine (7.20 g, 75%, 83% purity) as an off-white solid. It was used without further purification in the next step. MS: *m/z* = 285.9 $[M+H]^+$.

d. N-[7-iodo-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide

[0154] Into a 500-mL round-bottom flask was placed 4-chloro-5-iodo-2-methoxypyridin-3-amine (7.20 g, 21.0 mmol, 83%) in acetone (150 mL) and benzoyl isothiocyanate (5.21 g, 31.5 mmol, 99%) was added dropwise at room temperature. The solution was stirred for 1 h at 50 °C in an oil bath. The solids were collected by filtration, washed with acetone and dried in vacuo to give N-[7-iodo-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (8.73 g, 91%, 90% purity) as a white solid. MS: *m/z* = 412.2 $[M+H]^+$.

e. N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide

[0155] To a solution of N-[7-iodo-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (6.00 g, 13.1 mmol, 90%) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6.13 g, 27.7 mmol, 95%) in dioxane (200 mL) and water (40.00 mL) were added NaOH (2.90 g, 68.9 mmol, 95%) and Pd(dppf)Cl_2* dichloromethane (1.20 g, 1.40 mmol, 95%). After stirring for 1 h at 100°C under a nitrogen atmosphere, the mixture was concentrated to dryness under vacuo. The residue was purified by silica gel chromatography with ethyl acetate/hexane (95:5). This resulted in 3.32 g (62%, 90% purity) of N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide as colorless solid. MS: m/z= 368.1 $[M+H]^+$.

f. 7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-amine

[0156] To a stirred mixture of N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (3.27 g, 8.00 mmol, 90%) in water/methanol (1:1, 300 mL) was added NaOH (3.36 g, 80.0 mmol, 95%) at room temperature under nitrogen atmosphere. The mixture was stirred for overnight at 90°C under nitrogen atmosphere and evaporated to dryness. The residue was taken up in water and extracted 3 times with dichloromethane (100 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and evaporated to dryness. The residue was purified by silica gel column chromatography, eluted with petrol ether/ethyl acetate (1:1) to afford 7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-amine (1.50 g, 68%, 96% purity) as a light brownish solid. MS: *m/z* = 264.1 $[M+H]^+$.

g. phenyl N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate

[0157] To a stirred solution of 7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-amine (600 mg, 2.19 mmol, 96%) and phenyl chloroformate (1.81 g, 11.0 mmol, 95%) in THF (50 mL) was added K_2CO_3 (1.59 g, 11.0 mmol, 95%) and pyridine (913 mg, 11.0 mmol, 95%) at room temperature under nitrogen atmosphere. The mixture was stirred for 6 h at 50° and then after re-cooling to room temperature quenched by the addition of water (300 mL). The mixture was extracted 3 times with dichloromethane (200 mL), the combined organic layers were washed once with brine (200 mL), dried over anhydrous Na_2SO_4, filtered, and evaporated to dryness under reduced pressure. This resulted in phenyl N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate (1.00 g, 69%, 76% purity) as a light yellow solid. The crude product was used in the next step directly without further purification. MS: *m/z* = 504.1 $[M+H]^+$.

h. N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide

[0158] To a mixture of phenyl N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate (1.00 g, 1.52 mmol, 76.) and bis(7-oxa-2-azaspiro[4.5]decane), oxalic acid (1.19 g, 3.03 mmol, 95%) in THF (50 mL) was added diisopropylethyl amine (1.24 g, 9.09 mmol, 95%) at room temperature under nitrogen atmosphere. The mixture was stirred for 1 h at 60°. After re-cooling to room temperature, the mixture was extracted twice with dichloromethane (100 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and evaporated to dryness. The residue was purified by silica gel column chromatography, eluted with petrol ether/ethyl acetate (1:1) to afford N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide (600 mg, 92%) as a white solid. HPLC: 99.9 % purity, RT = 1.17 min. MS: m/z = 431.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 11.37 (s, 1H), 7.95 (s, 1H), 6.25 (s, 1H), 4.30-4.29 (m, 2H), 3.99 (s, 3H), 3.89 (t, J=5.4Hz, 2H), 3.61-3.29 (m, 8H), 2.55-2.51 (m, 2H), 1.82-1.54 (m, 6H).

i. (5R)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide 24 and (5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide 25

[0159] N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide (450 mg, 1.044 mmol, 1 equiv, 99.9%) was purified by chiral-preparative HPLC (Preparative HPLC-032, column: ChiralPak IA, 2*25cm, 5 µm; mobile phase, dichloromethane:ethanol (20:80); detector, UV). This resulted in (5R)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide (178 mg, 39%) as a white solid. HPLC: 99.7 % purity, RT (chiral) = 3.86 min, 100% ee. MS: m/z = 431.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.36 (s,1H), 7.94 (s,1H), 6.24 (s,1H), 4.29-4.27 (m, 2H), 3.97 (s,3H), 3.88 (t, J=5.2 Hz, 2H), 3.51-3.19 (m, 8H), 2.55-2.50 (m, 2H), 1.83-1.53 (m, 6H) and (5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide (171 mg, 38%) as a white solid. HPLC: 99.8 % purity, RT (chiral) = 5.23 min, 99.9% ee. MS: m/z = 431.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.35 (s,1H), 7.94 (s, 1H), 6.24 (s,1H), 4.29-4.28 (m, 2H), 3.99 (s, 3H), 3.88-3.85 (m, 2H), 3.61-3.29 (m, 8H), 2.55-2.50 (m,2H), 1.83-1.53 (m,6H).

2. N-[7-(3-aminophenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide 39

[0160]



j. N-[3-(2-benzamido-4-methoxy-1,3-benzothiazol-7-yl)phenyl]carbamate

[0161] To a solution of N-(7-iodo-4-methoxy-1,3-benzothiazol-2-yl)benzamide (400 mg, 0.878

mmol, 90%) and (3-[[(tert-butoxy)carbonyl]amino]phenyl)boronic acid (328 mg, 1.32 mmol, 95%) in 1,4-dioxane and water were added NaOH (369 mg, 8.78 mmol, 95%) and Pd(dppf)Cl2* dichloromethane (113 mg, 0.132 mmol, 95%) under inert atmosphere of nitrogen. After stirring for overnight at 100°C under a nitrogen atmosphere, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with petrol ether/ethyl acetate (0-100%,40min) to afford tert-butyl N-[3-(2-benzamido-4-methoxy-1,3-benzothiazol-7-yl)phenyl]carbamate (390 mg, 86%, 92%purity) as a yellow solid. MS: m/z = 477.0 $[M+H]^+$.

k. tert-butyl N-[3-(2-amino-4-methoxy-thiazolo[4,5-c]pyridin-7-yl)phenyl]carbamate

[0162] To a stirred solution of tert-butyl N-(3-[2-benzamido-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-7-yl]phenyl)carbamate (390 mg, 0.753 mmol, 92%) in MeOH was added NaOH (318 mg, 7.55 mmol, 95%) dissolved in water (10 mL) dropwise at room temperature. The mixture was stirred at 90°C overnight, was concentrated under vacuum and the aqueous layer extracted 3 time with dichloromethane (30mL). The combined organic layers were dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure to dryness to yield in tert-butyl N-[3-(2-amino-4-methoxy-thiazolo[4,5-c]pyridin-7-yl)phenyl]carbamate (220 mg, 54%, 69% purity) as a yellow solid. The crude product was used in the next step directly without further purification. MS: m/z = 372.9 [M+H]+.

l. Phenyl N-[7-(3-[[(tert-butoxy)carbonyl]amino]phenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate

[0163] To a stirred mixture of tert-butyl N-(3-[2-amino-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-7-yl]phenyl)carbamate (220 mg, 0.405 mmol, 69%) and K_2CO_3 (294 mg, 2.02 mmol, 95%) in THF (15 mL) were added phenyl carbonochloridate (333 mg, 2.02 mmol, 95%) and pyridine (168 mg, 2.02 mmol,95%) dropwise at room temperature under nitrogen atmosphere. The mixture was stirred additional 4h at 50°. The reaction mixture was concentrated under vacuum, diluted with water (30mL) and extracted 3 times with dichloromethane (30 mL). The combined organic layers were dried over anhydrous Na_2SO_4. After filtration, the filtrate was concentrated under reduced pressure to yield in phenyl N-[7-(3-[[(tert-butoxy)carbonyl]amino]phenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate (350 mg, 74%, 52% purity) as a yellow solid. The crude product was used in the next step directly without further purification. MS: m/z = 613.3 [M+H]+.

m. N-[4-methoxy-7-(1-methyl-1H-pyrazol-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(methoxymethyl)benzamide, 14

[0164] To a stirred mixture of phenyl N-[7-(3-[[(tert-butoxy)carbonyl]amino]phenyl)-4-methoxy-

[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate (350 mg, 0.297 mmol, 52%) and 8-oxa-2-azaspiro[4.5]decane hydrochloride (111 mg, 0.594 mmol, 95%) in THF was added diisopropylethylamine (242 mg, 1.78 mmol, 95%) dropwise at room temperature under nitrogen atmosphere. The mixture was stirred overnight at 60°and then concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with petrol ether/ethyl acetate (1:1) to afford tert-butyl N-[3-[4-methoxy-2-([8-oxa-2-azaspiro[4.5]decane-2-carbonyl]amino)-[1,3]thiazolo[4,5-c]pyridin-7-yl]phenyl]carbamate (176 mg, 89%, 81% purity) as a yellow solid. MS: m/z = 540.3 [M+H]+.

n. N-[7-(3-aminophenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide 39

[0165] To a stirred mixture of tert-butyl N-[3-[4-methoxy-2-([8-oxa-2-azaspiro[4.5]decane-2-carbonyl]amino)-[1,3]thiazolo[4,5-c]pyridin-7-yl]phenyl]carbamate (176 mg, 0.264 mmol, 81%) in MeOH was added 4 N HCl solution in 1,4-dioxane (2.00 mL, 8.00 mmol, 95%) dropwise at 0°C. The mixture was stirred additional 2h at room temperature, concentrated to dryness and purified by preparative HPLC (2#SHIMADZU (HPLC-01), column: XBridge Prep OBD C18 Column, 30x150mm 5 μm; mobile phase: water/ACN (30% Phase B up to 60% in 8 min); detector, 254 UV) to yield in N-[7-(3-aminophenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (60.0 mg, 80%, 99% purity) as white solid. HPLC: 99.0 % purity, RT = 3.19 min. MS: m/z = 440.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6, ppm) : 11.31 (s, 1H), 7.93 (s, 1H), 7.16 (t, J = 7.8 Hz, 1H), 6.84 (t, J = 2.0 Hz, 1H), 6.78 - 6.73 (m, 1H), 6.66 - 6.59 (m, 1H), 5.30 (s, 2H), 4.02 (s, 3H), 3.69 - 3.44 (m, 4H), 1.81 (s, 2H), 1.50 (t, J = 5.4 Hz, 4H).

3. N-(6-fluoro-4-methoxy-7-tetrahydropyran-4-yl-thiazolo[4,5-c]pyridin-2-yl)-8-oxa-2-azaspiro[4.5]decane-2-carboxamide

[0166]



o. N-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide

[0167] To a solution of N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (4.10 g, 9.90 mmol, 89%) in 100 mL MeOH was added Pd/C (10%, 19.6g) under nitrogen atmosphere in a 500 mL round-bottom flask. The mixture was stirred at 50°C for 3 days under hydrogen atmosphere, filtered through a Celite pad and concentrated under reduced pressure to dryness. The residue was purified by silica gel column chromatography, eluted with petrol ether/ethyl acetate (1:1) to afford N-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.60 g, 54%, 76% purity) as a yellow solid. MS: m/z = 370.1 [M+H]+.

p. N-[6-bromo-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide

[0168] Into a 50-mL round-bottom flask, was placed N-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.60 g, 5.34 mmol, 76%), N-brom-succinimid (1.20 g, 6.40 mmol, 95%) in DMF (30 mL). The resulting solution was stirred 18 h at room temperature. The reaction was then stopped by the addition of water and concentrated to dryness. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (0-50%) to obtain N-[6-bromo-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.50 g, 92%, 88 purity) as a yellow solid. MS: m/z = 449.1 [M+H]+.

q. N-[4-methoxy-7-(oxan-4-yl)-6-(trimethylstannyl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide

[0169] Into a 50-mL pressure tank reactor purged and maintained with an inert atmosphere of nitrogen was placed N-[6-bromo-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.50 g, 4.92 mmol, 88%), $Pd(PPh_3)_4$ (1.44 g, 1.18 mmol, 95%) and hexamethyldistannane (1.70 g, 4.92 mmol, 95%) in dioxane (35 mL). The resulting mixture was stirred for 1 h at 110°C. The reaction was then stopped by the addition of water and concentrated to dryness. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (0-50%). This resulted in 2.30 g (70%, 79% purity) of N-[4-methoxy-7-(oxan-4-yl)-6-(trimethylstannyl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide as a white solid. MS: m/z = 449.1 [M+H]+.

r. N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide

[0170] Into a 100-mL round-bottom flask was placed N-[4-methoxy-7-(oxan-4-yl)-6-(trimethylstannyl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.30 g, 3.43 mmol, 79%), Selectfluor® (2.56 g, 6.85 mmol, 95%) in acetonitrile (50 mL). The resulting solution was stirred for 18 h at room temperature. The reaction was then stopped by the addition of water and concentrated to dryness. The residue was applied onto a silica gel column with ethyl

acetate/hexane (0-50%). This resulted in 1.50 g (91%, 81% purity) of N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide as a white solid. MS: m/z = 388.1 [M+H]+.

s. 6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-amine

[0171] Into a 20-mL sealed tube purged and maintained with an inert atmosphere of nitrogen, was placed N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (1.50 g, 3.12 mmol, 81%) in MeOH (20 mL). NaOH (1.27 g, 31.2 mmol, 98%) dissolved in water (20 mL) was added at rt and the resulting solution was stirred for 16 h at 100°C. The resulting mixture was concentrated and the aqueous solution extracted 3 times with 100 mL of dichloromethane. After filtration the filtrate was evaporated to dryness and used without further purification to result in 6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-amine (320 mg, 32%, 89% purity) as an off-white solid. MS: m/z = 284.1 [M+H]+.

t. Phenyl N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate

[0172] To a mixture of 6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-amine (25 mg, 0.078 mmol, 89%) and K_2CO_3 (56.9 mg, 0.391 mmol, 95%) in THF (3.00 mL) was added phenyl chloroformate (64.5 mg, 0.391 mmol, 95%) and pyridine (32.6 mg, 0.391 mmol, 95%) dropwise at room temperature. The resulting mixture was stirred for 6 h at 50°C under nitrogen atmosphere. The reaction was stopped by the addition of water (10 mL) and the resulting mixture was extracted twice with dichloromethane (10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered and evaporated to dryness under reduced pressure to obtain N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate (60.0 mg, 73%, 50% purity). The crude product was used in the next step directly without further purification. MS: m/z = 524.1 [M+H]+.

u. N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide

[0173] To a mixture of phenyl N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate (50 mg, 0.047 mmol, 50%) and 8-oxa-2-azaspiro[4.5]decane hydrochloride (26.5 mg, 0.142 mmol, 95%) in THF (3.00 mL) was added diisopropylethylamine (38.6 mg, 0.284 mmol, 95%) at room temperature. The resulting mixture was stirred for 16 h at 60°C under nitrogen atmosphere. The mixture was diluted with water (10 mL) and extracted 3 times with dichloromethane (10 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and evaporated to dryness under reduced pressure. The crude product was purified by preparative HPLC (2#SHIMADZU (HPLC-01):

column: XBridge Prep OBD C18 30x150 mm, 5 μm; mobile phase: water/acetonitrile, detector: UV). This resulted in N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (12.4 mg, 57%) as a light yellow solid. HPLC: 97.9% purity, RT = 5.93 min. MS: m/z = 451.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6, ppm): 11.31 (s, 1H), 3.99-3.94 (m, 5H), 3.61-3.45 (m, 10H), 3.12 (t, J=12.4 Hz, 1H), 2.03 (q, J=12.5 Hz, 2H), 1.82 (s, 2H), 1.65-1.62 (m ,2H) ,1.50 (s, 4H).

4. N-[5-(difluoromethyl)-4-oxo-7-phenyl-5lambda4-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide

[0174]



v N-[4-hydroxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide

[0175] Into a 25-mL round-bottom flask, was placed N-[4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (200 mg, 0.458 mmol, 97%), in dichloromethane (8 mL). BBrs (0.138 mL, 0.138 mmol, 1M in dichloromethane) was added dropwise at 0°C and the resulting solution was stirred additional 2 hr at 0°C. The reaction was then stopped by the addition of ice water. The mixture was extracted 3 times with dichloromethane (10 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and evaporated to dryness under reduced pressure. The residue was applied onto a silica gel column with dichloromethane/methanol (0-30%) to result in 150 mg (78%, 98% purity) of N-[4-hydroxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide as a white solid. MS: m/z = 411.2 [M+H]+.

w N-[5-(difluoromethyl)-4-oxo-7-phenyl-5lambda4-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide

[0176] Into a 50-mL sealed tube purged and maintained with an inert atmosphere of nitrogen was placed N-[4-hydroxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (100 mg, 0.238 mmol, 98%), anhydrous Na_2SO_4 (3.37 mg, 0.024 mmol, 98%) in acetonitrile (5 mL). To this mixture 2,2-difluoro-2-(fluorosulfonyl)acetic acid (50.8 mg, 0.285 mmol, 98%) was added at room temperature and

the resulting solution was stirred additional 3 h at room temperature. The reaction was then stopped by the addition of water (20 mL). The mixture was extracted 3 times with dichloromethane (10 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and evaporated to dryness under reduced pressure. The crude product was purified by preparative HPLC (2#SHIMADZU (HPLC-01): column; Xselect CSH OBD Column 30*150 mm, 5µm, mobile phase: water/acetonitrile; detector: UV). This resulted in N-[5-(difluoromethyl)-4-oxo-7-phenyl-5lambda4-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (20.0 mg, 17%) as a white solid. Mp = 225-226°C. HPLC: 95.1% purity, RT = 6.27 min. MS: m/z = 461.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6, ppm) 11.57 (s, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.89 (s, 1H), 7.72 (d, J = 7.9 Hz, 2H), 7.54 (dt, J = 32.6, 7.5 Hz, 3H), 3.52 (s, 7H), 3.30 (s, 1H), 1.81 (d, J = 38.2 Hz, 2H), 1.50 (s, 4H).

Example 3: Testing compounds of the present invention for inhibitory activities against human adenosine receptors in recombinant cells.

[0177] The functional activities of human A_{2A}, A_{2B}, A_1 and A_3 receptors were determined by quantification of cAMP, being the second messenger for adenosine receptors. For this purpose recombinant HEK293 cells, expressing either human A_{2A} or A_{2B} receptors (both Gs coupled were seeded into 394-well microtiter plates, test compounds and agonist (NECA) were added. After a 15 min incubation, HTRF reagents (cAMP dynamic 2, Cis Bio) were added and the cellular cAMP levels were determined using the ENVISION (Perkin Elmer) plate reader.

[0178] For human A_1 and A_3 receptors, recombinant CHO cells, expressing either A_1 or A3-receptor, were used. As both receptors couple to Gi proteins, the assay protocol was adapted: Cells were seeded into 384-well plates, forskolin, test compounds and agonists (CPA for A_1- and IB-MECA for As-receptor) were added. After 30 min incubation, HTRF reagents (cAMP dynamic 2, Cis Bio) were added and the cellular cAMP levels were determined using the ENVISION (Perkin Elmer) plate reader. Obtained raw data were normalized against the inhibitor control and the neural control (DMSO) and the normalized data were fitted using GeneData software.

[0179] The compounds of the present invention show a high selectivity for adenosine A_{2A} and A_{2B} receptors over adenosine A_1 and A_3 receptors (see e.g. the data of some examples of the compounds of the present invention in table 4)

[0180] Particularly, in contrast to the known adenosine A_{2A} receptor antagonist Tozadenant and similar benzothiazole derivatives (see table 5), the compounds of the present invention surprisingly show an A_{2A}/A_{2B} dual activity (see table 4) which is preferred for the treatment and/or prevention of hyperproliferative and infectious diseases and disorders as it is disclosed above or the compounds of the present invention show at least a high A_{2A} inhibitory activity together with the other surprising advantages disclosed herein leading to a high efficacy in the treatment and/or prevention of hyperproliferative and infectious diseases and disorders.

Table 4 - Compounds of the present invention

The compound numbers 70, 78, 120, and 147-174 are reference examples and not according to the invention.				
No.	**Functional A2A receptor activity, HEK293, cAMP, IC50 [µM]**	**Functional A2B receptor activity, HEK293, cAMP, IC50 [µM]**	**Functional A1 receptor activity, CHO, cAMP, IC50 [µM]**	**Functional A3 receptor activity, CHO, cAMP, IC50 [µM]**
1	A	B	D	D
3	A	A	C	D
4	A	A	D	C
6	A	A	D	C
7	A	A	D	D
9	A	B	D	D
10	A	B	D	D
11	A	A	D	D
12	A	A	C	D
13	A	A	C	D
15	A	A	D	D
16	A	B	D	D
17	A	A	C	D
19	A	B	D	D
20	A	A	D	D
22	A	A	C	C
23	A	A	C	D
24	A	B	C	D
25	A	A	D	D
26	A	B	D	D
27	A	A	C	D
28	A	B	C	C
29	A	A	D	D
31	A	B	D	D
32	A	A	B	D
33	A	B	D	D
34	A	B	D	D
35	A	B	D	D
37	A	B	D	D
38	A	A	D	D

The compound numbers 70, 78, 120, and 147-174 are reference examples and not according to the invention.

No.	Functional A2A receptor activity, HEK293, cAMP, IC50 [µM]	Functional A2B receptor activity, HEK293, cAMP, IC50 [µM]	Functional A1 receptor activity, CHO, cAMP, IC50 [µM]	Functional A3 receptor activity, CHO, cAMP, IC50 [µM]
39	A	A	D	D
40	B	B	D	D
43	A	B	C	D
44	B	B	D	D
45	B	B	D	D
47	A	A	D	D
48	A	A	D	D
50	A	A	D	D
52	A	A	D	D
54	A	A	D	D
59	A	B	C	D
60	A	A	C	C
61	A	A	C	D
62	A	B	D	D
63	A	B	C	D
64	A	A	C	D
65	A	A	B	D
67	A	B	C	D
68	A	A		D
69	A	A	B	C
70	A	C	D	D
71	A	A	C	D
72	A	A	C	D
73	A	B	D	D
74	A	B	C	D
75	A	B	D	D
76	A	A	B	D
77	A	C	D	D
78	A	C	D	D
79	A	B	C	D
80	A	B	D	D

The compound numbers 70, 78, 120, and 147-174 are reference examples and not according to the invention.				
No.	**Functional A2A receptor activity, HEK293, cAMP, IC50 [µM]**	**Functional A2B receptor activity, HEK293, cAMP, IC50 [µM]**	**Functional A1 receptor activity, CHO, cAMP, IC50 [µM]**	**Functional A3 receptor activity, CHO, cAMP, IC50 [µM]**
81	A	A	C	D
82	A	A	B	D
83	A	A	C	D
84	A	B	B	D
88	A	B	D	D
89	A	B	D	D
90	A	A	D	D
91	A	A	D	D
92	A	A	B	C
94	A	B	D	D
95	A	A	C	C
97	A	B	D	D
98	A	B	D	D
99	A	A	D	D
100	A	A	C	D
101	A	B	D	D
102	A	B	D	D
103	A	B	C	D
104	A	B		D
105	A	B		D
106	A	B	C	D
108	A	A	C	D
109	A	A	D	D
110	A	B	D	D
111	A	B	C	D
112	A	B	D	D
113	A	B	D	D
114	A	B	C	D
115	A	A		C
116	A	A		C
117	A	A		C

The compound numbers 70, 78, 120, and 147-174 are reference examples and not according to the invention.

No.	Functional A2A receptor activity, HEK293, cAMP, IC50 [µM]	Functional A2B receptor activity, HEK293, cAMP, IC50 [µM]	Functional A1 receptor activity, CHO, cAMP, IC50 [µM]	Functional A3 receptor activity, CHO, cAMP, IC50 [µM]
118	A	B		D
119	A	B		D
120	B		D	D
121	A	B	D	D
122	A	B	D	D
123	A	B	D	D
124	A	A	D	D
125	A	A	C	D
129	A	B	C	D
131	A	A	C	D
135	A	A	C	C
137	A	A	C	D
139	A	B		D
140	A	B	C	D
147	A	A	D	C
149	A	A	C	D
150	A	B	D	D
153	A	A	C	D
156	A	A	C	D
157	A	A	C	D
158	A	A		D
160	A	A	C	D
161	A	B	D	D
162	A	A	C	D
163	A	B		D
164	A	A	D	D
165	A	A		D
166	A	B	D	D
167	A	A		D
168	A	B		D
169	A	B	D	D

The compound numbers 70, 78, 120, and 147-174 are reference examples and not according to the invention.				
No.	**Functional A2A receptor activity, HEK293, cAMP, IC50 [µM]**	**Functional A2B receptor activity, HEK293, cAMP, IC50 [µM]**	**Functional A1 receptor activity, CHO, cAMP, IC50 [µM]**	**Functional A3 receptor activity, CHO, cAMP, IC50 [µM]**
170	A	B	D	D
171	B	B	D	D
173	A	A	C	D
174	A	B	D	D

[0181] A means IC_{50} value is < 10 nM, B means IC_{50} value is < 100 nM, C means IC_{50} value is < 1 µM, D means IC_{50} value is > 1 µM.

Table 5 - Prior art compounds specifically disclosed in WO2005/028484 and WO2005/000842

No.	**Functional A2A receptor activity, HEK293, cAMP, IC50 [µM]**	**Functional A2B receptor activity, HEK293, cAMP, IC50 [µM]**	**Functional A1 receptor activity, CHO, cAMP, IC50 [µM]**	**Functional A3 receptor activity, CHO, cAMP, IC50 [µM]**
Tozadenant				
	B	D	D	D
	B	D		D
	B	D	D	D

No.	Functional A2A receptor activity, HEK293, cAMP, IC50 [µM]	Functional A2B receptor activity, HEK293, cAMP, IC50 [µM]	Functional A1 receptor activity, CHO, cAMP, IC50 [µM]	Functional A3 receptor activity, CHO, cAMP, IC50 [µM]
	A	C	D	D
	A	C	D	D
	B	C	D	C
	A	C	D	C
	A	C	D	B
	A	C	D	C

No.	Functional A2A receptor activity, HEK293, cAMP, IC50 [µM]	Functional A2B receptor activity, HEK293, cAMP, IC50 [µM]	Functional A1 receptor activity, CHO, cAMP, IC50 [µM]	Functional A3 receptor activity, CHO, cAMP, IC50 [µM]
				
	A	C	D	D
	B	C	D	C
	A	C	D	C
	A	C	D	B
	A	C	D	C
	A	C	D	D

No.	Functional A2A receptor activity, HEK293, cAMP, IC50 [μM]	Functional A2B receptor activity, HEK293, cAMP, IC50 [μM]	Functional A1 receptor activity, CHO, cAMP, IC50 [μM]	Functional A3 receptor activity, CHO, cAMP, IC50 [μM]
				
	A	C	C	D
	A	C	D	D
	A	C	C	C
	A	C	C	C

[0182] A means IC_{50} value is < 10 nM, B means IC_{50} value is < 100 nM, C means IC_{50} value is < 1 μM, D means IC_{50} value is > 1 μM.

Example 4: Testing the effects of the compounds of the present invention against endogenous human A_{2A} receptor

[0183] The endogenous functional activity of the Gs-coupled human A_{2A} receptor was

measured in T cells, where this receptor is highly expressed. Determination of receptor activity was done by quantification of cAMP, which is a second messenger for adenosine receptors.

[0184] In short, human pan T cells were isolated from human PBMC (MACS Pan T Cell Isolation Kit, Miltenyi Biotec) that have been derived from fresh whole blood. The T cells were seeded in 384-well microtiter plates and treated with test compounds. After 10min incubation at room temperature, the A_{2A} adenosine receptor agonist CGS-21680 was added, and the plates were incubated for another 45min. Finally, HTRF reagents (cAMP Femto Kit, CisBio) were added to the wells, and after 1h cellular cAMP levels were determined using the ENVISION (Perkin Elmer) plate reader.

[0185] The obtained raw data were normalized against the inhibitor control and the neutral control (DMSO) and the normalized data were fitted using Genedata Screener software.

[0186] The compounds of the present invention show that they are able to inhibit the A_{2A} receptor expressed in human T cells which incubated with the A_{2A} adenosine receptor agonist CGS-21680 (as measured by quantification of cAMP), which is preferred for the treatment and/or prevention of hyperproliferative and infectious diseases and disorders as it is disclosed above. Therefore, the compounds of the present invention surprisingly are able to prevent immunosuppression and thus are able to support anti-tumor T cell induced inhibition of tumor growth, reduction or destruction of metastases and prevention of neovascularization.

Example 5: Testing the pharmacokinetic properties of the compounds of the present invention in rat and mouse

[0187] The objective of the study was to obtain information on the pharmacokinetic properties of the compounds of the present invention in female Wistar rats/mice following single intravenous and oral administration.

Material and Methods:

Animal Experiments (In-Life Phase)

[0188] Female Wistar rats/mice (n=6) received either a single intravenous (bolus) injection or an oral administration (by gavage) of the tested compound. Doses of 0,2 and 10 mg/kg (per compound) were given intravenously and per os, respectively, as a solution in DMSO (0,2%)/PEG 200 (40%)/water for iv administration and as a suspension in Methocel (0,5%)/Tween 20 (0,25%) in water for oral dosing. Consecutive blood samples were taken sub-lingually under isoflurane inhalation from 3 animals per route of administration after 0.1 (only iv), 0.25 (only po), 0.5, 1, 2, 4, 6 and 24 h and were further processed to obtain plasma. Also,

urine and feces samples of 3 rats per route of administration were collected over the time interval from 0-24 h and were pooled for analysis.

Bioanalytics:

[0189] The concentrations of the compounds in plasma, feces were quantified using an UPLC method with tandem mass spectrometric detection (LC-MS/MS) previously developed at the `Institute of Drug Metabolism and Pharmacokinetics'. The LC-MS/MS system consisted of a Waters Acquity UPLC coupled to an AB Sciex mass spectrometer API 5500 Q-trap. The UPLC separation was carried out on a reversed phase column (HSS T3, 1.8 µM, 2.1 × 50 mm) using a mobile phase gradient with 0.1% formic acid and acetonitrile as eluents. The detection of the compounds was performed using multiple reaction monitoring in the positive ionization mode. Plasma samples were spiked with internal standard (20 µl) and the analyte was extracted from the matrix using tertiary-butyl methyl ether (tBME). The organic phase was evaporated to dryness under a stream of nitrogen. The residue was dissolved in acetonitrile/0.1% formic acid for LC-MS/MS analysis. Feces samples were homogenized with 4-times their volume of an ethanol/water mixture (4:1, v/v). Aliquots of the aqueous-ethanolic extracts were spiked with internal standard, diluted with acetonitrile/water (1:1, v/v) and directly injected into the LC-MS/MS system.

Pharmacokinetic Evaluation:

[0190] Pharmacokinetic parameters C_{max} and t_{max} were taken from the observed data. Area under the curve (AUC), clearance (CL), volume (V), half-life ($t_{1/2}$), F and all dose-normalized values were calculated using the custom-made software 'DDS-TOX'. 'DDS-TOX' values were evaluated for several compounds and shown comparable to the values given by the validated software WinNonLin. AUC values were calculated by non-compartmental analysis using the linear up/log down method. Numerical data for mean plasma concentrations and derived pharmacokinetic parameters were rounded to 3 significant digits for presentation. Oral bioavailability and excretion data - expressed as % of dose - are displayed using 2 significant digits.

[0191] In comparison with the known adenosine A_{2A} receptor antagonist Tozadenant and similar benzothiazole derivatives, the compounds of the present invention surprisingly show better pharmacokinetic properties in mouse as the animal model relevant for cancer (see table 6), which is preferred for the treatment and/or prevention of hyperproliferative and infectious diseases and disorders as it is disclosed above.

Table 6

No.	Name	CL [L/h/kg]	t1/2 [h]	Vss [L/kg]	Feces iv [%]	CMax (iv)@1 mg/kg [ng/ml]
	Tozadenant	8,68	0,184	2,03	23@0.2	337
25	(S)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	4.65	0.91	3.16	22@0.2	500

Example 6: Testing the effect of the compounds of the present invention on mouse T cells

Background:

[0192] Adenosine (Ado) in tumor microenvironment can inhibit T cell activity by signaling through A_{2A} receptors and suppress cytokine secretion by T cells. A_{2A} specific agonists like NECA does similar job of inhibition of T cell cytokine secretion in vitro and in vivo. Potential A_{2A} antagonists or A_{2A}/A_{2B} dual antagonists can rescue T cells from this inhibition. Herein, we describe the in vitro system we established using Pan T cells from mouse spleens to screen potential A_{2A} antagonists or A_{2A}/A_{2B} dual antagonists for their activity. The method described involves the use of CD3/CD28 pre-coated beads to stimulate Pan T cells purified from mouse splenocytes, combined with the addition of A_{2A} agonist along with potential A_{2A} or A_{2A}/A_{2B} dual antagonists to evaluate potentiation of T cell cytokine production.

mTcell assay, cAMP, asay description:

[0193] Pan T-cells are isolated from black 6 mice by manual dissociation and purified using a Miltenyi Pan T-cell isolation kit. The isolated T-cells are activated in 96 well plates for 48 hours using anti-CD3/CD28 beads in T-cell proliferation media.

[0194] After 48 hours, the T-cells are pooled, counted and suspended in serum free media containing 0.1% BSA. The cells are plated at 50,000 cells per well in 10 ul of media and incubated for 2 hours at 37 °C. Test compounds are dispensed into the wells at a 10-point dose response, starting at a concentration of 10 uM. Following the compound addition, the agonist, NECA, is added to all wells at a 1 uM concentration. The plates are incubated for 30 minutes at 37 °C and assayed for cAMP levels using the Cisbio cAMP Dynamic2 reagent kit by adding 10 ul of the kit reagents to each well. The plates are incubated for 1 hour at room

temperature and the HTRF signal is read on an Envision plate reader. The raw data is analyzed in Genedata Screener and the resulting data is loaded into the database.

mTcell assay, IL-2, asay description:

[0195] Briefly, mouse Pan T cells are purified from spleens of BALB/c mice using Pan T cell isolation kit Mouse II (MACS Miltenyi biotech Cat# Order no. 130-095-130) according to manufacturer's protocol. The purified T cells are seeded in Nunc™ 96-Well Polystyrene Round Bottom Microwell Plates in RPMI medium with 10% heat inactivated fetal bovine serum. The cells are rested at 37°C for 1 h before activating with CD3/CD28 pre-coated beads (Dynabeads™ Mouse T-Activator CD3/CD28; Cat# 11456D). After 30 min the cells are treated with varying doses of test antagonist(s). The cells are incubated for additional 30 min at 37°C before treating with A_{2A} agonist NECA (1 µM) or neutral control (DMSO). After 24 h incubation IL-2 levels in the supernatants are measured by ELISAs according to manufacturer's protocol (R&D systems Cat# DY402 (IL-2)). Once the concentrations are calculated, the difference of cytokine concentration of DMSO control and agonist alone control is calculated and the percentage of rescue by each concentration of antagonist is calculated by using Microsoft Excel. These percentages of cytokine rescue in a dose dependent manner of antagonist is plotted in GraphPad Prism software and IC_{50} is calculated.

[0196] In contrast to the known adenosine A_{2A} receptor antagonist Tozadenant and similar compounds (see table 8), the compounds of the present invention show that they are able to rescue T cells from inhibition and are able to prevent the suppression of cyctokine secretion as induced by adenosine or A_{2A} specific agonists like NECA (see table 7), which is preferred for the treatment and/or prevention of hyperproliferative and infectious diseases and disorders as it is disclosed above. Therefore, the compounds of the present invention surprisingly are able to prevent immunosuppression and thus are able to support anti-tumor T cell induced inhibition of tumor growth, reduction or destruction of metastases and prevention of neovascularization.

Table 7 - Compounds of the present invention

No.	Name / IUPAC	mTcell data, cAMP, IC50 [µM]	mTcell data IL-2, IC50 (µM)
1	(R)-3-Aminomethyl-pyrrolidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	B	
3	(S)-3-Aminomethyl-pyrrolidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	
6	N-(6-Fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-4-(1H-tetrazol-5-yl)-benzamide	B	
7	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid	A	

No.	Name / IUPAC	mTcell data, cAMP, IC50 [µM]	mTcell data IL-2, IC50 (µM)
	(6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide		
10	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	
11	(5S)-N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide		B
12	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	A
13	(5S)-N-{6-fluoro-4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-7-oxa-2-azaspiro[4.5]decane-2-carboxamide	A	
15	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide		B
19	(5S)-N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide	B	B
20	N-[6-Fluoro-4-methoxy-7-(tetrahyd ro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N',N'-dimethyl-terephthalamide	B	B
24	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	B	
25	(S)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	A
26	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	A
29	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-7-(4-fluoro-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	A
31	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
35	(5S)-N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide	A	A
38	(5S)-N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-	A	B

No.	Name / IUPAC	mTcell data, cAMP, IC50 [µM]	mTcell data IL-2, IC50 (µM)
	[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide		
39	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-aminophenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	A
47	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-thiophen-2-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	B	B
48	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-furan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	B	
50	N-[6-Fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N'-(2-hydroxy-ethyl)-N'-methyl-terephthalamide	B	
52	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-furan-3-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	B	
54	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methoxy-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	B
61	N4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N1,N1-dimethylbenzene-1,4-dicarboxamide		B
98	2,8-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	B	
99	4-(2,5-Dioxo-pyrrolidin-1-yl)-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	B	
100	4-(2,5-Dioxo-pyrrolidin-1-yl)-piperidine-1-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	B	
102	2,7-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
112	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methylamino-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
131	4-(2,5-Dioxo-imidazolidin-1-yl)-piperidine-1-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	B	
137	4-(2,5-Dioxo-imidazolidin-1-yl)-piperidine-1-	A	

No.	Name / IUPAC	mTcell data, cAMP, IC50 [µM]	mTcell data IL-2, IC50 (µM)
	carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide		

[0197] A means ICso value is < 10 nM, B means IC_{50} value is < 100 nM, C means IC_{50} value is < 1 µM, D means IC_{50} value is > 1 µM.

Table 8 - Prior art compounds specifically disclosed in WO2005/028484 and WO2005/000842

Name / Structure	mTcell data, cAMP, IC50 [µM]	mTcell data IL-2, IC50 (µM)
	C	NA
	D	NA
	D	NA
	C	
	D	

Name / Structure	mTcell data, cAMP, IC50 [μM]	mTcell data IL-2, IC50 (μM)
	C	NA
	C	
	C	NA
	C	NA
	D	NA
		NA

[0198] A means IC_{50} value is < 10 nM, B means IC_{50} value is < 100 nM, C means IC_{50} value is < 1 μM, D means IC_{50} value is > 1 μM.

Example 7: Testing the effect of the compounds of the present invention on human T cells

[0199] The endogenous functional activity of the Gs-coupled human A_{2A} receptor was measured in T cells, where this receptor is highly expressed. Determination of receptor activity was done by quantification of cAMP, which is a second messenger for adenosine receptors.

Assay description

[0200] In short, human pan T cells were isolated from human PBMC (MACS Pan T Cell Isolation Kit, Miltenyi Biotec) that have been derived from fresh whole blood. The T cells were seeded in 384-well microtiter plates and treated with test compounds. After 10min incubation at room temperature, the A_{2A} adenosine receptor agonist NECA was added, and the plates were incubated for another 45min. Finally, HTRF reagents (cAMP Femto Kit, CisBio) were added to the wells, and after 1h cellular cAMP levels were determined using the ENVISION (Perkin Elmer) plate reader.

[0201] The obtained raw data were normalized against the inhibitor control and the neutral control (DMSO) and the normalized data were fitted using Genedata Screener software.

[0202] The compounds of the present invention show that they are able to inhibit the A_{2A} receptor expressed in human T cells which incubated with the A_{2A} adenosine receptor agonist NECA (as measured by quantification of cAMP), which is preferred for the treatment and/or prevention of hyperproliferative and infectious diseases and disorders as it is disclosed above. Therefore, the compounds of the present invention surprisingly are able to prevent immunosuppression and thus are able to support anti-tumor T cell induced inhibition of tumor growth, reduction or destruction of metastases and prevention of neovascularization.

Table 9 - Compounds of the present invention

No.	Name/ IUPAC	hTcell data, cAMP, IC50 [µM]	hTcell data, IL-2, IC50 [µM]
1	(R)-3-Aminomethyl-pyrrolidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	
3	(S)-3-Aminomethyl-pyrrolidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	
6	N-(6-Fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-4-(1H-tetrazol-5-yl)-benzamide	B	A

No.	Name/ IUPAC	hTcell data, cAMP, IC50 [µM]	hTcell data, IL-2, IC50 [µM]
7	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	
10	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	
11	(5S)-N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide	A	A
12	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (6-fluoro-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	A
13	(5S)-N-{6-fluoro-4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-7-oxa-2-azaspiro[4.5]decane-2-carboxamide	A	
15	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide		A
19	(5S)-N-[6-fluoro-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide	A	B
20	N-[6-Fluoro-4-methoxy-7-(tetrahyd ro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N',N'-dimethyl-terephthalamide	A	A
24	(R)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	A
25	(S)-7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	A
26	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	B
29	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-7-(4-fluoro-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	A
31	7-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
35	(5S)-N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide	A	B

No.	Name/ IUPAC	hTcell data, cAMP, IC50 [µM]	hTcell data, IL-2, IC50 [µM]
37	(R)-2-Oxa-7-aza-spiro[4.4]nonane-7-carboxylic acid [6-fluoro-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
38	(5S)-N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonane-7-carboxamide	A	
39	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3-aminophenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	B
47	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (4-methoxy-7-thiophen-2-yl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	
48	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-furan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	B	
50	N-[6-Fluoro-4-methoxy-7-(tetrahyd ro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N'-(2-hydroxy-ethyl)-N'-methyl-terephthalamide	A	
54	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methoxy-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
59	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid (7-cyclohex-1-enyl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amide	A	
61	N4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N1,N1-dimethylbenzene-1,4-dicarboxamide	A	
63	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(4,4-difluoro-cyclohex-1-enyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
65	1H-Imidazole-4-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
68	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(1-pyridin-3-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
69	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(1-pyridin-2-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
71	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide	A	

No.	Name/ IUPAC	hTcell data, cAMP, IC50 [µM]	hTcell data, IL-2, IC50 [µM]
72	4-{[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}benzoic acid	B	
74	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid {7-[1-(2,2-difluoro-ethyl)-1H-pyrazol-4-yl]-4-methoxy-thiazolo[4,5-c]pyridin-2-yl}-amide	B	
89	3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(2-oxopyrrolidin-1-yl)phenyl]urea	A	
91	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(2,4-dioxo-1,3-thiazolidin-3-yl)piperidine-1-carboxamide	A	
97	[4-(4-Methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-ylcarbamoyl)-benzyl]-methyl-carbamic acid methyl ester	B	
98	2,8-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
99	4-(2,5-Dioxo-pyrrolidin-1-yl)-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	B	
100	4-(2,5-Dioxo-pyrrolidin-1-yl)-piperidine-1-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
102	2,7-Diaza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
112	8-Oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [4-methoxy-7-(3-methylamino-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
131	4-(2,5-Dioxo-imidazolidin-1-yl)-piperidine-1-carboxylic acid [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide	A	
137	4-(2,5-Dioxo-imidazolidin-1-yl)-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amide	A	

[0203] A means IC_{50} value is < 10 nM, B means IC_{50} value is < 100 nM, C means IC_{50} value is < 1 µM, D means IC_{50} value is > 1 µM.

Table 10 - Prior art compounds specifically disclosed in WO2005/028484 and WO2005/000842

Name/ Structure	hTcell data, cAMP, IC50 [µM]	hTcell data, IL-2, IC50 [µM]
	C	NA
	C	NA
	C	
	C	
	C	
	C	
	C	

Name/ Structure	hTcell data, cAMP, IC50 [µM]	hTcell data, IL-2, IC50 [µM]
		
	C	
	C	
		NA

[0204] A means IC_{50} value is < 10 nM, B means IC_{50} value is < 100 nM, C means IC_{50} value is < 1 µM, D means IC_{50} value is > 1 µM.

Example 8: Injection vials

[0205] A solution of 100 g of a compound of the present invention and 5 g of disodium hydrogen phosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, filtered under sterile conditions, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of a compound of the present invention.

Example 9: Solution

[0206] A solution is prepared from 1 g of a compound of the present invention, 9.38 g of NaH_2PO_4 2 H_2O, 28.48 g of Na_2HPO_4 12 H_2O and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 l and sterilised by irradiation.

Example 10: Ampoules

[0207] A solution of 1 kg of a compound of the present invention in 60 l of bidistilled water is filtered under sterile conditions, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of a compound of the present invention.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO1999035147A **[0017]**
- WO2001002400A **[0017]**
- WO03050241A **[0031]**
- WO2004089942A **[0032]**
- WO2005000842A **[0032]**
- WO2006008041A **[0032]**
- WO2004092171A **[0032]**
- WO2005028484A **[0032]**
- US4125828A **[0099]**
- US4207554A **[0099]**
- WO9722596A **[0140]**
- WO9730035A **[0140]**
- WO9732856A **[0140]**
- WO9813354A **[0140]**
- WO9902166A **[0140]**
- WO0040529A **[0140]**
- WO0041669A **[0140]**
- WO0192224A **[0140]**

- WO0204434A [0140]
- WO0208213A [0140]

Non-patent literature cited in the description

- **MULLER C. E.STEIN B**Current Pharmaceutical Design, 1996, vol. 2, 501- [0003]
- **MULLER C. E.**Exp. Opin. Ther. Patents, 1997, vol. 7, 5419- [0003]
- **FREDHOLM et al.**Pharm. Rev., 1994, vol. 46, 143-156 [0004]
- **LINDEN J.**Annu. Rev. Pharmacol. Toxicol., 2001, vol. 41, 775-87 [0004]
- **OLAH, M. E. et al.**J. Biol. Chem., 1992, vol. 267, 10764-10770 [0005]
- **KLOTZ, K. N. et al.**Naunyn Schmiedebergs Arch. Pharmacol., 1998, vol. 357, 1-9 [0005]
- **KLINGER et al.**Cell Signal., 2002, vol. 14, 299-108 [0009]
- **FREDHOLM et al.**Pharmacol. Rev., 1999, vol. 51, 183-133 [0010]
- **HUANG et al.**Nat Neurosci., 2005, vol. 8, 7858-9 [0010]
- **DIXON et al.**Br. J. Pharmacol., 1996, vol. 118, 61461-8 [0011]
- **KULL et al.**Mol. Pharmacol., 2000, vol. 58, 4772-7 [0011]
- **FREDHOLM et al.**Annu. Rev. Pharmacol. Toxicol., 2005, vol. 45, 385-412 [0012]
- **HIGGINS et al.**Behav. Brain Res., 2007, vol. 185, 32-42 [0012]
- **DALL' IGNA et al.**Exp. Neurol., 2007, vol. 203, 1241-5 [0012]
- **ARENDASH et al.**Neuroscience, 2006, vol. 142, 4941-52 [0012]
- Trends in Neurosci., 2006, vol. 29, 11647-654 [0012]
- Expert Opinion Ther. Patents, 2007, vol. 17, 979-991 [0012]
- Exp. Neurol., 2003, vol. 184, 1285-284 [0012]
- Prog. Brain Res, 2010, vol. 183, 183-208 [0012]
- J. Alzheimer Dis., Suppl, 2010, vol. 1, 117-126 [0012]
- J. Neurosci., 2009, vol. 29, 4714741-14751 [0012]
- Neuroscience, 2010, vol. 166, 2590-603 [0012]
- J. Pharmacol. Exp. Ther., 2009, vol. 330, 1294-303 [0012]
- Frontiers Biosci., 2008, vol. 13, 2614-2632 [0012]
- **WEISS et al.**Neurology, 2003, vol. 61, 688-93 [0012]
- **CHEN et al.**J. Neurosci., 1999, vol. 19, 219192-200 [0013]
- **MONOPOLI et al.**Neuroreport, 1998, vol. 9, 173955-9 [0013]
- **BLUM et al.**J. Neurosci., 2003, vol. 23, 125361-9 [0013]
- **EL YACOUBI et al.**Neuropharmacology, 2001, vol. 40, 3424-32 [0013]
- **CUNHA et al.**Exp. Neurol., 2008, vol. 210, 2776-81 [0013]
- **TAKAHASHI et al.**Front. Biosci., 2008, vol. 13, 2614-32 [0013]
- **MOREAU et al.**Brain Res. Reviews, 1999, vol. 31, 65-82 [0014]
- **SVENNINGSSON et al.**Progress in Neurobiology, 1999, vol. 59, 355-396 [0014]
- **BARA-HIMENEZ et al.**Neurology, 2003, vol. 61, 3293-6 [0015]
- **HAUSER et al.**Neurology, 2003, vol. 61, 3297-303 [0015]

- **NEUSTADT et al.**Bioorg. Med. Chem. Lett, 2001, vol. 17, 51376-80 [0015]
- **HUNTER J. C**poster Boston, 2006, [0015]
- Neurology, 2003, vol. 61, 682-87 [0016]
- Behav. Pharmacol., 2009, vol. 20, 2134-145 [0016]
- CNS Drug Discov., 2007, vol. 2, 11-21 [0016]
- Am. J. Path., 2007, vol. 6, 1774-1778 [0017]
- Arthritis & Rheumatism, 2006, vol. 54, 82632-2642 [0017]
- Clin. Neuropharmacol., 2010, vol. 33, 55-60 [0018]
- J. Neurosci., 2010, vol. 30, 4816284-16292 [0018]
- Parkinson Relat. Disord., 2010, vol. 16, 6423-426 [0018]
- Expert Opinion Ther. Patents, 2010, vol. 20, 8987-1005 [0018]
- Current Opinion in Drug Discovery & Development, 2010, vol. 13, 4466-480 [0018]
- Mov. Disorders, 2010, vol. 25, 2S305- [0018]
- **LIU et al.**J. Surgical Oncol, 2012, [0028]
- **LU et al.**World J. Gastroenterol., 2013, [0028]
- **XIONG et al.**Cell and Tissue Res., 2014, [0028]
- **ANTONIOLI et al.**Nat. rev. Cancer, 2013, [0028]
- **THIEL et al.**Microbes and Infection, 2003, [0028]
- **OHTA et al.**PNAS, 2006, vol. 103, 3513132-7 [0028]
- **WANG**Cancer. Semin. Cancer. Biol., 2006, vol. 16, 73-79 [0029]
- **GREENWALD et al.**Ann. Rev. Immunol., 2005, vol. 23, 515-48 [0029]
- **WATTS**Ann. Rev. Immunol., 2005, vol. 23, 23-68 [0029]
- **SADUM et al.**Clin. Cane. Res., 2007, vol. 13, 134016-4025 [0029]
- **BEAVIS et al.**Cancer Immunol. Res., 2015, [0029]
- **MITTAL et al.**Cancer Res., 2014, [0029]
- **HANZLIK et al.**J. Org. Chem., 1990, vol. 55, 3992-3997 [0059]
- **REIDER et al.**J. Org. Chem., 1987, vol. 52, 3326-3334 [0059]
- **FOSTER**Adv. Drug Res., 1985, vol. 14, 1-40 [0059]
- **GILLETTE et al.**Biochemistry, 1994, vol. 33, 102927-2937 [0059]
- **JARMAN et al.**Carcinogenesis, 1993, vol. 16, 4683-688 [0059]
- Greene's Protective Groups in Organic SynthesisWiley-Interscience20070000 [0069]
- **J. SHAFFER et al.**J. Pharm. Sciences, 1999, vol. 88, 313-318 [0120]
- Pharmaceutical Research, 1986, vol. 3, 6318- [0131]

Patentkrav

1. Forbindelse valgt fra gruppen bestående af:

1	(R)-3-aminomethyl-pyrrolidin-1-carboxylsyre (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid
2	N-{4-methoxy-7-[4-(oxan-4-yloxy)phenyl]-[1,3]thiazolo[4,5-c]pyridin-2-yl}-8-oxa-2-azaspiro[4.5]decan-2-carboxamid
3	(S)-3-aminomethyl-pyrrolidin-1-carboxylsyre (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid
4	cyclopropancarboxylsyre (6-fluor-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amid
6	N-(6-fluor-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-4-(1H-tetrazol-5-yl)-benzamid
7	7-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (6-fluor-4-methoxy-7-morpholin-4-yl-thiazolo[4,5-c]pyridin-2-yl)-amid
9	N-[7-(1H-indol-6-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decan-2-carboxamid
10	(R)-7-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (6-fluor-4-methoxy-7-morpholin-4-yl-thiazol[4,5-c]pyridin-2-yl)-amid
11	(5S)-N-[6-fluor-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decan-2-carboxamid
12	(R)-7-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (6-fluor-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid
13	(5S)-N-{6-fluor-4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-7-oxa-2-azaspiro[4.5]decan-2-carboxamid
14	3-dimethylaminomethyl-bicyclo[1.1.1]pentan-1-carboxylsyre (4-methoxy-7-morpholin-4-yl-thiazol[4,5-c]pyridin-2-yl)-amid
15	7-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid

16	N-[6-fluor-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonan-7-carboxamid
17	N-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-[(2-methoxyethyl)amino]-1,3-thiazol-5-carboxamid
18	(R)-2-oxa-7-aza-spiro[4.4]nonan-7-carboxylsyre (6-fluor-4-methoxy-7-morpholin-4-yl-thiazol[4,5-c]pyridin-2-yl)-amid
19	(5S)-N-[6-fluor-4-methoxy-7-(morpholin-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonan-7-carboxamid
20	N-[6-fluor-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N',N'-dimethyl-terephthalamid
21	1-imidazol-1-ylmethyl-cyclopropancarboxylsyre [6-fluor-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
22	N-[6-fluor-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-(2-methoxyethyl)-1H-pyrazol-4-carboxamid
23	N-[6-fluor-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-methyl-1H-pyrazol-4-carboxamid
24	(R)-7-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
25	(S)-7-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
26	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [6-fluor-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
27	4-hydroxy-4-methyl-piperidin-1-carboxylsyre [6-fluor-7-(4-fluor-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
28	cyclopropancarboxylsyre [6-fluor-4-methoxy-7-(tetrahydropyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
29	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [6-fluor-7-(4-fluor-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
30	cyclopropancarboxylsyre [7-(3-ethylaminomethyl-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid

31	7-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [6-fluor-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
32	1H-imidazol-4-carboxylsyre (6-fluor-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid
33	N-[6-fluor-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonan-7-carboxamid
34	(R)-7-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [6-fluor-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
35	(5S)-N-[6-fluor-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decan-2-carboxamid
37	(R)-2-oxa-7-aza-spiro[4.4]nonan-7-carboxylsyre [6-fluor-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
38	(5S)-N-[6-fluor-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonan-7-carboxamid
39	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(3-aminophenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
40	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(3-oxo-cyclopent-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amid
41	bicyclo[1.1.1]pentan-1,3-dicarboxylsyre [6-fluor-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid (2-hydroxy-ethyl)-methyl-amid
42	N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]cyclopropancarboxamid
43	N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1H-imidazol-4-carboxamid
44	N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decan-2-carboxamid
45	N-[7-(2,5-dihydrofuran-3-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decan-2-carboxamid

46	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(1-acetyl-1,2,3,6-tetrahydro-pyridin-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
47	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (4-methoxy-7-thiophen-2-yl-thiazolo[4,5-c]pyridin-2-yl)-amid
48	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (7-furan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amid
49	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(3-ethylaminomethyl-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
50	N-[6-fluor-4-methoxy-7-(tetrahydro-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-N'-(2-hydroxy-ethyl)-N'-methyl-terephthalamid
51	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (4-methoxy-7-piperidin-1-yl-thiazolo[4,5-c]pyridin-2-yl)-amid
52	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (7-furan-3-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amid
53	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(4-methyl-piperazin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
54	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(3-methoxy-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amid
56	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(6-methyl-pyridazin-3-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
57	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (7-azetidin-1-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amid
58	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(3-hydroxy-azetidin-1-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
59	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (7-cyclohex-1-enyl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amid
60	1H-imidazol-4-carboxylsyre (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid
61	N4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N1,N1-dimethylbenzen-1,4-dicarboxamid

62	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (7-cyclohexyl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amid
63	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(4,4-difluor-cyclohex-1-enyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
64	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(3,6-dihydro-2H-thiopyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
65	1H-imidazol-4-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
66	N-[4-methoxy-7-(4-methoxycyclohex-1-en-1-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decan-2-carboxamid
67	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(2-methyl-thiazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
68	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(1-pyridin-3-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
69	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(1-pyridin-2-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
71	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamid
72	4-{[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}benzoesyre
73	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (7-[1,4]dioxan-2-yl-4-methoxy-thiazolo[4,5-c]pyridin-2-yl)-amid
74	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre {7-[1-(2,2-difluorethyl)-1H-pyrazol-4-yl]-4-methoxy-thiazolo[4,5-c]pyridin-2-yl}-amid
75	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(1-pyridin-4-ylmethyl-1H-pyrazol-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
76	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(1-benzyl-1H-pyrazol-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
79	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(1-difluormethyl-1H-pyrazol-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid

80	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (4-difluormethoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid
81	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-[(2-methoxyethyl)amino]-1,3-thiazol-5-carboxamid
82	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-[(1H-imidazol-1-yl)methyl]benzamid
83	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-[(1R)-1-acetamidoethyl]benzamid
84	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre {4-methoxy-7-[1-(tetrahydro-pyran-2-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amid
85	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre {4-methoxy-7-[1-(tetrahydro-pyran-4-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amid
86	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(1,1-dioxo-hexahydro-1l6-thiopyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
87	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre {4-methoxy-7-[1-(tetrahydro-pyran-3-ylmethyl)-1H-pyrazol-4-yl]-thiazolo[4,5-c]pyridin-2-yl}-amid
88	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)piperidin-1-carboxamid
89	3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(2-oxopyrrolidin-1-yl)phenyl]urea
90	N-[4-({[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}amino)phenyl]-2-(dimethylamino)acetamid
91	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(2,4-dioxo-1,3-thiazolidin-3-yl)piperidin-1-carboxamid
92	N-[4-({[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]carbamoyl}amino)-2-methylphenyl]acetamid
93	N4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-hydroxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N1-(2-hydroxyethyl)-N1-methylbenzen-1,4-dicarboxamid
94	3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)phenyl]urea

95	3-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1-[4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]urea
96	N 1-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N4,N4-dimethylpiperidin-1,4-dicarboxamid
97	[4-(4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-ylcarbamoyl)-benzyl]-methyl-carbaminsyre-methylester
98	2,8-diaza-spiro[4.5]decan-2-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
99	4-(2,5-dioxo-pyrrolidin-1-yl)-piperidin-1-carboxylsyre (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid
100	4-(2,5-dioxo-pyrrolidin-1-yl)-piperidin-1-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
101	bicyclo[1.1.1]pentan-1,3-dicarboxylsyre (6-fluor-4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid (2-hydroxy-ethyl)-methylamid
102	2,7-diaza-spiro[4.5]decan-2-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
103	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (4-methoxy-7-{1-[2-(2-methoxy-ethoxy)-ethyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amid
104	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (4-methoxy-7-{1-[(R)-1-(tetrahydro-pyran-3-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amid
105	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (4-methoxy-7-{1-[(S)-1-(tetrahydro-pyran-3-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amid
106	N 1-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]piperidin-1,4-dicarboxamid
107	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-hydroxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonan-7-carboxamid
108	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-2-oxa-7-azaspiro[4.4]nonan-7-carboxamid

109	4-({4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}carbamoyl)benzoesyre
110	N-{4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-4-(1H-1,2,3,4-tetrazol-5-yl)benzamid
111	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(4,4-difluor-cyclohexyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
112	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(3-methylamino-phenyl)-thiazolo[4,5-c]pyridin-2-yl]-amid
113	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(5-methyl-thiophen-2-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
114	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(5-methyl-furan-2-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
115	4-[(4-methoxy-7-{1-[(pyridin-3-yl)methyl]-1H-pyrazol-4-yl}-[1,3]thiazolo[4,5-c]pyridin-2-yl)carbamoyl]benzoesyre
116	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-1H-pyrazol-4-carboxamid
117	N-{4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl}-1H-pyrazol-4-carboxamid
118	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (4-methoxy-7-{1-[(S)-1-(tetrahydro-pyran-2-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amid
119	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre (4-methoxy-7-{1-[(R)-1-(tetrahydro-pyran-2-yl)methyl]-1H-pyrazol-4-yl}-thiazolo[4,5-c]pyridin-2-yl)-amid
121	(R)-2,7-diaza-spiro[4.5]decan-2-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
122	(S)-2,7-diaza-spiro[4.5]decan-2-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
123	piperidin-1,4-dicarboxylsyre 4-dimethylamid 1-[(4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid]

124	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(2-amino-pyridin-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
125	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-4-(4-methyl-piperazin-1-carbonyl)-benzamid
126	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-N'-(2-piperidin-1-yl-ethyl)-terephthalamid
127	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(2-methylamino-pyridin-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
128	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(5-methyl-cyclohex-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amid
129	N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-4-(4-hydroxy-4-methyl-piperidin-1-carbonyl)-benzamid
130	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(3-fluor-5-methansulfonylamino-phenyl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
131	4-(2,5-dioxo-imidazolidin-1-yl)-piperidin-1-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
132	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(3-methyl-3,6-dihydro-2H-pyran-4-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
133	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(3-trifluormethyl-piperidin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
134	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(3-methoxy-piperidin-1-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
135	imidazo[1,2-a]pyridin-3-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
136	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-(5-oxo-2,5-dihydro-1H-pyrrol-3-yl)-thiazolo[4,5-c]pyridin-2-yl]-amid
137	4-(2,5-dioxo-imidazolidin-1-yl)-piperidin-1-carboxylsyre (4-methoxy-7-phenyl-thiazolo[4,5-c]pyridin-2-yl)-amid
138	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(5-amino-2-fluor-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid

139	N-(2-azetidin-1-yl-ethyl)-N'-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-terephthalamid
140	2-pyridin-3-yl-1H-imidazol-4-carboxylsyre [7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
141	N-{4-methoxy-7-[3-(trifluormethyl)phenyl]-[1,3]thiazolo[4,5-c]pyridin-2-yl}-8-oxa-2-azaspiro[4.5]decan-2-carboxamid
142	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(5-amino-6-fluor-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
143	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [7-(5-amino-pyridin-3-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amid
144	{4-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-ylcarbamoyl]-phenyl}-eddikesyre
145	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-((S)-3-methyl-cyclohex-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amid
146	8-oxa-2-aza-spiro[4.5]decan-2-carboxylsyre [4-methoxy-7-((R)-3-methyl-cyclohex-1-enyl)-thiazolo[4,5-c]pyridin-2-yl]-amid

og fysiologisk acceptable salte, solvater og stereoisomerer deraf, inklusive blandinger deraf i alle forhold.

2. Farmaceutisk præparat omfattende mindst en forbindelse ifølge krav 1 og/eller fysiologisk acceptable salte, solvater og stereoisomerer deraf, inklusive blandinger deraf i alle forhold.

3. Farmaceutisk præparat ifølge krav 2 omfattende yderligere excipienser og/eller adjuvanser.

4. Farmaceutisk præparat omfattende mindst en forbindelse ifølge krav 1 og/eller fysiologisk acceptable salte, solvater og stereoisomerer deraf, inklusive blandinger deraf i alle forhold, og mindst en yderligere aktiv lægemiddelforbindelse.

5. Fremgangsmåde til fremstillingen af et farmaceutisk præparat, **kendetegnet ved, at** en forbindelse ifølge krav 1 og/eller et af dets fysiologisk acceptable salte,

solvater og stereoisomerer, inklusive blandinger deraf i alle forhold, bringes til en passende doseringsform sammen med en fast, flydende eller halvflydende excipiens eller adjuvans.

6. Lægemiddel omfattende mindst en forbindelse ifølge krav 1 og/eller et af dets fysiologisk acceptable salte, solvater og stereoisomerer, inklusive blandinger deraf i alle forhold, til anvendelse i behandlingen og/eller profylaksen af patofysiologiske tilstande.

7. Lægemiddel omfattende mindst en forbindelse ifølge krav 1 og/eller et af dets fysiologisk acceptable salte, solvater og stereoisomerer, inklusive blandinger deraf i alle forhold, til anvendelse i behandlingen og/eller profylaksen af patofysiologiske tilstande, valgt fra gruppen bestående af hyperproliferative og infektiøsesygdomme og lidelser.

8. Lægemiddel til anvendelse ifølge krav 7, hvor den hyperproliferative sygdom eller lidelse er kræft.

9. Lægemiddel til anvendelse ifølge krav 8, hvor kræftformen er valgt fra gruppen bestående af akut og kronisk lymfatisk leukæmi, akut granulocytleukæmi, binyrebarkkræft, blærekræft, hjernekræft, brystkræft, livmoderhalskræft, cervikal hyperplasi, årehindekræft, kronisk granulocytleukæmi, kronisk lymfatisk leukæmi, kolonkræft, endometriekræft, spiserørskræft, essentiel trombocytose, urogenitalt karcinom, gliom, glioblastom, hårcelleleukæmi, hoved- og halskarcinom, Hodgkins sygdom, Kaposis sarkom, lungekarcinom, lymfom, malignt karcinoidt karcinom, malignt hypercalcæmi, malignt melanom, malignt pankreatisk insulinom, medullært thyroidt karcinom, melanom, multipelt myelom, mycosis fungoides, myeloid og lymfatisk leukæmi, neuroblastom, non-Hodgkins lymfom, ikke-småcellet lungekræft, osteogent sarkom, ovarialt karcinom, pankreatisk karcinom, polycythæmia vera, primært hjernekarcinom, primært makroglobulinæmi, prostatakræft, nyrecellekræft, rhabdomyosarkom, hudkræft, småcellet lungekræft, blødvævssarkom, pladecellekræft, mavekræft, testikelkræft, skjoldbruskkirtelkræft og Wilms tumor.

10. Lægemiddel til anvendelse ifølge krav 7, hvor den hyperproliferative sygdom eller lidelse er valgt fra gruppen bestående af aldersrelateret maculadegeneration, Crohns sygdom, cirrose, kroniske inflammationsrelaterede lidelser, proliferativ diabetisk retinopati, proliferativ vitreoretinopati, præmaturitetsretinopati, granulomatose, immun hyperproliferation associeret med organ- eller vævs-transplantation og en immunproliferativ sygdom eller lidelse valgt fra gruppen bestående af inflammatorisk tarmsygdom, psoriasis, reumatoid artritis, systemisk lupus erythematosus (SLE), vaskulær hyperproliferation som symptom på retinal hypoxi og vaskulitis.

11. Lægemiddel til anvendelse ifølge krav 7, hvor infektionssygdommen eller -lidelsen er valgt fra gruppen bestående af

i. virusinducerede infektionssygdomme som er forårsaget af retrovirusser, hepadnavirusser, herpesvirusser, flaviviridae og/eller adenovirusser, hvor retrovirusserne er valgt fra lentivirusser eller oncoretrovirusser, hvor lentivirussen er valgt fra gruppen bestående af HIV-1, HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV og EIAV, og oncoretrovirussen er valgt fra gruppen bestående af HTLV-I, HTLV-II og BLV, hepadnavirussen er valgt fra gruppen bestående af HBV, GSHV og WHV, herpesvirussen er valgt fra gruppen bestående af HSV I, HSV II, EBV, VZV, HCMV eller HHV 8, og flaviviridae er valgt fra gruppen bestående af HCV, vestnilfeber og gul feber,

ii. bakterieinfektionssygdomme som er forårsaget af Gram-positive bakterier, hvor de Gram-positive bakterier er valgt fra gruppen bestående af methicillin-modtagelig og methicillin-resistent staphylococci (herunder Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, og coagulase-negative staphylococci), glycopeptid-mellemprodukt modtagelig Staphylococcus aureus (GISA), penicillin-modtagelig og penicillin-resistent streptococci (herunder Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sanguis og gruppe C Streptococci (GCS), gruppe G Streptococci (GGS) og viridans streptococci), enterococci (herunder vancomycin-modtagelige og vancomycin-resistente stammer såsom Enterococcus faecalis og Enterococcus faecium), Clostridium difficile, listeria monocytogener, Corynebacterium jeikeium, Chlamydia spp (herunder C. pneumoniae) og Mycobacterium tuberculosis,

iii. bakterieinfektionssygdomme som er forårsaget af Gram-negative bakterier, hvor de Gram-negative bakterier er valgt fra gruppen bestående af slægten Enterobacteriacae, herunder Escherichia spp. (herunder Escherichia coli), Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia spp., Proteus spp., Providencia spp., Salmonella spp., Shigella spp., slægten Pseudomonas (herunder P. aeruginosa), Moraxella spp. (herunder M. catarrhalis), Haemophilus spp. og Neisseria spp.,

iv. infektionssygdomme induceret af intracellulære aktive parasitter valgt fra gruppen bestående af phylum Apicomplexa, eller Sarcomastigophora (herunder Trypanosoma, Plasmodia, Leishmania, Babesia eller Theileria), Cryptosporidia, Sacrocystida, Amoebia, Coccidia og Trichomonadia.

12. Sæt (kit) bestående af separate pakker af

a) en effektiv mængde af en forbindelse ifølge et eller flere af kravene 1 og/eller fysiologisk acceptable salte, solvater og stereoisomerer deraf, inklusive blandinger deraf i alle forhold, og

b) en effektiv mængde af en yderligere aktiv lægemiddelforbindelse.